Conditions: Atopic Dermatitis
Keywords: Eczema
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 86
Healthy volunteers: no

Brief summary:
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.

Detailed description:

Arms:
arm 1: Participants will receive Lebrikizumab by subcutaneous (SC) injection.

Interventions: intervention 1: Lebrikizumab
Intervention descriptions: intervention 1: Administered SC

Protocol document:
Prot_000.pdf: 
Protocol J2T-MC-KGBO(a)
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent 
Participants with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab
NCT05369403   
Approval Date: 27-Apr-2023 


CONFIDENTIAL 
J2T-MC-KGBO(a) 
1 
Title Page 
Confidential Information 
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical 
investigation of lebrikizumab (LY3650150), unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries.  
Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. 
In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries. 
Protocol Title: 
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and 
Adolescent Participants with Moderate-to-Severe Atopic Dermatitis Previously Treated with 
Dupilumab  
Protocol Number: J2T-MC-KGBO 
Amendment Number: a  
Compound: lebrikizumab (LY3650150) 
Brief Title:  
A Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent 
Participants with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab 
Study Phase: 3b 
Sponsor Name: Eli Lilly and Company 
Legal Registered Address: Indianapolis, Indiana, USA 46285 
Regulatory Agency Identifier Number: 
IND: 119866 
Document ID: VV-CLIN-093432 
Approval Date: Protocol Amendment (a) Electronically Signed and Approved by Lilly on date 
provided below.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
2 
Medical Monitor Name and Contact Information will be provided separately. 
 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
3 
Protocol Amendment Summary of Changes Table  
DOCUMENT HISTORY 
Document 
Date 
Original Protocol 
16-Aug-2022 
Amendment [a]  
This amendment is considered to be substantial. 
The amendment is considered to be substantial because it is likely to have a significant impact on 
the interpretation of the data generated in the clinical study. 
Overall Rationale for the Amendment: 
The main rationale for this amendment is provided below 
Section # and Name 
Description of Change 
Brief Rationale 
1.1. Synopsis and  
3. Objectives, Endpoints, 
and Estimands 
Revised the primary 
clinical research question 
and the attributes of the 
primary estimand. 
To ensure that the primary clinical 
research question, primary estimand, 
and primary analysis are in alignment.  
The original treatment policy 
estimand is not aligned with the as-
observed analysis 
6.6. Continued Access to 
Study Intervention after 
the End of the Study 
Updated to allow 
continued access to 
lebrikizumab for eligible 
participants who 
complete Visit 9 (Week 
24) 
Provide an uninterrupted supply of 
lebrikizumab to qualified participants, 
via the Continued Access addendum, 
until lebrikizumab is commercially 
available in the US 
6.8.1 Permitted 
Treatments and 
Procedures 
Added use of high-
potency TCS up to 10 
days 
Permitting high-potency TCS for up to 
10 days is similar to the real-world 
setting 
6.8.2 Prohibited 
Treatments and 
Procedures 
Updated use of high-
potency TCS for >10 
days 
Alignment with rescue treatment for 
Atopic Dermatitis 
6.8.3 Non-medicated 
moisturizers 
Clarified permitted use by 
adding the word ‘may’ 
The intent is to convey that the use of 
emollients is not mandatory, but 
recommended 
6.8.4 Topical treatment 
for Atopic Dermatitis 
Added use of high-
potency TCS >10 days 
Permitting high-potency TCS > 10 
days will be considered as rescue 
medication 
6.8.5 Rescue treatment 
for Atopic Dermatitis 
Added use of high-
potency TCS >10 days 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
4 
Section # and Name 
Description of Change 
Brief Rationale 
9.2. Analyses Sets 
Added “population” to 
describe ITT and Safety 
analysis set 
Clarification 
9.3.2. Primary 
Endpoint(s)/Estimand(s) 
Analysis 
Revised the primary 
clinical question of 
interest 
To align primary estimand with 
primary analysis. The original 
treatment policy estimand is not 
aligned with the as-observed analysis  
9.3.3. Secondary 
Endpoint(s)/Estimand(s) 
Analysis 
Removed reference to the 
treatment policy strategy 
for secondary endpoints 
To clarify that secondary endpoints 
will be analyzed similarly to the 
primary endpoint of the primary 
estimand, that is, using all observed 
data. The original treatment policy 
estimand is not aligned with the as-
observed analysis 
9.3.4. Exploratory 
Endpoint(s) Analysis 
Removed reference to the 
treatment policy strategy 
for exploratory endpoints 
To clarify that exploratory endpoints 
will be analyzed similarly to the 
primary endpoint of the primary 
estimand, that is, using all observed 
data. The original treatment policy 
estimand is not aligned with the as-
observed analysis 
10.3.6. Regulatory 
Reporting Requirements 
SAE Regulatory 
Reporting 
Added text for suspected 
unexpected serious 
adverse reactions 
Alignment with latest guidance 
Throughout  
Minor editorial changes 
have been made 
throughout  
These are minor, therefore they have 
not been individually summarized 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
5 
Table of Contents  
1. 
Protocol Summary ..........................................................................................................9 
1.1. 
Synopsis ............................................................................................................................9 
1.2. 
Schema ............................................................................................................................14 
1.3. 
Schedule of Activities (SoA) ..........................................................................................15 
2. 
Introduction ...................................................................................................................25 
2.1. 
Study Rationale ...............................................................................................................25 
2.2. 
Background .....................................................................................................................26 
2.3. 
Benefit/Risk Assessment ................................................................................................29 
3. 
Objectives, Endpoints, and Estimands .......................................................................30 
4. 
Study Design ..................................................................................................................34 
4.1. 
Overall Design ................................................................................................................34 
4.2. 
Scientific Rationale for Study Design ............................................................................34 
4.2.1. 
Participant Input into Design ..........................................................................................35 
4.3. 
Justification for Dose ......................................................................................................35 
4.4. 
End of Study Definition ..................................................................................................35 
5. 
Study Population ...........................................................................................................37 
5.1. 
Inclusion Criteria ............................................................................................................37 
5.2. 
Exclusion Criteria ...........................................................................................................38 
5.3. 
Lifestyle Considerations .................................................................................................41 
5.4. 
Screen Failures ................................................................................................................41 
5.4.1. 
Rescreening for Individuals Who Failed Screening .......................................................41 
5.5. 
Criteria for Temporarily Delaying Enrollment/Administration of 
Study Intervention of a Participant .................................................................................41 
6. 
Study Intervention(s) and Concomitant Therapy .....................................................42 
6.1. 
Study Intervention(s) Administered................................................................................42 
6.1.1. 
Medical Devices..............................................................................................................42 
6.2. 
Preparation, Handling, Storage, and Accountability ......................................................42 
6.3. 
Measures to Minimize Bias: Randomization and Blinding ............................................43 
6.4. 
Study Intervention Compliance ......................................................................................43 
6.5. 
Dose Modification ..........................................................................................................43 
6.6. 
Continued Access to Study Intervention after the End of the 
Study ...............................................................................................................................43 
6.7. 
Treatment of Overdose ...................................................................................................44 
6.8. 
Concomitant Therapy .....................................................................................................44 
6.8.1. 
Permitted Treatments and Procedures ............................................................................44 
6.8.2. 
Prohibited Treatments and Procedures ...........................................................................45 
6.8.3. 
Non-Medicated Moisturizers ..........................................................................................46 
6.8.4. 
Topical Treatment for Atopic Dermatitis .......................................................................46 
6.8.5. 
Rescue Medicine for Atopic Dermatitis .........................................................................47 
7. 
Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal........................................................................................48 
7.1. 
Discontinuation of Study Intervention ............................................................................48 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
6 
7.1.1. 
Liver Chemistry Stopping Criteria ..................................................................................49 
7.1.2. 
Temporary Discontinuation of Study Intervention .........................................................49 
7.2. 
Participant Discontinuation/Withdrawal from the Study ................................................50 
7.3. 
Lost to Follow-up............................................................................................................51 
8. 
Study Assessments and Procedures.............................................................................52 
8.1. 
Efficacy Assessments .....................................................................................................52 
8.1.1. 
Eczema Area and Severity Index ....................................................................................52 
8.1.2. 
Investigator’s Global Assessment (IGA) ........................................................................52 
8.1.3. 
Body Surface Area (BSA) ..............................................................................................53 
8.1.4. 
Face-Investigator’s Global Assessment (F-IGA)............................................................53 
8.1.5. 
SCORing Atopic Dermatitis (SCORAD) .......................................................................53 
8.1.6. 
Modified Total Lesion Symptom Scale ..........................................................................53 
8.1.7. 
Pruritus NRS ...................................................................................................................54 
8.1.8. 
Sleep-Loss Scale .............................................................................................................54 
8.1.9. 
Skin Pain Numeric Rating Scale (Skin Pain NRS) .........................................................54 
8.1.10. Dermatology Life Quality Index/Children’s Dermatology Life 
Quality Index (DLQI/cDLQI) .........................................................................................54 
8.1.11. Atopic Dermatitis Control Tool (ADCT) .......................................................................55 
8.1.12. Participant-Reported Satisfaction Question ....................................................................55 
8.1.13. Fitzpatrick Skin Phototype Assessment ..........................................................................55 
8.1.14. Work Productivity and Activity Impairment Questionnaire–
Atopic Dermatitis (WPAI-AD) .......................................................................................55 
8.2. 
Safety Assessments .........................................................................................................56 
8.2.1. 
Clinical Safety Laboratory Tests ....................................................................................56 
8.2.2. 
Hepatic Safety .................................................................................................................57 
8.2.3. 
Hepatitis B Testing and Monitoring ...............................................................................59 
8.2.4. 
Hepatitis C Testing .........................................................................................................60 
8.3. 
Adverse Events, Serious Adverse Events, and Product 
Complaints ......................................................................................................................60 
8.3.1. 
Timing and Mechanism for Collecting Events ...............................................................61 
8.3.2. 
Pregnancy ........................................................................................................................62 
8.3.3. 
Adverse Events of Special Interest .................................................................................64 
8.3.4. 
Facial Dermatitis .............................................................................................................64 
8.3.5. 
Hypersensitivity ..............................................................................................................64 
8.3.6. 
Injection Site Reactions ..................................................................................................64 
8.4. 
Pharmacokinetics ............................................................................................................64 
8.5. 
Pharmacodynamics .........................................................................................................65 
8.6. 
Genetics ..........................................................................................................................65 
8.7. 
Biomarkers ......................................................................................................................65 
8.8. 
Immunogenicity Assessments.........................................................................................65 
8.9. 
Health Economics ...........................................................................................................66 
9. 
Statistical Considerations .............................................................................................67 
9.1. 
Statistical Hypotheses .....................................................................................................67 
9.2. 
Analyses Sets ..................................................................................................................67 
9.3. 
Statistical Analyses .........................................................................................................67 
9.3.1. 
General Considerations ...................................................................................................67 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
7 
9.3.2. 
Primary Endpoint(s)/Estimand(s) Analysis ....................................................................67 
9.3.3. 
Secondary Endpoint(s)/Estimand(s) Analysis ................................................................68 
9.3.4. 
Exploratory Endpoint(s) Analysis...................................................................................68 
9.3.5. 
Safety Analyses ...............................................................................................................68 
9.3.6. 
Other Analyses ................................................................................................................68 
9.4. 
Interim Analysis ..............................................................................................................69 
9.5. 
Sample Size Determination ............................................................................................69 
10. 
Supporting Documentation and Operational Considerations ..................................71 
10.1. 
Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations ................................................................................................................71 
10.1.1. Regulatory and Ethical Considerations ...........................................................................71 
10.1.2. Financial Disclosure........................................................................................................71 
10.1.3. Informed Consent Process ..............................................................................................72 
10.1.4. Data Protection................................................................................................................72 
10.1.5. Dissemination of Clinical Study Data.............................................................................73 
10.1.6. Data Quality Assurance ..................................................................................................73 
10.1.7. Source Documents ..........................................................................................................75 
10.1.8. Study and Site Start and Closure ....................................................................................75 
10.1.9. Publication Policy ...........................................................................................................76 
10.1.10. Investigator Information .................................................................................................76 
10.1.11. Sample Retention ............................................................................................................76 
10.2. 
Appendix 2: Clinical Laboratory Tests ...........................................................................77 
10.2.1. Laboratory Samples to be Obtained at the Time of a Systemic 
Hypersensitivity Event ....................................................................................................79 
10.3. 
Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow-
up, and Reporting ............................................................................................................81 
10.3.1. Definition of AE .............................................................................................................81 
10.3.2. Definition of SAE ...........................................................................................................82 
10.3.3. Definition of Product Complaints ...................................................................................83 
10.3.4. Recording and Follow-Up of AE and/or SAE and Product 
Complaints ......................................................................................................................84 
10.3.5. Reporting of SAEs ..........................................................................................................86 
10.3.6. Regulatory Reporting Requirements ...............................................................................86 
10.4. 
Appendix 4: Contraceptive and Barrier Guidance ..........................................................87 
10.4.1. Definitions.......................................................................................................................87 
10.4.2. Contraception Guidance..................................................................................................87 
10.5. 
Appendix 5: Genetics......................................................................................................89 
10.6. 
Appendix 6: Liver Safety: Suggested Actions and Follow-up 
Assessments ....................................................................................................................90 
10.7. 
Appendix 7: American Academy of Dermatology: Criteria for 
the Diagnosis and Assessment of Atopic Dermatitis ......................................................92 
10.8. 
Appendix 8: Medical Device Adverse Events (AEs), Adverse 
Device Effects (ADEs), Serious Adverse Events (SAEs) and 
Device Deficiencies: Definition and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ............................................................................93 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
8 
10.9. 
Appendix 9: Examples of Infections That May Be Considered 
Opportunistic in the Setting of Biologic Therapy ...........................................................94 
10.10. 
Appendix 10: Provisions for Changes in Study Conduct During 
Exceptional Circumstances .............................................................................................96 
10.11. 
Appendix 11: Abbreviations and Definitions .................................................................98 
11. 
References ....................................................................................................................102 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
9 
1. 
Protocol Summary  
1.1. 
Synopsis  
Protocol Title:  
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and 
Adolescent Participants with Moderate-to-Severe Atopic Dermatitis Previously Treated with 
Dupilumab  
Brief Title:  
A Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent 
Participants with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab  
Rationale: 
Atopic dermatitis (AD) is a chronic heterogeneous inflammatory skin disorder caused by skin 
barrier dysfunction and dysregulation of the immune response. Due to the heterogeneous nature 
of the disease, patients have diverse treatment needs. Standard treatment modalities for the 
management of these patients are centered around the use of topical anti-inflammatory 
preparations and skin moisturizers, but patients with moderate-to-severe disease may require 
phototherapy or systemic treatment. Dupilumab, a monoclonal antibody which inhibits the 
signaling of interleukin (IL)-4 and IL-13, was approved for the treatment of patients with 
moderate-to-severe AD in 2017. Patients that undergo treatment with dupilumab may show a 
limited or partial response or even no response at all to treatment. Other patients may show an 
initial response to treatment but lose response over time. Still others are found to be intolerant or 
have adverse effects to dupilumab. Additionally, in real world practice other patients discontinue 
treatment due to issues such as cost or loss of access (for example, insurance) to the drug. Taken 
together, a significant number of patients do not continue dupilumab treatment over the course of 
their chronic disease. In the pivotal monotherapy dupilumab phase 3 trials, 36% to 38% of 
participants achieved the primary endpoint of an Investigator Global Assessment (IGA) (0,1) 
with a ≥2-point reduction in IGA and 44% to 51% achieved Eczema Area and Severity Index-75 
(EASI-75) data from baseline to Week 16, indicating that a significant proportion of the patients 
did not achieve clinical response. (Simpson et al. 2016).  
Therefore, there is an important gap in the clinical care of these patients for whom novel 
therapies are necessary to fulfill this unmet medical need. 
In patients with AD, IL-13, a central pathogenic mediator in the disease, is overexpressed, 
driving multiple aspects of AD pathophysiology by promoting T-helper type 2 (Th2) cell 
inflammation and resulting in skin barrier dysfunction, itch, infection, and lichenification. 
Dupilumab is a monoclonal antibody that binds to the shared α subunit of the IL-4 and IL-13 
receptors, thereby inhibiting the signaling of IL-4 and IL-13. IL-4 is the driver of the 
differentiation of naïve CD4+ T cells into Th2 cells and a negative regulator of Th1 and Th17 
pathways. Blockade of Th2 differentiation by dupilumab might cause a dysregulation in the 
T-helper balance, providing a mechanistic explanation for the development of Th1/Th17 diseases 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
10 
in dupilumab-treated patients (Tracey et al. 2018; Safa and Paumier 2019; Varma and Levitt 
2020; Heibel et al. 2021).  
IL-13 is considered a key cytokine in AD (Tsoi et al. 2019 and reviewed in Bieber et al. 2020). 
Lebrikizumab specifically blocks IL-13 and therefore also IL-13 signaling via the IL-4 receptor 
alpha (IL-4R)/IL-13 receptor alpha 1 (IL-13R1) heterodimer complex. Important differences 
between dupilumab and lebrikizumab include receptor vs cytokine targets, respectively, and 
known strong binding affinity and lack of effect on IL-4 signaling with lebrikizumab. In 
addition, IL-13 endogenous regulation remains intact when bound to lebrikizumab, because 
lebrikizumab does not inhibit the binding of IL-13 to the decoy receptor, IL-13Rα2. 
Lebrikizumab phase 2 and 3 data demonstrated its efficacy in AD. Leveraging data from both 
phase 2b monotherapy and phase 3 topical corticosteroids (TCS) combination therapy in which 
dupilumab experienced patients were included, lebrikizumab showed consistent treatment effects 
in both dupilumab naïve and dupilumab experienced participants. Nevertheless, those trials were 
not designed to evaluate this specific patient population.  
This trial aims to specifically evaluate the safety and efficacy of lebrikizumab in patients 
previously treated with dupilumab. 
Objectives, Endpoints, and Estimands: 
Objectives 
Endpoints 
Primary 
 
 
To evaluate efficacy of 
lebrikizumab 250 mg Q2W 
on reducing signs and 
symptoms of AD at Week 
16 in participants with 
moderate-to-severe AD 
previously treated with 
dupilumab 
 
Percentage of participants achieving EASI-75 
at Week 16 
Secondary 
 
 
To evaluate the efficacy of 
lebrikizumab on reducing 
signs and symptoms of AD 
at Week 16 and Week 24 in 
participants with 
moderate-to-severe AD 
previously treated with 
dupilumab 
 
Percentage of participants achieving EASI-75 
at Week 24 
 
Percentage of participants with an IGA score 
of 0 or 1 and a reduction ≥2 points from 
baseline to Weeks 16 and 24  
 
Percentage change in EASI from baseline to 
Weeks 16 and 24 
 
Change in EASI from baseline to Weeks 16 
and 24 
 
Percentage of participants achieving EASI-90 
from baseline to Weeks 16 and 24 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
11 
 
Percentage of participants with a Pruritus 
NRS of ≥4 points at baseline who achieve at 
least 4-point reduction at Weeks 16 and 24 
 
Percentage of participants with a Pruritus 
NRS ≥3 points at baseline who achieve at 
least 3-point reduction at Weeks 16 and 24 
 
Percentage change in Pruritus NRS score from 
baseline to Weeks 16 and 24 
 
Percentage of participants with a Sleep-Loss 
Scale of ≥2 points at baseline who achieve at 
least 2-point reduction at Weeks 16 and 24  
 
Change in Sleep-Loss Scale from baseline at 
Weeks 16 and 24 
 
Percentage of participants with a Skin Pain 
NRS of ≥4 points at baseline who achieve a 
4-point reduction from baseline at Weeks 16 
and 24  
 
Change in Skin Pain NRS from baseline to 
Weeks 16 and 24  
 
Change in DLQI from baseline to Weeks 16 
and Week 24 for participants ≥16 years of age 
at baseline 
 
Percentage of participants with at least 4-point 
at baseline achieving ≥4-point improvement in 
DLQI from baseline at Weeks 16 and 24 for 
participants ≥16 years of age at baseline  
 
Change in cDLQI from baseline to Weeks 16 
and 24 for participants <16 years of age at 
baseline 
 
Percentage change in SCORAD from baseline 
to Weeks 16 Week 24  
Abbreviations: AD = atopic dermatitis; cDLQI = Children’s Dermatology Life Quality Index; DLQI = Dermatology 
Life Quality Index; EASI = Eczema Area and Severity Index; EASI-75 = ≥75% reduction from baseline in EASI; 
EASI-90 = ≥90% reduction from baseline in EASI; IGA = investigator’s global assessment; NRS = numeric rating 
scale; Q2W = once every 2 weeks; SCORAD = SCORing atopic dermatitis.  
NOTE: Endpoints in the table above collected by visit references data collection visits.  
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
12 
Primary estimand 
The primary clinical question of interest is: What is the intervention effect in percentage of 
participants achieving EASI-75 after 16 weeks of lebrikizumab 250 mg once every 2 weeks 
(Q2W) intervention in participants with moderate-to-severe AD, who have been previously 
treated with dupilumab and who remain on study treatment until Week 16. 
The estimand is described by the following attributes: 
Population: participants with moderate-to-severe AD who have been previously treated with 
dupilumab and who remain on study treatment until Week 16.  
Further details can be found in Section 5. 
Endpoint: Do participants achieve at least 75% improvement from baseline to Week 16 in EASI. 
Intercurrent events: There are no intercurrent events for this population since participants who 
initiate rescue medication are discontinued from the study and hence study treatment. Therefore, 
participants who stay on study treatment through Week 16 will not have an intercurrent event 
such as initiating rescue medication or permanently discontinuing treatment.  
Population-level summary: Percentage of participants achieving EASI-75 response at Week 16. 
Secondary estimand(s) 
There is no secondary estimand planned at this stage, however, additional estimand(s) might be 
specified in the statistical analysis plan (SAP).  
Overall Design 
Study J2T-MC-KGBO (KGBO) is an open-label, Phase 3b study, which is 24 weeks in treatment 
duration. The study is designed to evaluate the safety and efficacy of lebrikizumab in adults and 
adolescents (≥12 years to <18 and weighing ≥40 kg) with moderate-to-severe AD and previously 
treated with dupilumab. 
During the 24-week Treatment Period, approximately 120 participants will receive treatment: 
 500 mg subcutaneous (SC) once every 2 weeks (Q2W) loading dose at baseline and 
Week 2, followed by 250 mg SC Q2W until Week 16. 
 Responders, defined as achieving IGA (0,1) or EASI-75 at Week 16, will receive 250 mg 
SC once every 4 weeks (Q4W). 
 Inadequate responders at Week 16 will continue to receive 250 mg SC Q2W. 
 
Brief Summary: 
The purpose of this study is to determine the proportion of participants achieving EASI-75 at 
Week 16 with lebrikizumab in participants with moderate-to-severe AD previously treated with 
dupilumab.  
Study details include: 
● The planned study duration will be up to 38 weeks.  
● The treatment duration will be up to 24 weeks.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
13 
● The visit frequency will be every 2 weeks for the first 2 visits, then every 4 weeks 
thereafter. 
Number of Participants: 
Approximately 120 participants previously treated with dupilumab will be enrolled to study 
intervention. Among those, approximately 80 participants will be enrolled who discontinued 
dupilumab due to: a) no response to treatment, b) a partial response to treatment, or c) who lost 
response to treatment. Additionally, approximately 15 participants will be enrolled who 
discontinued dupilumab treatment due to intolerance or adverse events (AEs). Finally, 
approximately 25 participants will be enrolled who stopped dupilumab treatment for other 
reasons (for example, cost, insurance coverage, access to medication, previous trial participants). 
Approximately 10% (n=12) of participants will be adolescents (12 to less than 18 who weigh at 
least 40 kg).  
Intervention Groups and Duration: 
Lebrikizumab drug product is provided as sterile liquids and contain no preservatives.  
Intervention Name 
Lebrikizumab 
Dose Formulation 
250 mg (125 mg/mL), 2 mL Solution 
Dosage Level 
Loading Dose: 
Week 0: 500 mg (2 injections of 250 mg) 
Week 2: 500 mg (2 injections of 250 mg) 
 
Post-loading dose: 
Weeks 4-16: 250 mg SC Q2W (1 injection of 250 mg)  
Responders at Week 16: 250 mg SC Q4W (1 injection of 250 mg) at W20 
Inadequate responders at Week 16: 250 mg SC Q2W (1 injection of 250 mg) 
at W18, W20, and W22 
Route of Administration 
SC 
Abbreviations: mg = milligram; mL = milliliter; SC = subcutaneously; Q2W = once every 2 weeks; Q4W = once 
every 4 weeks; W = week. 
Data Monitoring Committee: No 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
14 
1.2. 
Schema  
 
Abbreviations: EASI = Eczema Area and Severity Index; IGA = Investigator’s Global Assessment; n = number; Q2W = once every 2 weeks; Q4W = once every 
4 weeks; SC = subcutaneous; W = week. 
a Weeks 12 and 20 are phone visits.  
b 30-day screening window. 
c Lebrikizumab loading dose of 500 mg SC will be administered at baseline and Week 2. 
d Responders: Participants who reach IGA 0 or 1 (clear or almost clear) or a 75% reduction in the EASI score from baseline (EASI-75). Inadequate responders 
are participants who do not reach these criteria. 
e The safety follow-up visit will occur approximately 12 weeks after last study intervention injection. 
 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
15 
1.3. 
Schedule of Activities (SoA)  
 
Period I  
Period II 
Period III  
Comments 
Screening 
Baseline 
Treatment Period 
Post-
Treatment 
Follow-up 
 
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
ED 
801 
 
Week Relative to 
Study Drug Start  ≤30 (days) 
0 
2 
4 
8 
12 
16 
20 
24 
- 
Approximately 
12 weeks post 
last dose 
 
Visit Interval 
Tolerance (Days) 
 
– 
±3 
±3 
±5 
±5 
±5 
±5 
±5 
- 
±7 
 
Visit Detail 
 
 
 
 
 
T 
 
T 
 
 
 
 
Informed consent 
and assent 
X 
 
 
 
 
 
 
 
 
 
 
The informed consent must be signed before 
any protocol-specific tests or procedures are 
performed.  
Parent or legally authorized representative 
signs ICF as appropriate per local 
requirements. 
Assent will be collected as specified by ethics 
board. See Section 10.1.3 for additional details. 
Inclusion and 
exclusion criteria, 
review and 
confirm 
X 
X 
 
 
 
 
 
 
 
 
 
Inclusion or exclusion criteria should be 
confirmed prior to drug assignment and 
administration of first dose of study 
intervention. 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
Includes: 
 
ethnicity, sex, and race 
 
full date of birth for participants 12-17 
years of age, and 
 
year of birth for participants ≥18 years 
of age. 
Preexisting 
conditions and 
medical history, 
including relevant 
surgical history 
X 
 
 
 
 
 
 
 
 
 
 
All conditions ongoing and relevant past 
surgical and medical history should be 
collected.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
16 
 
Period I  
Period II 
Period III  
Comments 
Screening 
Baseline 
Treatment Period 
Post-
Treatment 
Follow-up 
 
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
ED 
801 
 
Week Relative to 
Study Drug Start  ≤30 (days) 
0 
2 
4 
8 
12 
16 
20 
24 
- 
Approximately 
12 weeks post 
last dose 
 
Visit Interval 
Tolerance (Days) 
 
– 
±3 
±3 
±5 
±5 
±5 
±5 
±5 
- 
±7 
 
Visit Detail 
 
 
 
 
 
T 
 
T 
 
 
 
 
Prespecified 
medical history 
(indication and 
history of interest) 
X 
 
 
 
 
 
 
 
 
 
 
Additional data for the indication and 
comorbidities of interest are collected, 
(including conjunctivitis and facial dermatitis).  
Record prior 
treatments for 
indication 
X 
 
 
 
 
 
 
 
 
 
 
Includes medications and therapies for AD. 
Review 
immunization 
record 
X 
 
 
 
 
 
 
 
 
 
 
The investigator should review the vaccination 
status of each pediatric participant <18 years of 
age to assess if the participant is up to date with 
immunizations following the local guidelines 
for vaccination with vaccines intended to 
prevent infectious disease prior to enrolling 
participants into the study.  
For participants who are under-vaccinated, the 
investigator should document the benefit or 
risk rationale for enrolling the participants in 
the study. 
Review menarche 
status with date of 
menarche (if 
applicable) 
X 
X 
X 
X 
X 
  
X 
  
X 
X 
  
For participants <18 years of age. 
If the participant reaches menarche at any time 
during the trial and is sexually active, 
pregnancy testing and contraception 
requirements will apply. See Section 10.4, 
Appendix 4.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
17 
 
Period I  
Period II 
Period III  
Comments 
Screening 
Baseline 
Treatment Period 
Post-
Treatment 
Follow-up 
 
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
ED 
801 
 
Week Relative to 
Study Drug Start  ≤30 (days) 
0 
2 
4 
8 
12 
16 
20 
24 
- 
Approximately 
12 weeks post 
last dose 
 
Visit Interval 
Tolerance (Days) 
 
– 
±3 
±3 
±5 
±5 
±5 
±5 
±5 
- 
±7 
 
Visit Detail 
 
 
 
 
 
T 
 
T 
 
 
 
 
Concomitant 
medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
AEs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Any events that occur after signing the ICF or 
assent are considered AEs as defined in Section 
10.3, Appendix 3. For AESIs, additional data 
could be collected. See Section 8.3.3.  
Physical Evaluation 
Height 
X 
 
 
 
 
 
 
 
X 
 
 
 
Weight 
X 
X 
 
 
 
 
X 
 
X 
X 
 
 
Vital signs 
X 
X 
 
 
 
 
X 
 
X 
X 
 
Includes pulse rate, blood pressure, respiratory 
rate, and temperature. Measured after 
participant has been sitting at least 5 minutes. 
Use size appropriate blood pressure cuffs.  
Physical 
examination 
X 
 
 
 
 
 
 
 
X 
X 
 
The physical examination is performed 
(excludes pelvic and rectal, unless clinically 
indicated). Full skin examination is required for 
BSA calculation.  
Symptom-
directed physical 
assessment  
 
X 
X 
X 
X 
 
X 
 
 
 
X 
As indicated based on participant status and 
standard of care. May be performed by 
qualified personnel per local regulations.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
18 
 
Period I  
Period II 
Period III  
Comments 
Screening 
Baseline 
Treatment Period 
Post-
Treatment 
Follow-up 
 
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
ED 
801 
 
Week Relative to 
Study Drug Start  ≤30 (days) 
0 
2 
4 
8 
12 
16 
20 
24 
- 
Approximately 
12 weeks post 
last dose 
 
Visit Interval 
Tolerance (Days) 
 
– 
±3 
±3 
±5 
±5 
±5 
±5 
±5 
- 
±7 
 
Visit Detail 
 
 
 
 
 
T 
 
T 
 
 
 
 
Participant Diary (Electronic) 
Diary dispensed 
X 
 
 
 
 
 
 
 
 
 
 
Diary includes daily collection of PRO 
assessments (Pruritus NRS, Sleep-Loss Scale, 
and Skin Pain NRS); bi-weekly collection of 
study drug administration information (as 
applicable). TCS usage will be collected daily 
beginning at V2.  
Pruritus NRS and Sleep-Loss Scale should be 
completed a minimum of 4 of 7 days before 
baseline. 
Review diary for 
completion of 
PRO and TCS 
assessments  
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
For details of these assessments see Section 
8.1. 
Drug 
administration 
diary compliance 
check 
 
 
 
 
X 
X 
X 
X 
X 
X 
 
 
Diary return 
 
 
 
 
 
 
 
 
X 
X 
 
 
PROs (Electronic) 
Complete prior to any clinical administered assessments  
DLQI 
 
X 
 
 
 
 
X 
 
X 
X 
 
Only for participants ≥16 years of age at 
baseline.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
19 
 
Period I  
Period II 
Period III  
Comments 
Screening 
Baseline 
Treatment Period 
Post-
Treatment 
Follow-up 
 
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
ED 
801 
 
Week Relative to 
Study Drug Start  ≤30 (days) 
0 
2 
4 
8 
12 
16 
20 
24 
- 
Approximately 
12 weeks post 
last dose 
 
Visit Interval 
Tolerance (Days) 
 
– 
±3 
±3 
±5 
±5 
±5 
±5 
±5 
- 
±7 
 
Visit Detail 
 
 
 
 
 
T 
 
T 
 
 
 
 
cDLQI 
 
X 
 
 
 
 
X 
 
X 
X 
 
Only for participants <16 years of age at 
baseline. 
WPAI-AD 
 
X 
 
 
 
 
X 
 
X 
X 
 
 
ADCT 
 
X 
 
X 
 
 
X 
 
X 
X 
 
  
Participant-
Reported 
Satisfaction 
Question  
 
 
 
 
 
 
X 
 
X 
X 
 
 
Clinical-Administered Assessments (Electronic) 
IGA 
X 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
F-IGA 
 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
EASI 
X 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
BSA 
X 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
mTLSS 
 
X 
 
X 
 
 
X 
 
X 
X 
 
 
SCORAD 
 
X 
 
 
 
 
X 
 
X 
X 
 
 
Clinical-Administered Assessments (Paper)  
Fitzpatrick Skin 
Type Assessment 
 
X 
 
 
 
 
 
 
 
 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
20 
 
Period I  
Period II 
Period III  
Comments 
Screening 
Baseline 
Treatment Period 
Post-
Treatment 
Follow-up 
 
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
ED 
801 
 
Week Relative to 
Study Drug Start  ≤30 (days) 
0 
2 
4 
8 
12 
16 
20 
24 
- 
Approximately 
12 weeks post 
last dose 
 
Visit Interval 
Tolerance (Days) 
 
– 
±3 
±3 
±5 
±5 
±5 
±5 
±5 
- 
±7 
 
Visit Detail 
 
 
 
 
 
T 
 
T 
 
 
 
 
Participant Education and Supplies 
Participant or 
caregiver 
instructions on 
diary completion 
X 
 
 
 
 
 
 
 
 
 
 
Education can also be performed, as needed. 
Remind 
participant of 
TCS usage 
restrictions and 
expectations 
X 
 
 
 
 
 
 
 
 
 
 
Required 2 week wash out of TCS prior to 
Visit 2. See Section 6.8.1 for TCS usage during 
the study. 
Train participant 
and/or caregiver 
on study 
intervention 
administration 
 
 
X 
X 
 
 
 
 
 
 
 
Participants and/or caregivers need to be 
adequately trained on injection technique prior 
to administering injections. 
Training can be done at Week 2 and/or Week 4 
prior to self-administration. 
Dispense ancillary 
supplies for at 
home dosing 
 
 
 
X 
X 
 
X 
 
 
 
 
 
Laboratory Tests and Sample Collections 
Hematology 
X 
X 
 
X 
 
 
X 
 
X 
X 
X 
 
Clinical chemistry 
X 
X 
 
 
 
 
X 
 
X 
X 
X 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
21 
 
Period I  
Period II 
Period III  
Comments 
Screening 
Baseline 
Treatment Period 
Post-
Treatment 
Follow-up 
 
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
ED 
801 
 
Week Relative to 
Study Drug Start  ≤30 (days) 
0 
2 
4 
8 
12 
16 
20 
24 
- 
Approximately 
12 weeks post 
last dose 
 
Visit Interval 
Tolerance (Days) 
 
– 
±3 
±3 
±5 
±5 
±5 
±5 
±5 
- 
±7 
 
Visit Detail 
 
 
 
 
 
T 
 
T 
 
 
 
 
Serum pregnancy 
X 
 
 
 
 
 
 
 
 
 
 
Only for WOCBP. Pregnancy tests prior to first 
dose of study intervention for females ≥12 
years of age if menarche reached or if there is 
reason to believe the participant is sexually 
active. Pregnancy test results from baseline 
must be known prior to first dose of study 
intervention. See Section 10.4, Appendix 4. 
Urine pregnancy 
(local) 
 
X 
 
X 
X 
 
X 
 
X 
X 
 
Collect for WOCBP only. Done locally and 
prior to administering study intervention.  
Additional pregnancy tests (beyond those 
required per the SoA) should be performed at 
any time during the trial if a menstrual period is 
missed, there is clinical suspicion of 
pregnancy. See Section 10.4, Appendix 4. 
If required per local regulations and/or 
institutional guidelines, pregnancy testing can 
occur at other times during the study treatment 
period. 
HIV screening 
tests 
X 
 
 
 
 
 
 
 
 
 
 
 
HCV screening 
tests 
X 
 
 
 
 
 
 
 
 
 
 
If anti-HCV is positive, it must be followed by 
a HCV RNA test. See Section 8.2.4.  
HBV screening 
tests 
X 
 
 
 
 
 
 
 
 
 
 
Includes testing for HBsAg, 
HBcAb and HBsAb. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
22 
 
Period I  
Period II 
Period III  
Comments 
Screening 
Baseline 
Treatment Period 
Post-
Treatment 
Follow-up 
 
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
ED 
801 
 
Week Relative to 
Study Drug Start  ≤30 (days) 
0 
2 
4 
8 
12 
16 
20 
24 
- 
Approximately 
12 weeks post 
last dose 
 
Visit Interval 
Tolerance (Days) 
 
– 
±3 
±3 
±5 
±5 
±5 
±5 
±5 
- 
±7 
 
Visit Detail 
 
 
 
 
 
T 
 
T 
 
 
 
 
HBV DNA 
X 
 
 
 
 
 
X 
 
 
X 
X 
If HBsAg is negative and HBcAb is positive at 
screening, further testing for HBV DNA is 
required. See Section 8.2.3.   
IgE 
 
X 
 
X 
 
 
X 
 
X 
X 
 
Collect prior to dosing. 
Exploratory 
Biomarkers 
 
X 
 
X 
 
 
X 
 
X 
X 
 
Collect prior to dosing. 
PK samples 
 
X 
 
X 
 
 
 
 
X 
X 
 
Samples to be collected predose.  
If an immediate or nonimmediate systemic drug 
hypersensitivity reaction occurs in any participant, 
then also collect an additional unscheduled sample 
as detailed in Section 8.4.  
Immunogenicity 
(ADA) samples 
 
X 
 
X 
 
 
 
 
X 
X 
 
Samples to be collected predose. 
If an immediate or nonimmediate systemic drug 
hypersensitivity reaction occurs in any participant 
then also collect an additional unscheduled sample 
as detailed in Section 10.2.1. 
Stored Samples 
Genetics sample 
 
X 
 
 
 
 
 
 
 
 
 
Sample can be obtained at or after the specified 
visit. 
Exploratory 
biomarker 
samples 
 
X 
 
X 
 
 
X 
 
X 
X 
 
Collect predose. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
23 
 
Period I  
Period II 
Period III  
Comments 
Screening 
Baseline 
Treatment Period 
Post-
Treatment 
Follow-up 
 
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
ED 
801 
 
Week Relative to 
Study Drug Start  ≤30 (days) 
0 
2 
4 
8 
12 
16 
20 
24 
- 
Approximately 
12 weeks post 
last dose 
 
Visit Interval 
Tolerance (Days) 
 
– 
±3 
±3 
±5 
±5 
±5 
±5 
±5 
- 
±7 
 
Visit Detail 
 
 
 
 
 
T 
 
T 
 
 
 
 
Registration and Dosing 
Register visit with 
IWRS 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Dispense study 
intervention via 
IWRS 
 
X 
X 
X 
X 
 
X 
 
 
 
 
 
Administer study 
intervention in 
clinic 
 
X 
X 
X 
X 
 
X 
 
 
 
 
Week 0 (Visit 2) and Week 2, dose to be 
administered in the clinic by site.  
Weeks 4, 8, and 16 dosing to be performed in 
clinic administered by site or participant or 
caregiver.  
Dispense study 
intervention to 
participant for at 
home dosing 
 
 
 
X 
X 
 
X 
 
 
 
 
Injections will be administered by participant 
or caregiver at home on Weeks 6, 10, 12, 
and 14. 
Responders at Week 16 who will receive Q4W 
dose will administer study intervention at 
Week 20. 
Inadequate responders at Week 16 who will 
receive Q2W dosing will administer study 
intervention at Weeks 18, 20, and 22. 
Observe 
participant or 
caregiver 
administer study 
intervention 
 
 
 
X 
 
 
 
 
 
 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
24 
 
Period I  
Period II 
Period III  
Comments 
Screening 
Baseline 
Treatment Period 
Post-
Treatment 
Follow-up 
 
Visit Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
ED 
801 
 
Week Relative to 
Study Drug Start  ≤30 (days) 
0 
2 
4 
8 
12 
16 
20 
24 
- 
Approximately 
12 weeks post 
last dose 
 
Visit Interval 
Tolerance (Days) 
 
– 
±3 
±3 
±5 
±5 
±5 
±5 
±5 
- 
±7 
 
Visit Detail 
 
 
 
 
 
T 
 
T 
 
 
 
 
Participant returns 
study intervention 
 
 
 
 
X 
 
X 
 
X 
X 
 
If study intervention was administered at home 
by participant or caregiver, the injection 
supplies should be saved and returned at the 
next on-site visit. 
Assess study 
intervention 
compliance 
 
 
 
 
X 
 
X 
 
X 
 
 
 
Abbreviations: AD = atopic dermatitis; ADA = anti-drug antibody; ADCT = atopic dermatitis control tool; AE = adverse event; AESI = adverse event of special 
interest; BSA = body surface area; cDLQI = Children’s Dermatology Life Quality Index; DLQI = Dermatology Life Quality Index; DNA = deoxyribonucleic 
acid; EASI = Eczema Area and Severity Index; ED = early discontinuation; F-IGA = face-IGA; HBcAb = hepatitis B core antibody; HBsAb = hepatitis B 
surface antibody; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; ICF = 
informed consent form; IgE = immunoglobulin E; IGA = investigator’s global assessment; IWRS = interactive web-response system; mTLSS = Modified 
Total Lesion Symptom Scale; NRS = numeric rating scale; PK = pharmacokinetics; PRO = patient-reported outcome; Q2W = once every 2 weeks; Q4W = 
once every 4 weeks; RNA = ribonucleic acid; SCORAD = SCORing atopic dermatitis; T = Telephone; TCS = topical corticosteroids; WOCBP = women of 
child-bearing potential; WPAI-AD = Work Productivity and Activity Impairment Questionnaire - Atopic Dermatitis.
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
25 
2. 
Introduction  
Lebrikizumab (LY3650150) is a monoclonal antibody based on the immunoglobulin G4 
antibody stabilized by a mutated Fc region. Lebrikizumab binds with high affinity specifically to 
soluble interleukin (IL)-13 and blocks IL-13 signaling through the IL-4 receptor alpha (IL-4R) 
or IL-13 receptor alpha 1 (IL-13R1) pathway, thereby preventing the downstream effects of 
human IL-13 with high potency. Blockade of IL-13 signaling is expected to be of benefit in 
diseases in which IL-13 is a key contributor to the disease pathogenesis. 
2.1. 
Study Rationale  
Atopic dermatitis (AD) is a chronic heterogeneous inflammatory skin disorder caused by skin 
barrier dysfunction and dysregulation of the immune response. Due to the heterogeneous nature 
of the disease, patients have diverse treatment needs. Standard treatment modalities for the 
management of these patients are centered around the use of topical anti-inflammatory 
preparations and skin moisturizers, but patients with moderate-to-severe disease may require 
phototherapy or systemic treatment. Dupilumab, a monoclonal antibody which inhibits the 
signaling of IL-4 and IL-13, was approved for the treatment of patients with moderate-to-severe 
AD. Dupilumab was the first available biologic for patients with chronic moderate-to-severe AD 
for which topical treatment provided inadequate control or was medically inadvisable. A 
proportion of patients that undergo treatment with dupilumab may show a limited or partial 
response or even no response at all to treatment. Other patients may show an initial response to 
treatment but lose response over time. Still others are found to be intolerant or have adverse 
effects to dupilumab. Additionally, in real world practice other patients discontinue treatment 
due to issues such as cost or loss of access (for example, insurance) to the drug. Taken together, 
a significant number of patients do not continue dupilumab treatment over the course of their 
chronic disease. In the pivotal monotherapy dupilumab Phase 3 trials, 36% to 38% of 
participants achieved the primary endpoint of an Investigator’s Global Assessment (IGA) (0,1) 
with a ≥2-point reduction in IGA and 44% to 51% achieved Eczema Area and Severity Index-75 
(EASI-75) data from baseline to Week 16, indicating that a significant proportion of the patients 
did not achieve clinical response. (Simpson et al. 2016).  
 
Therefore, there is an important gap in the clinical care of these patients for whom novel 
therapies are necessary to fulfill this unmet medical need. 
In patients with AD, IL-13, a central pathogenic mediator in the disease, is overexpressed, 
driving multiple aspects of AD pathophysiology by promoting T-helper type 2 (Th2) cell 
inflammation and resulting in skin barrier dysfunction, itch, infection, and lichenification. 
Dupilumab is a monoclonal antibody that binds to the shared α chain subunit of the IL-4 and 
IL-13 receptors, thereby inhibiting the signaling of IL-4 and IL-13. IL-4 is the driver of the 
differentiation of naïve CD4+ T cells into T-helper Type 2 (Th2) cells and a negative regulator of 
T-helper Type 1 (Th1) and T-helper Type 17 (Th17) pathways. Blockade of Th2 differentiation 
by dupilumab might cause a dysregulation in the T-helper balance, providing a mechanistic 
explanation for the development of Th1 or Th17 diseases in dupilumab-treated patients (Tracey 
et al. 2018; Safa and Paumier 2019; Varma and Levitt 2020; Heibel et al. 2021).  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
26 
IL-13 is considered a key cytokine in AD (Tsoi 2019 and reviewed in Bieber et al. 2020). 
Lebrikizumab specifically blocks IL-13 and therefore also IL-13 signaling via the IL-4Rα - IL-
13Rα1 heterodimer complex. Important differences between dupilumab and lebrikizumab 
include receptor vs cytokine targets, respectively, and known strong binding affinity and lack of 
effect on IL-4 signaling with lebrikizumab. In addition, IL-13 endogenous regulation remains 
intact when bound to lebrikizumab, because lebrikizumab does not inhibit the binding of IL-13 
to the decoy receptor, IL-13Rα2. 
Lebrikizumab Phase 2 and 3 data demonstrated its efficacy in AD. Leveraging data from both 
Phase 2b monotherapy and Phase 3 TCS combination therapy in which dupilumab experienced 
patients were included, lebrikizumab showed consistent treatment effects in both dupilumab 
naïve and dupilumab experienced participants. Nevertheless, those trials were not designed to 
evaluate this specific patient population. 
This trial aims to specifically evaluate the safety and efficacy of lebrikizumab in patients 
previously treated with dupilumab. Biologics experienced patients requiring a second biological 
therapy constitute an important and constantly expanding clinical conundrum in immune 
mediated diseases. The results from this trial will provide insights into the clinical response in 
this difficult to treat population and its comparison with the response in dupilumab naïve 
population studied in the pivotal Phase 3 programs. 
2.2. 
Background  
Atopic dermatitis is a complex heterogeneous disease that is determined by genetic, 
environmental, and immunologic factors (Werfel et al. 2016; Simon et al. 2019). Genetic studies 
of AD (Bieber 2012; Auriemma et al. 2013; Weidinger et al. 2018) have shown that genes 
encoding for cytokines involved in the regulation of the immune system (IL-4, IL-5, and IL-13) 
are strongly associated with the development of AD (Novak et al. 2002; He et al. 2003; 
Hummelshoj et al. 2003). In addition, variants of genes that encode for proteins involved in skin 
barrier function such as filaggrin (FLG) and loricrin (LOR) are also associated with AD (Van 
Bever and Llanora 2011). Since FLG plays a central role in skin barrier integrity, loss of function 
mutations of the FLG gene are considered a major contributor to the development of early 
childhood AD (Bieber 2008; Tanei 2009; Bieber 2012; Flohr and Irvine 2013). 
Reduced epithelial barrier function, which represents the first line of protection against the 
environment, is thought to lead to sensitization to environmental allergens, associated with 
elevated immunoglobulin E (present in about 50% to 80% of all patients with AD), particularly 
in children (Werfel et al. 2016) and consistent with the presence in the skin of Type 2 cytokines 
(IL-4, IL-5, IL-9, IL-13, IL-25, IL-31, IL-33, and thymic stromal lymphopoietin) and 
inflammation. Type 2 cytokines increase epidermal thickening, sensitization, inflammation, 
pruritus and decrease the expression of antimicrobial peptides and the barrier proteins FLG, 
LOR, and involucrin (Caretti et al. 2015). IL-13 in particular can reduce epithelial integrity and 
barrier function through downregulation of FLG, LOR, and involucrin (Kim et al. 2008) and can 
act on keratinocytes in the skin to downregulate their differentiation (Howell et al. 2008). IL-13 
also induces T-cell chemoattractants that mediate T-cell infiltration into AD lesions (Purwar et 
al. 2006) and may also induce IL-5 expression and eosinophil infiltration through the induction 
of eosinophil chemoattractants (Esche et al. 2004). Increased expression of IL-13 has 
consistently been reported in AD skin lesions and is associated with disease severity (Hamid et 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
27 
al. 1996; Jeong et al. 2003; Tazawa et al. 2004; La Grutta et al. 2005; Neis et al. 2006; Choy et 
al. 2012; Suárez-Fariñas et al. 2013). The elevation of IL-13 expression in the nonlesional skin of 
patients with AD supports the evaluation of anti-IL-13 therapies in patients with AD (Suárez-
Fariñas et al. 2011). Itch is one of the predominant symptoms in AD and studies have shown 
IL-13 acts as a potent neuronal enhancer to itch signals, resulting in amplification of 
histaminergic and non-histaminergic itch in human sensory neurons and driving the persistence 
of heightened chronic itch, as seen in AD. Miron et al. recently published results from human 
cadaveric neurons stimulated with IL-13, in the absence or presence of lebrikizumab. 
Lebrikizumab blocked the neuronal response to multiple itch stimuli and may be an effective 
treatment for chronic itch (Miron et al. 2022). 
Epidemiology of Atopic Dermatitis 
The one-year prevalence of AD among adults is estimated between 2% to 7% in the US, Europe, 
and Japan (Saeki et al. 2006; Harrop et al. 2007; Diepgen et al. 2016; Sacotte and Silverberg 
2018). Approximately 30% of adult patients with AD have moderate-to-severe disease (Bieber 
and Straeter 2015).  
Clinical Manifestations 
Clinically, AD is characterized by erythematous and sometimes violaceous to brown macules, 
papules and/or plaques with scale, lichenification, and intense pruritus (Bieber 2008), which, 
along with the distribution, chronicity, and history of skin lesions, form the basis for making a 
diagnosis of AD. Flares are frequently triggered by exposure to environmental factors, irritants 
and allergens (Bieber and Novak 2009). Several clinical patterns, with differing distributions of 
skin lesions in distinct age groups and skin types, have been noted (Weidinger and Novak 2016; 
Weidinger et al. 2018). 
Classic AD lesions, which are most common in adolescents and adults, present on the antecubital 
and popliteal fossae. Lesions frequently localize to the face and neck, and a considerable portion 
of patients (around 30%) develop atopic hand dermatitis, which may interfere with workplace 
activities. Lesions may have associated lichenification and crusting, and patients with AD may 
be at increased risk for bacterial cutaneous superinfection.  
Quality of Life (QoL) 
Patients with AD have a high disease burden, and their quality of life (QoL) is significantly 
affected. In one study, AD was shown to have a greater negative effect on patient mental health 
than diabetes and hypertension (Zuberbier et al. 2006). Adolescent patients with moderate-to-
severe AD have a higher prevalence of social dysfunction and sleep impairment, which are 
directly related to the severity of the disease (Williams et al. 2008). Depression, anxiety, and 
social dysfunction not only affect adolescent patients with AD but also affect their caregivers 
(Zuberbier et al. 2006). Compared with patients with psoriasis, another common and debilitating 
skin disease, adult and adolescent patients with AD have lower physical vitality, social 
functioning, role-emotional, and mental health scores (Kiebert et al. 2002; Langan et al. 2020; 
Eckert et al. 2018, 2019; Vakharia et al. 2017; Silverberg et al. 2018, 2019). 
Treatment for Atopic Dermatitis 
The therapeutic approach to AD consists primarily of trigger avoidance, skin hydration, and use 
of moisturizers and anti-inflammatory therapies consisting predominantly of topical 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
28 
corticosteroids (TCS). In many patients, treatment with TCS provides some measure of 
symptomatic relief but does not always adequately control the disease. In patients not responding 
adequately to TCS, the topical TCI step-up options include phototherapy and systemic 
immunosuppressive agents such as oral or injected corticosteroids, cyclosporine, azathioprine, 
methotrexate, and mycophenolate mofetil. In 2017, dupilumab, a monoclonal antibody that binds 
specifically to the shared α chain subunit of the IL-4 and IL-13 receptors, thereby inhibiting the 
signaling of IL-4 and IL-13, was approved for the treatment of adult patients with moderate-to-
severe AD (Seegräber et al. 2018; Gooderham et al. 2018). In 2 randomized clinical trials, SOLO 
1 and SOLO 2, dupilumab demonstrated better results than placebo over 16 weeks of treatment 
across multiple outcome measures that reflected objective signs of AD, subjective symptoms (for 
example, pruritus), important aspects of mental health (that is, anxiety and depression), and QoL. 
In these trials, 36% to 38% of participants achieved the primary endpoint of an IGA (0,1) with a 
≥2-point reduction in IGA and 44% to 51% achieved EASI-75 data from baseline to Week 16, 
indicating that a significant proportion of the patients did not achieve clinical response. (Simpson 
et al. 2016).  
In 2021 an IL-13 antagonist, tralokinumab, was approved for adults with moderate-to-severe 
AD. Also in 2021, the topical Janus kinase (JAK) inhibitor ruxolitinib was approved for the 
treatment of mild to moderate AD in adults and children age 12 and older, and in 2022 the oral 
JAK inhibitors, upadacitinib, and abrocitinib, were approved for treatment of moderate-to-severe 
AD in adults and children age 12 and older and adults, respectively.  
Despite this availability of new medications for the treatment of moderate-to-severe AD, 
dupilumab was the first available biologic for the treatment of moderate-to-severe AD, and may 
continue to be widely used. However, dupilumab is not effective or acceptable for every patient 
and discontinuation of dupilumab therapy is known to occur; there is a need to fill this clinical 
care gap to improve the lives of patients. (Marniquet et al. 2022 and Faiz et al. 2019). There are 
limited data on the reasons for dupilumab discontinuation. A multicenter study confirmed that 
15.5% (150/968) of patients discontinued dupilumab over a 3.5-year period. (Marniquet et al. 
2022) Reasons for discontinuation included side effects (40.7%), lack of efficacy (14.7%), both 
side effects and lack of efficacy (15.3%), planned pregnancy (8%), disease remission (4%) and 
“other” (17.3%). Side effects included ophthalmological (24%), facial erythema (8%), diffuse 
AD exacerbation (6.7%), eosinophilia (4%), alopecia areata (2.7%), psoriasis (2.7%), headache 
(0.7%), injection site reaction (0.7%) and “other” (5.3%). Another French study confirmed that 
of 241 patients taking dupilumab for moderate-to-severe AD from 29 centers, 79.7% remained 
on the medication at 6 months. (Faiz et al. 2019). Of the 42 patients for which data were 
available, reasons for discontinuation included adverse event (AE) (11.3%), inefficiency (3.8%), 
patient wish (3.4%), pregnancy (<1%), surgery (1.7%) and improvement of AD (<1%). AEs 
included ophthalmologic (4.2%), eosinophilia (2.1%) and “other” (5%). 
Lebrikizumab is an IL-13 inhibitor which has been shown to be highly effective and safe for the 
treatment of adults and adolescents with moderate-to-severe AD in Phase 2 and 3 clinical trials. 
Lebrikizumab is a potential treatment candidate to fill the clinical care gap for patients with 
moderate-to-severe AD who discontinued dupilumab because of lack of efficacy, loss of effect, 
intolerance or AEs, or for other reasons. 
A detailed description of the chemistry, pharmacology, efficacy, and safety of lebrikizumab is 
provided in the Investigator’s Brochure (IB). 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
29 
2.3. 
Benefit/Risk Assessment  
As of 22 September 2021, cumulatively, approximately 7795 participants have been enrolled into 
the lebrikizumab clinical program, of which approximately 6374 participants have received 
lebrikizumab. Lebrikizumab has been given to 525 healthy people and 5849 study participants 
with AD, asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and 
Hodgkin’s lymphoma. Approximately 2051 have been treated with lebrikizumab in the Phase 2 
and Phase 3 AD programs.  
The use of lebrikizumab for the treatment of AD is supported by numerous preclinical studies 
demonstrating that AD is characterized by the increased expression of IL-13 in skin. Moreover, 
Phase 2 efficacy studies of lebrikizumab (J2T-DM-KGAG/TREBLE, J2T-DM-KGAH/ARBAN 
and J2T-DM-KGAF/DRM06-AD01) demonstrated significant clinical benefit in participants 
with AD. The top-line results from the 2 monotherapy Phase 3 studies of lebrikizumab 
(ADvocate 1 and ADvocate 2) achieved the primary and all key secondary endpoints, including 
skin clearance and itch improvement at Week 16. A third completed pivotal Phase 3 trial of 
lebrikizumab in combination with topical steroids (ADhere) also met all primary and key 
secondary endpoints at Week 16. 
Potential risks associated with lebrikizumab include conjunctivitis, eosinophilia and eosinophilic 
conditions, herpes zoster and herpes infections (Section 8.3.3), anaphylaxis and hypersensitivity 
reactions (Section 8.3.4), and other infections (Section 8.3.3.1).  
In the initial 16-week placebo-controlled period of ADvocate 1 and ADvocate 2, the incidence of 
treatment-emergent AEs and serious AEs among patients treated with lebrikizumab was 
consistent with that of the previous Phase 2 lebrikizumab studies in AD. The most common AEs 
included conjunctivitis, nasopharyngitis, and headache for lebrikizumab-treated patients. 
Discontinuations due to AEs were similar in the lebrikizumab group (1.4%) compared to placebo 
(1.7%). The safety profile of lebrikizumab observed in the 3 Phase 3 studies was found to be 
consistent with prior lebrikizumab studies in AD.  
No immediate systemic hypersensitivity or anaphylaxis events were reported in the Phase 3 trials 
ADvocate 1, ADvocate 2, and ADhere. No parasitic or opportunistic infections were reported. 
No eosinophilic related events were reported. 
Participants will be monitored for these events and will be provided appropriate intervention or 
supportive care as needed. If events occur additional testing and data collection may be required 
as described further in Sections 8.3.3, 8.3.4, and 8.3.5.  
Additionally, to monitor participant safety during the course of the study the sponsor will 
conduct trial-level safety reviews at periodic intervals throughout the study. 
In summary, in the context of the cumulative knowledge for lebrikizumab, the benefit/risk 
balance is assessed to be acceptable for testing in this Phase 3b study. 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of lebrikizumab may be found in the IB or Development Safety Update Report. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
30 
3. 
Objectives, Endpoints, and Estimands  
Objectives 
Endpoints 
Primary 
 
 
To evaluate efficacy of 
lebrikizumab 250 mg Q2W on 
reducing signs and symptoms 
of AD at Week 16 in 
participants with moderate-to-
severe AD previously treated 
with dupilumab  
 
Percentage of participants achieving EASI-
75 at Week 16  
Secondary 
 
 
To evaluate the efficacy of 
lebrikizumab on reducing signs 
and symptoms of AD at Week 
16 and Week 24 in participants 
with moderate-to-severe AD 
previously treated with 
dupilumab 
 
Percentage of participants achieving EASI-
75 at Week 24 
 
Percentage of participants with an IGA 
score of 0 or 1 and a reduction ≥2 points 
from baseline to Weeks 16 and 24  
 
Percentage change EASI from baseline to 
Weeks 16 and 24 
 
Change in EASI from baseline to Weeks 16 
and 24 
 
Percentage of participant achieving EASI-
90 from baseline to Weeks 16 and 24 
 
Percentage of participants with a Pruritus 
NRS of ≥4 points at baseline who achieve at 
least 4-point reduction at Weeks 16 and 24 
 
Percentage of participants with a Pruritus 
NRS of ≥3 points at baseline who achieve at 
least 3-point reduction at Weeks 16 and 24 
 
Percentage change in Pruritus NRS score 
from baseline to Weeks 16 and 24 
 
Percentage of participants with a Sleep-Loss 
Scale of ≥2 points at baseline who achieve 
at least 2-point reduction at Weeks 16 and 
24  
 
Change in Sleep-Loss Scale from baseline 
at Weeks 16 and 24 
 
Percentage of participants with a Skin Pain 
NRS of ≥4 points at baseline who achieve a 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
31 
 
4-point reduction from baseline at Weeks 
16 and 24  
 
Change in Skin Pain NRS from baseline to 
Weeks 16 and 24  
 
Change in DLQI from baseline to Weeks 16 
and 24 for participants ≥16 years of age at 
baseline 
 
Percentage of participants with at least 
4 point at baseline achieving ≥4-point 
improvement in DLQI from baseline at 
Weeks 16 and 24 for participants ≥16 years 
of age at baseline 
 
Change in cDLQI from baseline to Weeks 
16 and 24 for participants <16 years of age 
at baseline 
 
Percentage change in SCORAD from 
baseline to Weeks 16 and 24  
Exploratory  
 
To evaluate the efficacy of lebrikizumab in 
participants with moderate-to-severe AD 
previously treated with dupilumab 
 
Percentage change from baseline in mTLSS 
(hands) at Weeks 16 and 24 
 
Percentage change in ADCT from baseline 
by visit 
 
Proportion of TCS/TCI-free days from 
baseline to Weeks 16 and 24 
 
Using WPAI-AD by visit, change in 
baseline in: 
 
absenteeism, in those who are 
currently employed (working for 
pay)  
 
presenteeism, in those who are 
currently employed (working for 
pay),  
 
overall work impairment, in those 
who are currently employed 
(working for pay),  
 
impairment in activities (all 
participants) 
 
Percentage of participants with an F-IGA 
score of 0 or 1 and a reduction ≥2 points 
from baseline by visit in those who have 
baseline at least 2 points  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
32 
 
Percentage of participants achieving EASI-
75 by visit 
 
Percentage of participants with an IGA 
score of 0 or 1 and a reduction ≥2 points 
from baseline by visit 
 
Percentage change in EASI by visit 
 
 Change in EASI by visit  
 
Percentage of participants achieving EASI-
90 by visit 
 
Percentage of participants with a Pruritus 
NRS of ≥4 points at baseline who achieve a 
4-point reduction by visit 
 
Percentage of participants with a Pruritus   
NRS of ≥3 points at baseline who achieve a 
3-point reduction by visit 
 
Percentage change in Pruritus NRS score 
from baseline to Weeks 16 and 24 
 
Percentage of participants with a Sleep-Loss 
Scale of ≥2 points at baseline who achieve a 
2-point reduction by visit 
 
Change in Sleep-Loss Scale from baseline 
by visit 
 
Percentage of participants with a Skin Pain 
NRS of ≥4 points at baseline who achieve a 
4-point reduction from baseline by visit 
 
Distribution of responses for participant 
satisfaction (1 question) at Weeks 16 and 24  
To discern responder variability within the study 
and to track response variability to lebrikizumab 
Changes from baseline in serum proteins related to AD 
pathogenesis; Refer to Section 10.2, Appendix 2 
Abbreviations: AD = atopic dermatitis; ADCT = atopic dermatitis control tool; cDLQI = Children’s Dermatology 
Life Quality Index; DLQI = Dermatology Life Quality Index; EASI = Eczema Area and Severity Index; EASI-75 = 
≥75% reduction from baseline in EASI; EASI-90 = ≥90% reduction from baseline in EASI; F-IGA = face - 
investigator’s global assessment; IGA = investigator’s global assessment; mTLSS = Modified Total Lesion 
Symptom Scale; NRS = numeric rating scale; Q2W = once every 2 weeks; SCORAD = SCORing atopic dermatitis; 
TCI = topical calcineurin inhibitors, TCS = topical corticosteroid; WPAI-AD = work productivity and activity 
impairment questionnaire–atopic dermatitis. 
NOTE: Endpoints in the table above collected by visit references data collection visits.  
Primary estimand 
The primary clinical question of interest is: What is the intervention effect in percentage of 
participants achieving EASI-75 after 16 weeks of lebrikizumab 250 mg once every 2 weeks 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
33 
(Q2W) intervention in participants with moderate-to-severe AD, who have been previously 
treated with dupilumab and who remain on study treatment until Week 16. 
The estimand is described by the following attributes: 
Population: participants with moderate-to-severe AD who have been previously treated with 
dupilumab and who remain on study treatment until Week 16.  
Further details can be found in Section 5. 
Endpoint: Do participants achieve at least 75% improvement from baseline to Week 16 in EASI. 
Intercurrent events: There are no intercurrent events for this population since participants who 
initiate rescue medication are discontinued from the study and hence study treatment. Therefore, 
participants who stay on study treatment through Week 16 will not have an intercurrent event 
such as initiating rescue medication or permanently discontinuing treatment. Further details on 
study interventions and concomitant medications, including rescue treatments, can be found in 
Section 6.8.1. 
Population-level summary: Percentage of participants achieving EASI-75 response at Week 16. 
 
Secondary estimand(s) 
There is no secondary estimand planned at this stage, however, additional estimand(s) might be 
specified in the SAP.  
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
34 
4. 
Study Design  
4.1. 
Overall Design  
Study J2T-MC-KGBO (KGBO) is an open-label, phase 3b study, which is 24 weeks in treatment 
duration. The study is designed to evaluate the safety and efficacy of lebrikizumab in male and 
female adult and adolescent participants with moderate-to-severe AD who have been previously 
treated with dupilumab. 
Study Periods 
This trial has 3 study periods: 
 Screening (Visit 1: ≤30 days prior to baseline) 
 Treatment (Visits 2-9: 24 weeks) 
 Safety follow-up (Visit 801: approximately 12 weeks after last treatment) 
Visit Types 
Study visits at Week 12 (Visit 6) and Week 20 (Visit 8) will be performed virtually, that is, via 
telephone or telemedicine tools. 
All other visits will be conducted at the clinical trial site. 
Dosing 
During the 24-week Treatment Period, approximately 120 participants will receive treatment: 
 500 mg subcutaneous (SC) once every 2 weeks (Q2W) loading dose at baseline and 
Week 2, followed by 250 mg SC Q2W until Week 16. 
 Responders, defined as achieving IGA (0,1) or EASI-75 at Week 16, will receive 250 mg 
SC Q4W. 
 Inadequate responders at Week 16 will continue to receive 250 mg SC Q2W.  
The study population is described in Section 5. 
The efficacy and safety assessments are described in Sections 8.1 and 8.2 respectively. 
4.2. 
Scientific Rationale for Study Design  
The top-line results from 2 randomized controlled monotherapy phase 3 studies of lebrikizumab 
(ADvocate 1 and ADvocate 2) and a third completed phase 3 trial of lebrikizumab in 
combination with topical steroids (ADhere) demonstrated positive risk benefit in adult and 
adolescent patients with moderate-to-severe AD at Week 16. The safety profile of these 3 studies 
was consistent with prior AD lebrikizumab studies and demonstrated favorable benefit: risk 
profile in moderate-to-severe AD patients. Additional detailed discussion of the lebrikizumab 
studies (preclinical and clinical) is provided in the lebrikizumab IB.  
Since randomized controlled data is already available, this study will be conducted as an open 
label study to mimic the real-world patient experience. Week 16 data will be used as the primary 
endpoint in this study and the safety and efficacy until Week 24 will also be evaluated to 
understand the durability of effect post Week 16. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
35 
The open-label trial design is appropriate as no direct comparison of therapeutic treatments will 
be made. Rather, this study will determine the efficacy and safety of lebrikizumab treatment in a 
patient population that previously discontinued use of dupilumab, the first targeted therapy 
available for treatment of AD. The participants recruited into this study have taken dupilumab 
for treatment of moderate-to-severe AD; it is possible that many of these patients may have more 
difficult to treat AD and they may therefore need adjunct topical therapy to control their 
symptoms. To make the study closer to a real world-setting and also to avoid participant 
discomfort, use of mild/moderate potency topical steroids/topical calcineurin inhibitors 
(TCI)/topical phosphodiesterase-4 (PDE4) inhibitors will be allowed during the study. 
4.2.1. Participant Input into Design  
Throughout this protocol, the term “participant” is used to indicate an individual who participates 
in a clinical trial, either as a recipient of an investigational drug or as a control. This usage 
reflects preferences indicated by patient advocates to more accurately reflect the role of people 
who take part in clinical trials. 
No participant input was provided for this study design. 
4.3. 
Justification for Dose  
The lebrikizumab dosing regimen of 500 mg loading dose at baseline and Week 2, followed by 
250 mg Q2W up to, and including Week 16, was selected based on an evaluation of safety, 
efficacy, and PK data from the Phase 2 and Phase 3 lebrikizumab trials. 
In the lebrikizumab Phase 3 programs, IGA 0/1 or EASI-75 responders at Week 16 were 
re-randomized to Q4W, Q2W, or withdrawal arms, and inadequate responders were assigned to 
Q2W dosing. These Phase 3 results have demonstrated that lebrikizumab Q4W and Q2W are 
similar in efficacy, and that inadequate responders benefited from continued Q2W dosing. The 
dose regimens in the present study post Week 16 are based on the results of these Phase 3 
studies. 
Adolescent Participants 
In this phase 3b study, adolescent participants (≥12 to <18 years weighing ≥40 kg) will be 
included and will receive the same doses of lebrikizumab as adult participants. PK analyses of 
SC doses of lebrikizumab reveal similar kinetics for adults and adolescents ≥12 to <18 years. 
Although maximal exposures are slightly higher for any given dose in adolescent participants, 
due to their lower weight ranges, the safety profile observed in adolescent participants is 
comparable to the safety profile observed in adults. Therefore, a similar exposure-response 
relationship is expected in this age group compared to adults based on partial extrapolation and 
propose to include adolescent participants in this study. It is expected that the adolescent AD 
participants ≥40 kg will demonstrate a similar overall safety profile as adult participants. 
4.4. 
End of Study Definition  
A participant is considered to have completed the study if the participant has completed all 
periods of the study including the last scheduled procedure shown in the SoA. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
36 
The end of the study is defined as the date of the last visit of the last participant in the study or 
last scheduled procedure shown in the Schedule of Activities (SoA) for the last participant in the 
study. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
37 
5. 
Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1. 
Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply: 
Age 
1. Participant must be ≥12 years of age inclusive at the time of signing the informed 
consent/assent.  
Type of Participant and Disease Characteristics 
2. All participants must have prior treatment with dupilumab meeting one of the following 
conditions: 
 Participants who stopped dupilumab treatment due to non-response, partial 
response, loss of efficacy must have been previously treated with dupilumab (at 
labeled dose level) for at least 4 months. 
 Participants who stopped dupilumab treatment due to intolerance or AEs to the 
drug may enter the study with no required prior length of dupilumab treatment.  
 Participants who stopped dupilumab treatment due to cost or loss of access to 
dupilumab (for example, insurance coverage) may enter the study with no 
required prior length of dupilumab treatment.  
3. Participants who have chronic AD (according to American Academy of Dermatology 
Consensus Criteria; Eichenfield et al. 2014) that has been present for ≥1 year before 
screening visit.  
4. Have EASI ≥16 at the baseline visit.  
5. Have IGA score ≥3 (Scale of 0 to 4) at the baseline visit.  
6. Have ≥10% body surface area (BSA) of AD involvement at the baseline visit 
7. Have a history of inadequate response to treatment with topical medications; or 
determination that topical treatments are otherwise medically inadvisable. 
Weight 
8.  Adolescents body weight must be ≥40 kg at baseline. 
Sex and Contraceptive/ Barrier Requirements 
9. Male and/or female  
a. Male participants are not required to use any contraception except in compliance 
with specific local government study requirements. 
b. Female participants of child-bearing potential: must agree to remain abstinent 
(refrain from heterosexual intercourse) or use a highly effective contraceptive 
method during the treatment period and for at least 18 weeks after the last dose of 
study drug. Women of non-child-bearing potential (non-WOCBP) may participate 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
38 
without any contraception requirements. For definitions of women of child-
bearing potential (WOCBP) and non-WOCBP, see Section 10.4, Appendix 4. 
Contraceptive use by participants should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies. For the contraception 
requirements of this protocol, see Section 10.4, Appendix 4. 
Informed Consent 
10. Informed consent/assent 
a. For adult participants: capable of giving signed informed consent as described in 
Section 10.1, Appendix 1, which includes compliance with the requirements and 
restrictions listed in the informed consent form (ICF) and in this protocol. 
b. For adolescent participants: a parent or legal guardian must be able to read, 
understand, and give documented informed consent for a child to participate in 
this study as described in Section 10.1.3, which includes compliance with the 
requirements and restrictions listed in the ICF and in this protocol.  
NOTE: Adolescents reaching the age of maturity while on study must provide 
consent to continue participation in the study. 
Other Inclusions 
11. Are willing and able to comply with all clinic visits and study-related procedures and 
questionnaires. 
5.2. 
Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply: 
Medical Conditions 
12. History of human immunodeficiency virus (HIV) infection or positive HIV serology at 
screening. 
13. Have a current infection or chronic infection with hepatitis B virus (HBV) at screening 
(that is, positive for hepatitis B surface antigen and/or polymerase chain reaction positive 
for HBV DNA Section 8.2.3). 
14. Have a current infection with hepatitis C virus (HCV) at screening (that is, positive for 
HCV RNA Section 8.2.4). 
15. Have an uncontrolled chronic disease that might require multiple intermittent uses of oral 
corticosteroids at screening, as defined by the investigator. 
16. Have uncontrolled asthma that 
a. might require bursts of oral or systemic corticosteroids, or 
b. required the following due to ≥1 exacerbations within 12 months before baseline 
i. systemic (oral and/or parenteral) corticosteroid treatment, or 
ii. hospitalization for >24 hours. 
17. Have known liver cirrhosis and/or chronic hepatitis of any etiology. 
18. History of malignancy, including mycosis fungoides or cutaneous T-cell lymphoma, 
within 5 years before the screening, except completely treated in situ carcinoma of the 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
39 
cervix of completely treated and resolved non-metastatic squamous or basal cell 
carcinoma of the skin with no evidence of recurrence in the past 12 weeks. 
19. Are diagnosed with active endoparasitic infections or at high risk of these infections. 
20. Have a known or suspected history of immunosuppression, including history of invasive 
opportunistic infections (for example, tuberculosis, histoplasmosis, listeriosis, 
coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution; or 
unusually frequent, recurrent, or prolonged infections, per the investigator’s judgment. 
21. Have presence of skin comorbidities that may interfere with study assessments. 
22. Have a severe concomitant illness(es) that in the investigator’s judgment would adversely 
affect the participant’s participation in the study.  
23. Have any other medical or psychological condition that in the opinion of the investigator 
may suggest a new and/or insufficiently understood disease, may present an unreasonable 
risk to the study participant because of their participation in this clinical trial, may make 
participant’s participation unreliable, or may interfere with study assessments. 
24. Have had any of the following types of infection within 3 months of screening or develop 
any of these infections during screening 
a. Serious (requiring hospitalization, and/or intravenous or equivalent oral antibiotic 
treatment) 
b. Opportunistic (as defined in Winthrop et al. 2015, see Section 10.9, Appendix 9) 
NOTE: Herpes zoster is considered active and ongoing until all vesicles are dry 
and crusted over 
c. Chronic (duration of symptoms, signs, and/or treatment of 6 weeks or longer) 
d. Recurring (including, but not limited to recurring cellulitis, chronic osteomyelitis) 
 
NOTE: Participants with only recurrent, mild and uncomplicated orolabial and/or 
genital herpes may be discussed with the sponsor’s medical monitor to determine 
whether the participants meet this exclusion criterion. 
25. Have an active or acute infection requiring treatment with systemic antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit 
(baseline; Visit 2), or superficial skin infections within 1 week before the baseline visit.  
NOTE:  
Participants may be rescreened after infections resolves.  
Participants who have an upper respiratory infection, a vaginal candida infection, 
or an oral candida infection and who are being treated only symptomatically and 
not requiring systemic anti-infectives may be considered for enrollment if other 
study eligibility criteria are met. Enrollment of participants with other 
uncomplicated local infections should be discussed with the sponsor’s designated 
medical monitor. 
Prior/Concomitant Therapy 
26. Dupilumab treatment within 4 weeks prior to the baseline visit. 
27. Prior treatment with tralokinumab. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
40 
28. Treatment with topical agents (corticosteroids, calcineurin inhibitors, JAK inhibitors, or 
phosphodiesterase-4 inhibitors) within 2 weeks prior to baseline visit. 
29. Treatment with any of the following agents known to affect AD within 4 weeks prior to 
the baseline visit: 
a. systemic immunosuppressive/immunomodulating drugs (for example, systemic 
corticosteroids, cyclosporine, mycophenolate mofetil, IFN-gamma, azathioprine, 
methotrexate, and other immunosuppressants);  
b. small molecules (for example, JAK inhibitors); 
c. phototherapy and photochemotherapy for AD. 
30. Have regularly used (more than 2 visits per week) a tanning booth or parlor within 4 
weeks of the screening visit (Visit 1). 
31. Are currently receiving build-up dosing of allergen immunotherapy (allergy shots).  
32. Treatment with B cell-depleting biologics, including rituximab, within 6 months prior to 
the baseline visit. 
33. Use of prescription moisturizers within 7 days of the baseline visit. 
34. Have received a Bacillus Calmette-Guerin vaccination or treatment within less than 4 
weeks before the baseline visit or intend to receive Bacillus Calmette-Guerin vaccination 
or treatment during the study. 
35. Have received any live attenuated vaccine within less than 4 weeks of the baseline visit 
or intend to receive a live attenuated vaccine during the study, or within 4 weeks after 
receiving the last dose of study intervention. 
NOTE: The following are not considered live vaccines: RNA vaccines, vaccines with 
inactive viral elements, and/or non-replicating viral vector vaccines. 
36. Use of cannabis or cannabinoids for the treatment of pruritus, pain and/or AD. 
Diagnostic Assessments 
37. In the opinion of the investigator, have clinically significant laboratory results from the 
chemistry or hematology tests obtained at the screening visit (Visit 1).  
Prior/Concurrent Clinical Study Experience 
38. Are currently enrolled in any other clinical study involving an investigational product or 
any other type of medical research judged not to be scientifically or medically compatible 
with this study. 
39. Treatment with an investigational drug within 8 weeks or within 5 half-lives (if known), 
whichever is longer prior to the baseline visit. 
40. Have received a dose of lebrikizumab in any prior lebrikizumab clinical study. 
Other Exclusions 
41. Are Lilly employees (or are employees of any third-party involved in study who require 
exclusion of their employees). 
42. Are investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
41 
43. Are pregnant or breastfeeding or are planning to become pregnant or to breastfeed during 
the study. 
44. Have a known hypersensitivity to any component of lebrikizumab. 
45. Participant or caregiver who is unwilling to administer SC injections of study medication. 
5.3. 
Lifestyle Considerations  
Not applicable.  
5.4. 
Screen Failures  
A screen failure occurs when a participant who consents to participate in the clinical study is not 
subsequently enrolled in the study. A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants to meet the Consolidated Standards of 
Reporting Trials publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, screen failure details, eligibility criteria, and any 
serious adverse event (SAE). 
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened as defined below. Rescreened participants should be assigned a new participant 
number for every screening or rescreening event.  
5.4.1. 
Rescreening for Individuals Who Failed Screening  
Informed consent for rescreenings 
Individuals who are to be rescreened must first sign a new ICF/assent form as applicable 
(Section 10.1, Appendix 1, Section 10.1.3). Such individuals will be assigned a new participant 
number. 
Rescreening after failure to meet study entry criteria 
An individual who does not meet the criteria for participation in this study for any reason may be 
rescreened one time.  
When rescreening, all of the screening tests and procedures should be repeated.  
5.5. 
Criteria for Temporarily Delaying Enrollment/Administration of 
Study Intervention of a Participant  
Not applicable. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
42 
6. 
Study Intervention(s) and Concomitant Therapy   
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to/used by a study participant 
according to the study protocol. 
6.1. 
Study Intervention(s) Administered  
Lebrikizumab drug product is provided as sterile liquids and contain no preservatives.  
Intervention Name 
Lebrikizumab 
Dose Formulation 
250 mg (125 mg/mL), 2 mL Solution 
Dosage Level 
Loading Dose: 
Week 0: 500 mg (2 injections of 250 mg) 
Week 2: 500 mg (2 injections of 250 mg) 
 
Post-loading Dose: 
Weeks 4-16: 250 mg SC Q2W (1 injection of 250 mg) 
Responders at Week 16: 250 mg SC Q4W (1 injection of 250 mg) at W20 
Inadequate responders at Week 16: 250 mg SC Q2W (1 injection of 250 mg) 
at W18, W20, and W22 
Route of Administration 
SC 
Abbreviations: mg = milligram; mL = milliliter; SC = subcutaneously; Q2W = every 2 weeks; Q4W = once every 4 
weeks; W = week. 
 
6.1.1. 
Medical Devices  
1. Lebrikizumab will be administered using a sterile prefilled syringe with needle safety 
device. Each prefilled syringe is intended for a single 2 mL dose (250 mg) administered 
subcutaneously device.  
2. Instructions on how to use the device will be provided. 
3. All Product Complaints (PCs) (including malfunction, use error and inadequate labelling) 
shall be documented and reported by the investigator throughout the clinical investigation 
(see Section 8.3) and appropriately managed by the sponsor. 
6.2. 
Preparation, Handling, Storage, and Accountability  
1. The investigator or designee must confirm appropriate storage conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention. 
2. Only participants enrolled in the study may receive study intervention. Only authorized 
study personnel may supply, prepare, or administer study intervention, except for study 
intervention intended to be administered by the participant or caregiver. All study 
intervention must be stored in a secure, environmentally controlled, and monitored 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
43 
(manual or automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized study personnel. 
3. The investigator or authorized study personnel are responsible for study intervention 
accountability, reconciliation, and record maintenance, that is, receipt, reconciliation, and 
final disposition records. 
4. Further guidance and information for the final disposition of unused study interventions 
are provided in the Study Reference Manual.  
6.3. 
Measures to Minimize Bias: Randomization and Blinding  
In this open-label study, potential bias will be reduced by specifying treatment response 
ascertained from all eligible participants and safety reporting. Adherence to the study design 
requirements, including those specified in the SoA, is essential and required for study conduct. 
The site will contact the interactive web-response system (IWRS), prior to the start of study 
intervention administration and at the primary endpoint for each eligible participant, to provide 
demographic information and IGA/EASI results, respectively.  
6.4. 
Study Intervention Compliance  
Study intervention will be administered under medical supervision by the investigator or 
designee at the baseline (Week 0, Visit 2) and Week 2 (Visit 3) visits. The dose of study 
intervention and study participant identification will be confirmed prior to dispensing study drug. 
The date and time of each dose administered will be recorded in the source documents and will 
be provided to the sponsor as requested.  
Beginning Week 4 (Visit 4) the participant/caregiver will be encouraged to administer the study 
intervention while in the clinic or at home. Participants may choose to continue to receive study 
drug injections administered by trained clinic staff for any visit occurring in the clinic. Home 
dosing must be self-administered or given by a caregiver that has received proper injection 
technique training. 
When participants self-administer study intervention(s) at home, compliance with study 
intervention will be assessed at each visit. Compliance will be assessed by direct questioning, 
counting returned injection supplies, and documented in the source documents.  
A record of the number of lebrikizumab injections supplies dispensed to and administered by 
each participant or caregiver must be maintained and reconciled with study intervention and 
compliance records.  
6.5. 
Dose Modification  
Dose modifications of lebrikizumab are not allowed in this study.  
6.6. 
Continued Access to Study Intervention after the End of the Study  
Lebrikizumab will be made available to eligible participants who complete Visit 9 (Week 24) via 
the Continued Access addendum, until lebrikizumab is commercially available in the US. Please 
refer to KGBO Protocol Addendum 2 for additional information. Otherwise, lebrikizumab will 
not be provided after participants exit this study. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
44 
6.7. 
Treatment of Overdose  
For this study, any dose of lebrikizumab greater than 500 mg (baseline and Week 2) and 250 mg 
Q2W (Week 4 and beyond) will be considered an overdose. 
Sponsor does not recommend specific treatment for an overdose. 
In the event of an overdose, the investigator/treating physician should: 
● Contact the medical monitor immediately. 
● Evaluate the participant to determine, in consultation with the medical monitor, 
whether study intervention should be interrupted or whether the dose should be 
reduced. 
● Closely monitor the participant for any AE/SAE and laboratory abnormalities 
until lebrikizumab can no longer be detected systemically (at least 18 weeks). 
6.8. 
Concomitant Therapy  
Any medication or vaccine (including over-the-counter or prescription medicines, vitamins, 
antacids, and/or herbal supplements) that the participant is receiving at the time of enrollment or 
receives during the study must be recorded along with: 
● reason for use 
● dates of administration including start and end dates 
● dosage information including dose and frequency for concomitant therapy of 
special interest 
The medical monitor should be contacted prior to entering the participant into the study if there 
are any questions regarding concomitant or prior therapy. 
Participants should be instructed to consult with the investigator prior to initiating any new 
medication (either self-administered non-prescription drugs or prescription therapy prescribed by 
another physician) while participating in the study. The investigator is expected to examine the 
acceptability of all concomitant medications, topical preparations, and dietary supplements taken 
by participants in the study. 
The use of any concomitant medication must relate to an AE listed on the AE case report form 
(CRF) or the participant’s medical history, unless the medication is a supplement or used as 
preventive care. 
6.8.1. 
Permitted Treatments and Procedures  
The following therapies will be permitted during the study: 
Permitted Concomitant Medications and Vaccines 
Comments  
Medications 
 
Medications for medical conditions other than AD 
(for example, hypertension or diabetes) 
 
Low and /or mid potency TCS, TCIs (for example, 
tacrolimus and pimecrolimus), or topical PDE-4 
Permitted as needed on AD lesions 
and must be documented in the 
diary 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
45 
Permitted Concomitant Medications and Vaccines 
Comments  
inhibitors (for example, crisaborole) for treatment of 
AD (see Section 6.8.4) 
High-potency TCS for treatment of AD 
Permitted up to 10 days 
Non-medicated moisturizers 
 
Intranasal corticosteroids 
 
Inhaled corticosteroids and bronchodilators to control 
asthma 
 
Single intra-articular (bursa, tendons, and ligaments) 
corticosteroid injection 
 
Non-sedating antihistamines  
 
Ophthalmic drugs containing antihistamines, 
corticosteroids, or other immunosuppressants 
 
Allergen immunotherapies 
If on maintenance dose  
Leukotriene inhibitors 
 
Acute Systemic and topical anti-infectives/antibiotics 
For treatment of acute infections  
Sedating systemic antihistamines including, but not 
limited to, alimemazine, chlorphenamine, clemastine, 
cyproheptadine, diphenhydramine, hydroxyzine, 
ketotifen, and promethazine 
On an as needed basis 
 
Systemic/oral sleep aid medications 
On an as needed basis 
 
Recreational use of cannabis and cannabinoid (if 
allowed per local regulations/law) 
Not allowed for the treatment of 
pruritus, pain and/or AD  
Vaccines 
 
Non-live vaccinations 
Including non-live SARS-CoV-2 
vaccines, RNA vaccines, vaccines 
with inactive viral elements, and/or 
non-replicating viral vectors that 
are clinically indicated 
Abbreviations: AD = atopic dermatitis; RNA = Ribonucleic acid; SARS-CoV-2 = severe acute respiratory 
syndrome coronavirus 2; PDE-4 = phosphodiesterase-4; TCI = topical calcineurin inhibitors; TCS = topical 
corticosteroids. 
NOTE: In the context of this table, “during the study” = from screening to post-treatment safety 
follow-up visit. 
6.8.2. 
Prohibited Treatments and Procedures  
The following therapies will be prohibited during the study: 
Prohibited Concomitant Medications, 
Vaccinations, and Procedures 
Comments  
Medications or procedures 
 
Systemic corticosteroids (IM, PO, or IV) 
NOTE: Any use of systemic 
corticosteroids will be considered as 
rescue medication (see Section 6.8.5) 
Any investigational drug other than the study 
drug 
 
 
 
B cell-depleting biologics, including rituximab 
 
Other biologic agents (other than the study 
interventions) 
 
Topical JAK inhibitor for treatment of AD 
Any use will be considered as rescue 
medication (see Section 6.8.5) 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
46 
Prohibited Concomitant Medications, 
Vaccinations, and Procedures 
Comments  
TCS (high potency) 
Use for >10 days is prohibited 
Medications or therapies for other medical conditions 
known to affect AD (for example, 
immunosuppressive/immunomodulating drugs such as 
systemic corticosteroids, mycophenolate mofetil, IFN-
gamma, topical, and systemic JAK inhibitors, 
cyclosporine, azathioprine, or methotrexate; phototherapy 
or PUVA; or systemic PDE-4 inhibitors) 
 
Chronic Systemic and topical anti-infectives 
For chronic treatment during the study 
Planned or anticipated major medical procedures 
or surgeries 
 
Tanning booth/parlor 
 
Bleach bath 
 
Use of cannabis or cannabinoids for the 
treatment of pruritus, pain and/or AD 
 
Vaccines 
 
Live or live attenuated vaccines, as well as BCG 
vaccine 
 
Abbreviations: AD = atopic dermatitis; AE = adverse event; BCG = Bacillus Calmette-Guerin; JAK = 
Janus kinase; IFN = interferon; IM = intramuscular; IV = intravenous; PDE-4 = phosphodiesterase-4; 
PUVA = photochemotherapy; TCS = topical corticosteroids; PO = by mouth. 
 
NOTE: in the context of this table, “during the study” = from screening to post-treatment safety 
follow-up visit. 
6.8.3. 
Non-Medicated Moisturizers  
Participants may apply a stable dose of non-medicated topical moisturizer at least twice daily for 
≥7 days prior to the baseline visit and throughout the study.  
The participants may continue their current over-the-counter moisturizer regimen, if approved by 
the investigator.  
All moisturizer use should be recorded in the CRF. 
6.8.4. 
Topical Treatment for Atopic Dermatitis  
The goal of this Phase 3b study is to demonstrate the safety and efficacy of lebrikizumab for 
moderate-to-severe AD in a population previously treated with dupilumab. Regular use of non-
medicated, non-prescription moisturizers should be used by all participants. During this study, 
topical therapies may be needed if the participant experiences intolerable clinical worsening of 
symptoms. If needed, investigators are encouraged to recommend therapy in a staged fashion, 
beginning with a topical low-potency treatment first, then topical mid-potency treatment if 
needed. In sensitive skin areas (that is, face, neck, intertriginous, and genital areas), only low-
potency topical treatments should be used. 
If AD lesions recur or a participant experiences a flare, as needed use of low- and/or mid-
potency TCS, TCI (tacrolimus or pimecrolimus), and/or topical PDE4 inhibitors (crisaborole) 
may be initiated at the participant’s discretion but must be communicated to the investigator and 
documented in the patient diary or as concomitant medications.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
47 
Escalation to high-potency topical corticosteroid medications should only occur if participants do 
not respond adequately after at least 7 days of low/mid potency TCS, TCI and/or topical PDE4 
inhibitors. Use of high-potency TCS for more than 10 days is considered rescue therapy 
(Section 6.8.5). Participants that receive Rescue therapy must be discontinued from the study. 
(see Section 7.1). All topical therapy usage must be recorded in the CRF or patient diary. 
6.8.5. 
Rescue Medicine for Atopic Dermatitis  
To be consistent with real world practice, defined topical medications are allowed in this study 
(see Section 6.8.4). However, rescue therapies may be needed if the participant experiences 
intolerable clinical worsening of symptoms. Escalation to high potency topical TCS, topical JAK 
inhibitors, phototherapy and/or systemic medications (including but not limited to 
corticosteroids, immunosuppressants, biologics, small molecules, etc.) for the treatment of AD 
should only occur if participants do not respond adequately after at least 7 days of low/mid 
potency TCS, TCI and/or topical PDE4 inhibitors. Any use of topical JAKs, phototherapy, 
and/or systemic medications will be considered rescue therapy. Use of high-potency TCS for 
more than 10 days is also considered rescue therapy.  Participants that receive Rescue therapy 
must be discontinued from the study. (see Section 7.1). 
All rescue medication must be recorded in the CRF.  
  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
48 
7. 
Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1. 
7.1. 
Discontinuation of Study Intervention  
When necessary, a participant may be permanently discontinued from study intervention. If so, 
the participant will remain in the study to complete procedures for an early discontinuation visit 
and post-treatment follow-up, if applicable, as shown in the SoA.  
A participant should be permanently discontinued from study intervention if 
 the participant becomes pregnant during the study 
 in the opinion of the investigator, the participant should permanently discontinue the 
study intervention for safety reasons 
 the participant develops a malignancy, except for successfully treated basal or squamous 
cell skin carcinoma 
 the participant tests positive for HBV DNA (see Section 8.2.3)  
 the participant tests positive for HCV RNA (Section 8.2.4) 
 if the participant experiences a hepatic event or liver test abnormality as specified in the 
liver chemistry stopping criteria (see Section 7.1.1) 
 the participant develops HIV infection  
 the participant requires rescue medication treatment for symptoms of AD in the treatment 
period 
 the participant develops any infection that is opportunistic, such as active tuberculosis 
and other infections whose nature or course may suggest an immuno-compromised status, 
and 
 the participant has an AE or an SAE or a clinically significant change in a laboratory 
value that, in the opinion of the investigator, merits discontinuation of study intervention 
and appropriate measures being taken. 
Hepatitis 
 prior to discontinuation of any immunomodulatory and/or immunosuppressive therapy 
due to hepatitis, including study intervention, the participant is to be referred to, 
evaluated, and managed by a specialist physician with expertise in evaluation and 
management of viral hepatitis.  
 the timing of discontinuation from study intervention relative to the initiation of any 
antiviral treatment for hepatitis is to be based on the recommendation of the consulting 
specialist physician, in conjunction with the investigator, and aligned with medical 
guidelines and standard of care. 
Hypersensitivity 
 if the investigator determines that a systemic hypersensitivity reaction has occurred 
related to study intervention administration, the participant may be permanently 
discontinued from the study intervention, and the sponsor’s designated medical monitor 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
49 
should be notified. If the investigator is uncertain about whether a systemic 
hypersensitivity reaction has occurred and whether discontinuation of study intervention 
is warranted, the investigator may consult the sponsor. 
7.1.1. 
Liver Chemistry Stopping Criteria  
The study drug should be interrupted and close hepatic monitoring initiated (see Section 8.2.2) if 
1 or more of these conditions occur: 
Elevationa 
Exceptiona 
ALT or AST >8x ULN 
 
ALT or AST >5x ULN for more than 2 weeks 
 
ALT or AST >3x ULN and either TBL >2x ULN or 
INR >1.5  
For participants with Gilbert’s 
syndrome: If baseline direct 
bilirubin is >0.5 mg/dL, then 
doubling of direct bilirubin should 
be used for drug interruption 
decisions rather than TBL >2x ULN. 
ALT or AST >3x ULN with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or 
tenderness, fever, and/or rash 
 
ALP >3x ULN, when the source of increased ALP is 
the liver 
 
ALP >2.5x ULN and TBL > 2x ULN  
For participants with Gilbert’s 
syndrome: If baseline direct 
bilirubin is >0.5 mg/dL, then 
doubling of direct bilirubin should 
be used for drug interruption 
decisions rather than TBL >2x ULN. 
ALP >2.5x ULN with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or 
tenderness, fever, and rash 
 
Source: FDA Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical 
Evaluation, July 2009 and other consensus guidelines, with minor modifications. 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
INR = international normalized ratio; TBL = total bilirubin; ULN = upper limit of normal. 
a All ULN values should be age adjusted (AAULN) for participants <18 years of age. 
Resumption of the study intervention can be considered only in consultation with the Lilly-
designated medical monitor and only if liver test results return to baseline and if a self-limiting 
non-drug etiology is identified. Otherwise, study intervention should be discontinued.  
7.1.2. 
Temporary Discontinuation of Study Intervention  
Temporary withholding of study intervention is required if the participant meets any of the 
following infection-related criteria during the study: 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
50 
● Serious or opportunistic infections, as defined in Section 5.2. Study intervention is 
to be withheld until resolution of all acute clinical signs and symptoms, and 
completion of all appropriate anti-infective treatment. 
● HBV DNA results that are reported as positive, or as detecting HBV DNA, but 
HBV DNA is below the level of quantification. In this situation, the sponsor’s 
designated medical monitor should be contacted regarding the participant’s status. 
HBV DNA testing is to be repeated as soon as is feasible. If HBV DNA is 
confirmed as positive, the participant must be permanently discontinued from 
study intervention as described in Section 7.1. 
 If a participant <18 years of age loses a clinically significant amount of weight (below 
40 kg), the investigator should assess rationale for weight loss and use clinical judgment 
to determine if the participant should temporarily discontinue the treatment. 
7.2. 
Participant Discontinuation/Withdrawal from the Study  
Discontinuation is expected to be uncommon. 
A participant may withdraw from the study 
● at any time at the participant’s own request 
● at the request of the participant’s designee (for example, parents or legal 
guardian) 
● at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons 
● if enrolled in any other clinical study involving an investigational product, or 
enrolled in any other type of medical research judged not to be scientifically or 
medically compatible with this study, and 
● if the participant, for any reason, requires rescue medication or treatment with a 
therapeutic agent that is prohibited by the protocol and has been demonstrated to 
be effective for treatment of the study indication. In this case, discontinuation 
from the study occurs prior to introduction of the new agent. 
At the time of discontinuing from the study, the participant will complete procedures for an early 
discontinuation visit and post-treatment follow-up, if applicable, as shown in the SoA. If the 
participant has not already discontinued the study intervention, the participant will be 
permanently discontinued from the study intervention at the time of the decision to discontinue 
the study. 
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent. If a participant 
withdraws from the study, the participant may request destruction of any samples taken and not 
tested, and the investigator must document this in the site study records. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
51 
7.3. 
Lost to Follow-up  
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site. Site personnel or designee are 
expected to make diligent attempts to contact participants who fail to return for a scheduled visit 
or were otherwise unable to be followed up by the site.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
52 
8. 
Study Assessments and Procedures  
● Study procedures and their timing are summarized in the SoA.  
● Immediate safety concerns should be discussed with the sponsor immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention. 
● Adherence to the study design requirements, including those specified in the SoA, 
is essential and required for study conduct. 
● All screening evaluations must be completed and reviewed to confirm that 
potential participants meet all eligibility criteria. The investigator will maintain a 
screening log to record details of all participants screened and to confirm 
eligibility or record reasons for screening failure, as applicable.  
8.1. 
Efficacy Assessments  
8.1.1. 
Eczema Area and Severity Index  
The EASI is an investigator-reported, 20-item scale that evaluates 2 dimensions of AD: extent of 
disease at 4 body regions (head or neck, trunk, upper and lower extremities) and 4 clinical signs 
(erythema, induration or papulation, excoriation, and lichenification). The clinical signs are 
assessed for severity on a scale of 0 (absent) to 3 (severe). 
The scores are added up for each of the 4 body regions. The assigned percentages of BSA for 
each section of the body are 10% for head or neck, 20% for upper extremities, 30% for trunk, 
and 40% for lower extremities, respectively. Each subtotal score is multiplied by the BSA 
represented by that region.  
In addition, an area score of 0 to 6 is assigned for each body region, depending on the percentage 
of AD-affected skin in that area: 0 (none), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 
(50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Each of the body area scores is multiplied 
by the area affected. The resulting EASI ranges from 0 to 72 points, with the highest score 
indicating worse severity of AD (Hanifin et al. 2001).  
Assessors must be trained and certified by the sponsor prior to conducting this assessment. A 
single assessor should be assigned to each participant for as many visits as possible to avoid 
inter-assessor variability in scoring. The recall period of this assessment is present time. 
8.1.2. 
Investigator’s Global Assessment (IGA)  
The IGA is an investigator-reported, single-item scale that rates the severity of the participant’s 
AD. The IGA is composed of a 5-point scale ranging from 0 (clear) to 4 (severe), and a score is 
selected using descriptors that best describe the overall appearance of the lesions at a given time 
point.  
Assessors must be trained and certified by the sponsor prior to conducting this assessment. A 
single assessor should be assigned to each participant for as many visits as possible to avoid 
inter-assessor variability in scoring. The recall period of this assessment is present time. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
53 
8.1.3. 
Body Surface Area (BSA)  
BSA is an investigator-reported assessment, which estimates the extent of disease or skin 
involvement of a participant’s AD. BSA is expressed as a percentage of total body surface and 
will be reported by body location. The recall period of this assessment is present time. 
Assessors must be trained and certified by the sponsor prior to conducting this assessment. A 
single assessor should be assigned to each participant for as many visits as possible to avoid 
inter-assessor variability in scoring. 
8.1.4. 
Face-Investigator’s Global Assessment (F-IGA)  
The F-IGA is an investigator-administered, single-item scale that rates the severity of the 
participant’s AD on the face. The F-IGA is composed of a 5-point scale ranging from 0 (clear) to 
4 (severe), and a score is selected using descriptors that best describe the overall appearance of 
the facial lesions at a given time point.  
Assessors must be trained and certified by the sponsor prior to conducting this assessment. A 
single assessor should be assigned to each participant for as many visits as possible to avoid 
inter-assessor variability in scoring. The recall period of this assessment is present time. 
8.1.5. 
SCORing Atopic Dermatitis (SCORAD)  
The SCORAD index is an investigator- and participant-reported, 9-item assessment in both 
adults and adolescent participants that assesses 3 aspects as provided below. 
 The extent (1-item) of AD is assessed by the investigator as a percentage of each defined 
body area and reported as the sum of all areas. The maximum score is 100%. The recall 
period of this scale is present time. 
 The severity of 6 specific symptoms of AD is assessed by the investigator: erythema, 
edema or papulation, oozing or crusts, excoriation, lichenification, and dryness are 
assessed by the investigator using a 4-point scale (that is, none = 0, mild = 1, moderate = 
2, severe = 3) with a maximum possible total of 18 points. The recall period of this scale 
is present time. 
 The subjective symptoms of pruritus and sleep loss (2 items) are assessed by the 
participant via a 10-cm visual analog scale. The symptoms (itch and sleeplessness) are 
recorded by the participant or caregiver on a visual analogue scale, where 0 is no 
symptoms and 10 is the worst imaginable symptom, with a maximum possible score of 
20. The recall period of this scale is over the last 3 days. 
The maximum possible SCORAD score calculated based on the above 3 aspects is 103. The 
higher scores indicate poorer or more severe condition (Stalder and Taïeb 1993; Oranje et al. 
2007; Schram et al. 2012). The recall period is present time for extent and intensity and average 
for the last 3 days or nights for subjective symptoms of AD. 
8.1.6. 
Modified Total Lesion Symptom Scale  
The Modified Total Lesion Symptom Scale is an investigator-reported scale that combines the 
evaluation of hand eczema (HE) lesion severity (erythema, edema, desquamation, fissures, 
hyperkeratosis or lichenification, and vesicles) with the intensity of pruritus or pain (Bissonnette 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
54 
et al. 2010) to assess the severity of symptoms. This composite score assigns 0 (mild) to 3 
(severe) to each component, giving a maximum disease severity of 21. The recall period for this 
scale is the present time. While no validation of this score has been published, it has been used as 
a secondary endpoint in studies investigating alitretinoin in HE (Ruzicka et al. 2008; Fowler et 
al. 2014), and as a primary outcome measure in recent Phase 2 studies of dupilumab and 
gusacitinib for HE (NCT03861455; NCT03728504).  
8.1.7. 
Pruritus NRS  
The Pruritus Numeric Rating Scale (NRS) is a participant-reported, single-item, daily, 11-point 
scale. The Pruritus NRS is used by participants to rate their worst itch severity over the past 24 
hours with 0 indicating “No itch” and 10 indicating “Worst itch imaginable.” Assessments will 
be recorded daily by the participant. The minimal clinically important change is 3 points. 
(Yosipovitch et al. 2019, 2021).  
Participants will record the pruritus assessments daily using an electronic diary at home. As 
indicated in the SoA (Section 1.3), initial electronic diary entries for Pruritus NRS should be 
completed a minimum of 4 of 7 days before baseline. 
8.1.8. 
Sleep-Loss Scale  
The Sleep-Loss Scale is a participant-reported, single-item, daily scale that measures the extent 
of sleep loss due to interference of itch over the last night. The Sleep-Loss Scale is rated based 
on a 5-point Likert scale (0 [not at all] to 4 [unable to sleep at all]). Assessment will be recorded 
daily by the participant. The minimal clinically important change is 3 points. (Yosipovitch et al. 
2021).  
Participants will record the pruritus assessments daily using an electronic diary at home. As 
indicated in the SoA (Section 1.3), initial electronic diary entries for Sleep-Loss Scale should be 
completed a minimum of 4 of 7 days before baseline.  
8.1.9. 
Skin Pain Numeric Rating Scale (Skin Pain NRS)  
The Skin Pain NRS is a participant-reported, 11-point horizontal scale anchored at 0 and 10, with 
0 representing “no pain” and 10 representing “worst pain imaginable.” Overall severity of a 
participant’s skin pain is indicated by selecting the number that best describes the worst level of 
skin pain in the past 24 hours (Newton et al. 2019; Silverberg et al. 2021). Assessment will be 
recorded daily by the participant. 
8.1.10. 
Dermatology Life Quality Index/Children’s Dermatology Life Quality Index 
(DLQI/cDLQI)  
The DLQI is a simple, participant-reported, 10-item, QoL questionnaire in adults that covers 6 
domains (symptoms and feelings, daily activities, leisure, work and school, personal 
relationships, and treatment). The recall period of this scale is over the “last week.” Response 
categories include “not at all,” “a little”, “a lot,” and “very much,” with corresponding scores of 
0, 1, 2, and 3, respectively, and unanswered (or “not relevant”) responses scored as 0. Scores 
range from 0 to 30 with higher scores indicating greater impairment of QoL. A DLQI total score 
of 0 to 1 is considered as having no effect on a participant’s HRQoL (Hongbo et al. 2005), and a 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
55 
4-point change from baseline is considered as the minimal clinically important difference 
threshold (Khilji et al. 2002; Basra et al. 2015).  
Participants <16 years at baseline will complete the cDLQI and should continue to complete the 
cDLQI for the duration of the study. 
8.1.11. 
Atopic Dermatitis Control Tool (ADCT)  
The Atopic Dermatitis Control Tool is a patient-reported, simple, brief tool for adults and 
adolescents that evaluates 6 symptoms and effects associated with AD over the past week: 
overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem 
with sleep, impact on daily activities, and impact on mood or emotions. Each of the 6 Atopic 
Dermatitis Control Tool items has a score range from 0 (no problem) to 4 (worst), rating the 
severity of each concept; the total score ranges from 0 to 24, which is the summation of the 
responses to all the items. A score of ≥7 points was derived as the threshold to identify 
participants “not in control.” The threshold for meaningful within-person change was estimated 
to be 5 points (Simpson et al. 2019; Pariser et al. 2020). 
8.1.12. 
Participant-Reported Satisfaction Question  
The question on participant satisfaction asks “How satisfied are you with this treatment’s ability 
to treat your skin condition?” The response options range from 1 (not satisfied) to 5 (completely 
satisfied). 
8.1.13. 
Fitzpatrick Skin Phototype Assessment  
The Fitzpatrick Scale is a clinician-rated scale and is based on a participant’s cutaneous reaction 
to sun exposure and baseline skin pigmentation. Fitzpatrick skin phototypes range from I to VI, 
with a score of I indicating “always burns, does not tan, white skin tone” and a score of VI 
indicating “never burns, tans very easily, skin color black” (High et al. 2012). Investigators will 
follow the descriptive terms included in this protocol when recording the Fitzpatrick skin 
phototype. The sun sensitivity measure will represent the Fitzpatrick Scale score for each 
participant. The recall period for this scale is the present time. 
8.1.14. 
Work Productivity and Activity Impairment Questionnaire–Atopic Dermatitis 
(WPAI-AD)  
The Work Productivity and Activity Impairment Questionnaire–Atopic Dermatitis is a 
participant-reported, 6-item questionnaire that records impairment due to AD over the past 7 
days in adolescents and adults. The Work Productivity and Activity Impairment Questionnaire–
Atopic Dermatitis consists of 6 items grouped into 4 domains: absenteeism (work time missed), 
presenteeism (impairment at work or reduced on the job effectiveness), work productivity loss 
(overall work impairment or absenteeism plus presenteeism), and activity impairment. 
Absenteeism, presentism, and work productivity will only be reported by those who are currently 
employed (working for pay) at the time of the scale completion. The recall period for the scale is 
over the past 7 days. Scores are calculated as impairment percentages (Reilly et al. 1993), with 
higher scores indicating greater impairment and less productivity.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
56 
8.2. 
Safety Assessments  
Planned time points for all safety assessments are provided in the SoA. 
The routine safety assessments include physical examinations, clinical safety laboratory tests 
(including hematology and chemistry), and collection of vital signs and spontaneously reported 
AEs. The study design includes a Post-treatment Follow-Up Period with at least 1 study visit for 
safety assessments. 
8.2.1. 
Clinical Safety Laboratory Tests  
● See Appendix 2 for the list of clinical laboratory tests to be performed and the 
SoA for the timing and frequency. 
● Local anesthetics  
o Use of local anesthetics, for example, Eutectic Mixture of Local Anesthetics 
(EMLA) cream, consistent with local prescribing information are permitted 
during the study visit to ease discomfort associated with venipunctures. 
● The investigator must review the laboratory results, document this review, and 
consider whether or not any clinically relevant changes occurring during the study 
constitute as an AE. The laboratory results must be retained with source 
documents unless a Source Document Agreement or comparable document cites 
an electronic location that accommodates the expected retention duration. 
Clinically significant abnormal laboratory findings are those which are not 
associated with the underlying disease, unless judged by the investigator to be 
more severe than expected for the participant’s condition. 
● All laboratory tests with values considered clinically significantly abnormal 
during participation in the study or within 28 days after the last dose of study 
intervention should be repeated until the values return to normal or baseline or are 
no longer considered clinically significant by the investigator or medical monitor. 
○ If such values do not return to normal or baseline within a period of time 
judged reasonable by the investigator, the etiology should be identified and 
the sponsor notified. 
○ All protocol-required laboratory assessments, as defined in Appendix 2, must 
be conducted in accordance with the SoA, standard collection requirements, 
and laboratory manual. 
● If laboratory values from non-protocol-specified laboratory assessments 
performed at an investigator-designated local laboratory require a change in 
participant management or are considered clinically significant by the 
investigator, for example, SAE or AE or dose modification, then report the 
information as an AE.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
57 
8.2.2. 
Hepatic Safety  
Close hepatic monitoringa 
Laboratory tests (Appendix 6), including alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (TBL), direct bilirubin, 
gamma-glutamyl transferase, and creatine kinase, should be repeated within 48 to 72 hours to 
confirm the abnormality and to determine if it is increasing or decreasing, if 1 or more of these 
conditions occur: 
If a participant with baseline results 
of... 
develops the following elevations: 
ALT or AST <1.5x ULN 
ALT or AST ≥3x ULN 
ALP <1.5x ULN 
ALP ≥2x ULN 
TBL <1.5x ULN 
TBL ≥2x ULN, except for patients with Gilbert’s 
syndrome 
ALT or AST ≥1.5x ULN 
ALT or AST ≥2x baseline 
ALP ≥1.5x ULN 
ALP ≥2x baseline 
TBL ≥1.5x ULN 
TBL ≥1.5x baseline, except for patients with Gilbert’s 
syndrome 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
TBL = total bilirubin; ULN = upper limit of normal. 
a All ULN values should be age adjusted (AAULN) for participants <18 years of age. 
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver tests should be initiated by the investigator in consultation with 
the Lilly-designated medical monitor. At a minimum, this evaluation should include physical 
examination and a thorough medical history, including symptoms, recent illnesses (for example, 
heart failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including over-the-counter), herbal and dietary supplements, and history of alcohol 
drinking and other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clinical condition and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant’s clinical condition and lab results stabilize. Monitoring of ALT, AST, ALP, and TBL 
should continue until levels normalize or return to approximate baseline levels. For participants 
<18 years of age, special care should be taken to minimize the volume of blood taken during 
hepatic monitoring. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
58 
Comprehensive hepatic evaluationa 
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
one or more of these conditions occur: 
If a participant with baseline 
results of...  
develops the following elevations: 
ALT or AST <1.5x ULN 
ALT or AST ≥3x ULN with hepatic signs or symptoms
b, or  
ALT or AST ≥5x ULN 
ALP <1.5x ULN 
ALP ≥3x ULN 
TBL <1.5x ULN 
TBL ≥2x ULN (except for patients with Gilbert’s syndrome) 
ALT or AST ≥1.5x ULN 
ALT or AST ≥2x baseline with hepatic signs or symptoms
b, or 
ALT or AST ≥3x baseline 
ALP ≥1.5x ULN 
ALP ≥2x baseline 
TBL ≥1.5x ULN 
TBL ≥2x baseline (except for patients with Gilbert’s 
syndrome)  
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
TBL = total bilirubin; ULN = upper limit of normal. 
a All ULN values should be age adjusted (AAULN) for participants <18 years of age. 
b Hepatic signs or symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, and 
rash. 
For Adult Participants (≥18 years old) 
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for prothrombin time-international normalized ratio; 
tests for viral hepatitis A, B, C, or E; tests for autoimmune hepatitis; and an abdominal imaging 
study, for example, ultrasound or computed tomography scan.  
Based on the patient’s history and initial results, further testing should be considered in 
consultation with the Lilly-designated medical monitor, including tests for hepatitis D virus, 
cytomegalovirus, Epstein-Barr virus, acetaminophen levels, acetaminophen protein adducts, 
urine toxicology screen, Wilson’s disease, blood alcohol levels, urinary ethyl glucuronide, and 
blood phosphatidylethanol. Based on the circumstances and the investigator’s assessment of the 
participant’s clinical condition, the investigator should consider referring the participant for a 
hepatologist or gastroenterologist consultation, magnetic resonance cholangiopancreatography, 
endoscopic retrograde cholangiopancreatography, cardiac echocardiogram, or a liver biopsy. 
For Adolescent Participants (<18 years old) 
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for prothrombin time-international normalized ratio 
and direct bilirubin, if total bilirubin was elevated. 
Based on the participant’s age, medical history, and initial results, further testing should be 
considered in consultation with the Lilly-designated medical monitor, including tests for viral 
hepatitis A, B, C, E; autoimmune hepatitis; and/or an abdominal imaging study, for example, 
ultrasound, MRI, or computed tomography scan. Consider additional tests, based on the medical 
history and clinical picture, including tests for hepatitis D virus, cytomegalovirus, Epstein-Barr 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
59 
virus, acetaminophen levels, acetaminophen protein adducts, urine toxicology screen, Wilson’s 
disease, blood alcohol levels, urinary ethyl glucuronide, and blood phosphatidylethanol. Special 
care should be taken to prioritize more pertinent blood tests and minimize the volume of blood 
taken during hepatic evaluation. Based on the circumstances and the investigator’s assessment of 
the participant’s clinical condition, the investigator should consider referring the participant for a 
pediatric hepatologist or gastroenterologist consultation, magnetic resonance 
cholangiopancreatography, endoscopic retrograde cholangiopancreatography, cardiac 
echocardiogram, or a liver biopsy as deemed appropriate for the clinical condition and 
participant’s age.  
Additional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liver tests during the study 
Additional hepatic safety data collection in hepatic safety CRF should be performed in study 
participants who meet 1 or more of the following 5 conditions:a 
1. Elevation of serum ALT to ≥5x ULN on 2 or more consecutive blood tests, if baseline 
ALT <1.5x ULN 
➢ In participants with baseline ALT ≥1.5x ULN, the threshold is ALT ≥3x baseline 
on 2 or more consecutive tests 
2. Elevated TBL to ≥2x ULN, if baseline TBL <1.5x ULN (except for cases of known 
Gilbert’s syndrome) 
➢ In participants with baseline TBL ≥1.5x ULN, the threshold should be TBL ≥2x 
baseline 
3. Elevation of serum ALP to ≥2x ULN on 2 or more consecutive blood tests, if baseline 
ALP <1.5x ULN 
➢ In participants with baseline ALP ≥1.5x ULN, the threshold is ALP ≥2x baseline 
on 2 or more consecutive blood tests 
4. Hepatic event considered to be a SAE 
5. Discontinuation of study drug due to a hepatic event  
NOTE: the interval between the 2 consecutive blood tests should be at least 2 days. 
a All ULN values should be age adjusted (AAULN) for participants <18 years of age. 
8.2.3. 
Hepatitis B Testing and Monitoring  
As specified in the SoA (Section 1.3), initial testing for HBV infection includes HBsAg and 
hepatitis B core antibody (HBcAb). 
● If HBsAg is positive, the participant is excluded. 
● If HBsAg is negative and HBcAb is negative, the participant is not excluded. 
● If HBsAg is negative and HBcAb is positive, further testing for HBV DNA is 
required. 
○ If the screening HBV DNA is positive, the participant is excluded. 
○ If the screening HBV DNA is negative, the participant is not excluded. Repeat 
testing for HBV DNA is required at least every 3 months during the study as 
described in the SoA. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
60 
Management of enrolled participants with detectable HBV DNA during the study 
If HBV DNA is detected, study intervention will be temporarily withheld or permanently 
discontinued, as described in Sections 7.1.2 and 7, and the participant should be referred for 
appropriate follow-up medical care. 
8.2.4. 
Hepatitis C Testing  
As specified in the SoA (Section 1.3), initial testing for HCV infection includes testing for 
antibodies to HCV (anti-HCV). 
● If anti-HCV is positive, a test for circulating HCV RNA is required. 
● If HCV RNA test is negative, the participant is not excluded. 
● If HCV RNA test is positive, the participant is excluded (see Section 5.2). 
Participants who have had HCV infection and have been successfully treated, defined as a 
sustained virologic response (HCV RNA by polymerase chain reaction negative for at least 24 
weeks following treatment completion), are not excluded on the basis of HCV as long as HCV 
RNA test is negative at screening. 
If HCV RNA is detected during the study, the study intervention will be discontinued 
(Section 7), and the participant should receive appropriate follow-up medical care. 
8.3. 
Adverse Events, Serious Adverse Events, and Product Complaints  
The definitions of the following events can be found in Appendix 3: 
 AEs 
 SAEs, and 
 PCs. 
These events will be reported by the participant, or when appropriate, by a caregiver, surrogate, 
or the participant’s legally authorized representative. 
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet these definitions and remain responsible for following up events that 
are serious, considered related to the study intervention or study procedures, or that caused the 
participant to discontinue the study intervention or study (see Section 7). 
Care will be taken not to introduce bias when detecting events. Open-ended and non-leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences. 
After the initial report, the investigator is required to proactively follow each participant at 
subsequent visits or contacts. All SAEs and AEs of special interest, as defined in Section 8.3.3, 
will be followed until resolution, stabilization, the event is otherwise explained, or the participant 
is lost to follow-up (as defined in Section 7.3). For PCs, the investigator is responsible for 
ensuring that follow-up includes any supplemental investigations as indicated to elucidate nature 
and/or causality. Further information on follow-up procedures is provided in Section, 10.3, 
Appendix 3.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
61 
8.3.1. 
Timing and Mechanism for Collecting Events  
This table describes the timing, deadlines, and mechanism for collecting events. 
Event 
Collection 
Start 
Collection 
Stop 
Timing for Reporting 
to Sponsor or 
Designee 
Mechanism for 
Reporting 
Back-up 
Method of 
Reporting 
Adverse Event 
AE 
Signing of 
the ICF 
Participation 
in study has 
ended 
As soon as possible 
upon site awareness 
AE CRF 
N/A 
Serious Adverse Event 
SAE and SAE 
updates – prior 
to start of study 
intervention and 
deemed 
reasonably 
possibly related 
to study 
procedures 
Signing of 
the ICF 
Start of 
intervention 
Within 24 hours of 
awareness 
SAE paper form 
SAE paper 
form 
SAE and SAE 
updates – after 
start of study 
intervention 
Start of 
intervention 
Participation 
in study has 
ended 
Within 24 hours of 
awareness 
SAE paper form 
SAE paper 
form 
SAEa – after 
participant’s 
study 
participation has 
ended and the 
investigator 
becomes aware 
After 
participant’s 
study 
participation 
has ended 
N/A 
Promptly 
SAE paper form 
N/A 
Pregnancy 
Pregnancy in 
female 
participants and 
female partners 
of male 
participants 
After the 
start of study 
intervention 
At least 18 
weeks after 
the last dose 
of study 
intervention 
Within 24 hours (see 
Section 8.3.2) 
Pregnancy paper 
form 
Pregnancy 
paper form 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
62 
Event 
Collection 
Start 
Collection 
Stop 
Timing for Reporting 
to Sponsor or 
Designee 
Mechanism for 
Reporting 
Back-up 
Method of 
Reporting 
Product Complaints 
PC associated 
with an SAE or 
might have led 
to an SAE 
Start of study 
intervention 
End of study 
intervention 
Within 24 hours of 
awareness 
PC form 
N/A 
PC not 
associated with 
an SAE 
Start of study 
intervention 
End of study 
intervention 
Within 1 business day 
of awareness 
PC form 
N/A 
Updated PC 
information 
— 
— 
As soon as possible 
upon site awareness 
Originally 
completed PC form 
with all changes 
signed and dated by 
the investigator 
N/A 
PC, if 
investigator 
becomes aware 
Participation 
in study has 
ended 
N/A 
Promptly 
PC form 
 
Abbreviations: AE = adverse event; ICF = informed consent form; N/A = not applicable; PC = product complaint 
SAE = serious adverse event. 
a Serious adverse event should not be reported unless the investigator deems them to be possibly related to study 
treatment or study participation. 
8.3.2. 
Pregnancy  
Collection of pregnancy information 
Male participants with partners who become pregnant 
● The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is 
in this study. This applies only to male participants who receive study 
intervention. 
● After learning of a pregnancy in the female partner of a study participant, the 
investigator 
o will request a consent or assent to release information from the pregnant 
female partner directly, and 
o within 24 hours after obtaining this consent or assent, will record pregnancy 
information on the appropriate form and submit it to the sponsor.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
63 
The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to 
the sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks 
following the estimated delivery date. Any termination of the pregnancy will be 
reported regardless of gestational age, fetal status (presence or absence of 
anomalies), or indication for the procedure. 
Female participants who become pregnant 
● The investigator will collect pregnancy information on any female participant 
who becomes pregnant while participating in this study. The initial information 
will be recorded on the appropriate form and submitted to the sponsor within 24 
hours of learning of a participant’s pregnancy.  
● The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow-up information on the participant and the neonate, 
and the information will be forwarded to the sponsor. Generally, follow-up will 
not be required for longer than 6 to 8 weeks beyond the estimated delivery date. 
Any termination of pregnancy will be reported, regardless of gestational age, fetal 
status (presence or absence of anomalies), or indication for the procedure. 
● While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
● A spontaneous abortion, occurring at <20 weeks gestational age, or still birth, 
occurring at ≥20 weeks gestational age, is always considered to be an SAE and 
will be reported as such.  
● Any post-study pregnancy-related SAE considered reasonably related to the study 
intervention by the investigator will be reported to the sponsor as described in 
Section 8.3.1. While the investigator is not obligated to actively seek this 
information in former study participants, they may learn of an SAE through 
spontaneous reporting. 
● Any female participant who becomes pregnant while participating in the study 
will discontinue study intervention. If the participant is discontinued from the 
study, follow the standard discontinuation process and continue directly to the 
follow-up phase. The follow-up on the pregnancy outcome should continue 
independent of intervention or study discontinuation. 
Prior to continuation of study intervention following pregnancy, the following must occur: 
● The sponsor and the relevant institutional review board/independent ethics committee 
(IRB/IEC) give written approval. 
● The participant gives signed informed consent (or assent, as applicable). 
● The investigator agrees to monitor the outcome of the pregnancy and the status of the 
participant and the participant’s offspring. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
64 
8.3.3. Adverse Events of Special Interest  
The following TEAEs will be designated AE of special interest (AESI): 
 conjunctivitis 
 herpes infection or zoster, and  
 parasitic infection or an infection-related to an intracellular pathogen. 
If these AESIs are reported, sites will be prompted to collect additional data. Participant records 
must include any follow-up information regarding these AESI. Study intervention should be 
discontinued if an AE is deemed persistent and if continuation of study intervention would not be 
in the best interest of the participant. Discuss discontinuation of study intervention with the 
sponsor or designee prior to implementation. 
8.3.3.1. 
Infections, Including Serious Infections and Opportunistic Infections  
Completion of the Infection CRF page is required for each infection reported as an AE or SAE. 
The sponsor will identify infections considered to be opportunistic based on the article by 
Winthrop et al. (2015) (Section 10.9, Appendix 9). 
8.3.4. 
Facial Dermatitis  
Completion of the facial dermatitis follow-up CRF page is required for each facial dermatitis 
event reported as an AE or SAE. 
8.3.5. 
Hypersensitivity  
Many drugs, including oral agents and biologic agents, carry the risk of systemic hypersensitivity 
reactions. If such a reaction occurs, additional data should be provided to the sponsor in the 
designated CRFs. 
Sites should have appropriately trained medical staff and appropriate medical equipment 
available when study participants are receiving study intervention. It is recommended that 
participants who experience a systemic hypersensitivity reaction be treated per national and 
international guidelines. 
In the case of a suspected systemic hypersensitivity event, additional blood samples should be 
collected as described in Section 10.2.1. Laboratory results are provided to the sponsor via the 
central laboratory. 
8.3.6. 
Injection Site Reactions  
Symptoms and signs of a local injection site reaction may include erythema, induration, pain, 
pruritus, and edema.  
If an injection site reaction is reported by a participant or site staff, the injection site reaction 
CRF will be used to capture additional information about this reaction, for example, injection site 
pain, degree and area of erythema, induration, pruritis, and edema. 
8.4. 
Pharmacokinetics  
At the visits and times specified in the SoA, venous blood samples will be collected and stored 
for potential analysis of serum concentrations of lebrikizumab.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
65 
Samples will be stored at a facility designated by the sponsor and may be assessed at a later date 
at a laboratory approved by the sponsor using a validated enzyme-linked immunosorbent assay 
method. 
Instructions for the collection and handling of blood samples will be provided by the sponsor. 
The actual data and time (24-hour clock time) of each sample and the most recent lebrikizumab 
dose prior to PK blood draw must be recorded. 
Sample retention is described in Section 10.1.11. Bioanalytical samples collected to measure 
investigational product concentrations will be retained for a maximum of 1 year following last 
participant visit for the study. During this time, samples remaining after the bioanalysis may be 
used for exploratory analyses such as bioanalytical assay validation or cross-validation exercises. 
8.5. 
Pharmacodynamics  
Pharmacodynamic parameters are not evaluated in this study. 
8.6. 
Genetics  
A blood sample for DNA isolation will be collected from participants.  
See Appendix 10.5 for Information regarding genetic research and Section 10.1.11 for details 
about sample retention and custody.  
8.7. 
Biomarkers  
 Serum samples will be collected to discern responder variability within the study and to 
track response variability to lebrikizumab. Biomarkers will include but not limited to 
 
 Samples will be collected according to the 
schedule described in the SoA and as detailed in laboratory manual provided separately 
to sites. 
 The sponsor may store samples according to Section 10.1.11. Additionally, with 
participants’ consent, samples may be used for further research by the sponsor or others 
such as universities or other companies to contribute to the understanding of AD or other 
diseases, the development of related or new treatments, or research methods. 
8.8. 
Immunogenicity Assessments  
At the visits and times specified in the SoA, venous blood samples will be collected for the 
purpose of determining antibody production against lebrikizumab. To aid interpretation of these 
results, a blood sample for PK analysis will be collected at the same time points.  
All samples for immunogenicity should be taken predose when applicable and possible. 
Instructions for the collection and handling of blood samples will be provided by the sponsor. 
The actual date and time (24-hour clock time) of each sample collection will be recorded. 
Immunogenicity samples will be stored at a facility designated by the sponsor and may be later 
assessed by a validated assay designed to detect ADAs in the presence of lebrikizumab at a 
laboratory designated by the sponsor. Samples may also be used for the development and control 
of an immunogenicity assay. 
Approved on 27 Apr 2023 GMT
CCI


CONFIDENTIAL 
J2T-MC-KGBO(a) 
66 
Treatment-emergent ADAs are defined in Section 9.3.6.4. 
Sample retention is described in Section 10.1.11. 
8.9. 
Health Economics  
Health economics and/or medical resource utilization will not be collected as part of this study. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
67 
9. 
Statistical Considerations  
The SAP will be finalized prior to first participant visit, and it will include a more technical and 
detailed description of the statistical analyses described in this section. This section is a summary 
of the planned statistical analyses of the most important endpoints, including primary and key 
secondary endpoints. 
9.1. 
Statistical Hypotheses  
The primary objective is to evaluate efficacy of lebrikizumab 250 mg Q2W on reducing skin 
sign of AD, measured by percentage of participants who achieve at least 75% improvement in 
baseline EASI at Week 16 in participants with moderate-to-severe AD who were previously 
treated with dupilumab. There is no hypothesis testing planned nor inference statistical analysis 
planned.  
9.2. 
Analyses Sets  
Participant Analysis Set 
Description 
ITT population 
All enrolled participants. Participants will be included in the analyses 
according to the planned intervention. 
Safety population 
All participants who are exposed to study intervention.  
 Abbreviation: ITT = intent-to-treat. 
9.3. 
Statistical Analyses  
9.3.1. General Considerations  
Statistical analysis of this study will be the responsibility of Lilly or its designee. A detailed SAP 
describing the statistical methodologies will be developed by Lilly or its designee. 
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the CSR. Additional exploratory analyses of the data will be conducted as deemed appropriate. 
All analyses will be descriptive. Frequencies, percentages, and 90% CI for percentages will be 
reported for discrete efficacy endpoints. Mean, standard deviation, minimum, Q1, median, Q3, 
maximum, and the number of participants will be reported for continuous efficacy endpoints. 
AEs, discontinuation, and other categorical safety data will be summarized using frequencies and 
percentage. Continuous vital signs, body weight, and other continuous safety variables including 
laboratory variables will be summarized descriptively as well. 
9.3.2. 
Primary Endpoint(s)/Estimand(s) Analysis  
The primary endpoint is EASI-75 response rate at Week 16. The primary clinical question of 
interest is: What is the intervention effect in percentage of participants achieving EASI-75 after 
16 weeks of lebrikizumab 250 mg intervention in participants with moderate-to-severe AD who 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
68 
have been previously treated with dupilumab and who remain on study treatment until Week 16. 
There are no intercurrent events since participants who initiate rescue medication are 
discontinued from the study and hence study treatment. Therefore, participants who stay on 
study treatment through Week 16 will not have an intercurrent event such as initiating rescue 
medication or permanently discontinuing treatment. All observed data will be included in 
summary statistics. All summary statistics will be based on observed data.  
9.3.3. 
Secondary Endpoint(s)/Estimand(s) Analysis  
Secondary endpoints outlined in the objective will be analyzed similarly to the primary endpoint 
of the primary estimand, that is, using all observed data. For categorical endpoints related to 
reaching a threshold, analyses will be evaluated in participants who satisfy baseline minimum 
value (for xx-point improvement, baseline value need to be ≥xx) in intent-to-treat set. 
9.3.4. 
Exploratory Endpoint(s) Analysis  
Other exploratory endpoints specified in Section 3 will be summarized using all observed data. 
9.3.5. 
Safety Analyses  
All safety data will be descriptively summarized using the safety population. 
Treatment-emergent AEs are defined as AEs that first occurred or worsened in severity after the 
first dose of study treatment. The number of TEAEs as well as the number and percentage of 
participants who experienced at least 1 TEAE will be summarized using MedDRA (Medical 
Dictionary for Regulatory Activities) for each system organ class (or a body system) and each 
preferred term. SAEs and AEs that lead to discontinuation of study intervention will also be 
summarized. 
All clinical laboratory results will be descriptively summarized. Individual results that are 
outside of normal reference ranges will be flagged in data listings. Quantitative clinical 
hematology, chemistry, and urinalysis variables obtained at the baseline to postbaseline visits 
will be summarized as changes from baseline. Categorical variables, including the incidence of 
abnormal values and incidence of AEs of special interest, will be summarized by frequency and 
percentage of participants in corresponding categories. Shift tables might be presented for 
selected measures. 
Observed values and changes from baseline (predose or screening if missing) for vital signs and 
physical characteristics will be descriptively summarized by time point.  
The SAP may include additional safety analyses if needed. 
9.3.6. 
Other Analyses  
9.3.6.1. 
Subgroup Analyses  
Subgroup (subpopulation) analyses of the primary endpoint and selected secondary endpoints at 
Weeks 16 and 24 may be conducted for intended-to-treat set. Subgroup to be evaluated may 
include baseline severity, sex, age, race, and reasons for discontinuation for previously treated 
with dupilumab.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
69 
Definitions for the levels of the subgroup variables and any additional subgroup analyses will be 
defined in the SAP if applicable. All analyses will be descriptive and should be treated as 
exploratory.  
9.3.6.2. 
Biomarker Analyses  
Biomarker analyses will be described in the SAP. 
9.3.6.3. 
Pharmacokinetic Analyses  
PK samples will be stored and may be later assessed. If assessed, PK analyses may be described 
in the SAP. 
9.3.6.4. 
Immunogenicity Assessments  
Immunogenicity samples will be stored and may be later assessed. If assessed, the frequency and 
percentage of participants with preexisting anti-drug antibody (ADA) and who are treatment-
emergent ADA positive (TE ADA+) to lebrikizumab will be tabulated. 
Treatment-emergent ADAs are defined as participants 
 with a 2-fold (1 dilution) increase in titer than the minimum required dilution if no ADAs 
were detected at baseline (treatment-induced ADA), or 
 with a 4-fold (2 dilutions) increase in titer compared with baseline if ADAs were detected 
at baseline (treatment-boosted ADA). 
The distribution of titers and frequency of neutralizing antibodies (if assessed) for TE ADA+ 
participants may also be tabulated. 
The relationship between the presence of ADA and PK parameters, efficacy response, or safety 
to lebrikizumab may also be assessed. 
Additional details may be provided in the SAP. 
9.4. 
Interim Analysis  
One interim analysis (primary lock) will be conducted after all enrolled participants have been 
evaluated at Week 16 or discontinued prior to Week 16. This interim database lock will include 
all efficacy and safety data collected by the cutoff date. Due to the open-label and descriptive 
nature of this study, this is no unblind nor alpha adjustment. 
Additional analyses and snapshots of study data may be performed to fulfill the need for 
regulatory interactions or publication purposes. 
The SAP will describe the planned interim analyses in greater detail. 
9.5. 
Sample Size Determination  
Based on available data, the anticipated EASI-75 response rate is approximately 50%. A total 
sample size of 120 enrolled participants will provide >95% probability that the 2-sided 90% CI 
of the EASI-75 response rate with half-width is at most 10%. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
70 
With a total sample size N = 120, example point estimate of response rates and corresponding 2-
sided 90% CI based on Wilson (Score) method are summarized in the table below. The values 
are provided as reference rather than a basis of any decision criteria. 
Estimated 90% CI with Sample Size of 120 Participants 
Example Point Estimates 
Lower Bound of 90% CI 
Upper Bound of 90% CI 
40% 
32.9% 
47.5% 
45% 
37.7% 
52.5% 
50% 
42.6% 
57.4% 
55% 
47.5% 
62.3% 
60% 
52.5% 
67.1% 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
71 
10. 
Supporting Documentation and Operational Considerations  
10.1. 
Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1. 
Regulatory and Ethical Considerations  
● This study will be conducted in accordance with the protocol and with the 
following: 
○ Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences International Ethical Guidelines 
○ Applicable ICH GCP Guidelines 
○ International Organization for Standardization 14155 
○ Applicable laws and regulations 
● The protocol, protocol amendments, ICF, IB, and other relevant documents (for 
example, advertisements) must be submitted to an IRB/IEC by the investigator 
and reviewed and approved by the IRB/IEC before the study is initiated. 
● Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants. 
● Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants. 
● The investigator will be responsible for the following: 
○ Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by the IRB/IEC 
○ Notifying the IRB/IEC of SAEs or other significant safety findings as required 
by IRB/IEC procedures 
○ Providing oversight of study conduct for participants under their responsibility 
and adherence to requirements of 21 Code of Federal Regulations, ICH 
guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations 
● Investigator sites are compensated for participation in the study as detailed in the 
clinical trial agreement. 
10.1.2. 
Financial Disclosure  
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
72 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study. 
10.1.3. 
Informed Consent Process  
● The investigator or the investigator’s representative will explain the nature of the 
study, including the risks and benefits, to the participant, or the participant’s 
legally authorized representative, and answer all questions regarding the study. 
● Participants must be informed that their participation is voluntary. Participants, or 
their legally authorized representatives, will be required to sign a statement of 
informed consent that meets the requirements of 21 Code of Federal Regulations 
50, local regulations, ICH guidelines, privacy and data protection requirements, 
where applicable, and the IRB/IEC or study center. 
● For adult participants, the medical record must include a statement that written 
informed consent was obtained before the participant was entered in the study and 
the date the written consent was obtained. The authorized person obtaining the 
informed consent must also sign the ICF. 
● For adolescent participants, the medical record must include a statement that legally 
acceptable representative or parent(s) consent and child/adolescent assent (if deemed 
appropriate by local ethics review) was obtained before the participant was enrolled in 
the study and the date the written consent was obtained. The medical record should also 
describe how the clinical investigator determined that the person signing the ICF was the 
participant’s legally acceptable representative or parent(s). The acceptable person 
obtaining the informed consent must also sign the ICF. Adolescent participants who 
become 18 years of age while on study, will need to re-consent.  
● Participants (or their legally acceptable representative, parent(s), or legal 
guardian) must be reconsented to the most current version of the ICF(s) during 
their participation in the study. 
● A copy of the ICF(s) must be provided to the participant, or the participant’s 
legally authorized representative, and is kept on file. 
Participants who are rescreened are required to sign a new ICF. 
10.1.4. 
Data Protection  
● Participants will be assigned a unique identifier by the sponsor. Any participant 
records, datasets, or tissue samples that are transferred to the sponsor will contain 
the identifier only; participant names or any information which would make the 
participant identifiable will not be transferred. 
● The participant must be informed that the participant’s personal study-related data 
will be used by the sponsor in accordance with local data protection law. The 
level of disclosure must also be explained to the participant who will be required 
to give consent for their data to be used as described in the informed consent.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
73 
● The participant must be informed that their medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by 
the sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities. 
● The sponsor has processes in place to ensure data protection, information security, 
and data integrity. These processes include appropriate contingency plan(s) for 
appropriate and timely response in the event of a data security breach. 
10.1.5. 
Dissemination of Clinical Study Data  
Reports 
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly available websites where required by local law or regulation.  
Data  
The sponsor provides access to all individual participant data collected during the trial, after 
anonymization, with the exception of PK or genetic data. Data are available to request 6 months 
after the indication studied has been approved in the US and EU and after primary publication 
acceptance, whichever is later. No expiration date of data requests is currently set once data are 
made available.  
Access is provided after a proposal has been approved by an independent review committee 
identified for this purpose and after receipt of a signed data sharing agreement. Data and 
documents, including the study protocol, statistical analysis plan, clinical study report, and blank 
or annotated CRFs, will be provided in a secure data sharing environment for up to 2 years per 
proposal.  
For details on submitting a request, see the instructions provided at www.vivli.org. 
10.1.6. 
Data Quality Assurance  
● All participant data relating to the study will be recorded on printed or electronic 
CRFs unless transmitted to the sponsor or designee electronically (for example, 
laboratory data). The investigator is responsible for verifying that data entries are 
accurate and correct by physically or electronically signing the CRF. 
● The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF. 
● The investigator must permit study-related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct access to source data 
documents. 
● Quality tolerance limits (QTLs) will be pre-defined to identify systematic issues 
that can impact participant safety and/or reliability of study results. These pre-
defined parameters will be monitored during the study and important excursions 
from the QTLs and remedial actions taken will be summarized in the clinical 
study report. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
74 
● Monitoring details describing strategy (for example, risk-based initiatives in 
operations and quality such as risk management and mitigation strategies and 
analytical risk-based monitoring), methods, responsibilities and requirements, 
including handling of noncompliance issues and monitoring techniques are 
provided in the Monitoring Plan. 
● The sponsor or designee is responsible for the data management of this study 
including quality checking of the data. 
● The sponsor assumes accountability for actions delegated to other individuals (for 
example, contract research organizations). 
● Study monitors will perform ongoing source data verification to confirm that data 
transcribed into the CRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements. 
● Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by the investigator for the time period outlined in the 
clinical trial agreement unless local regulations or institutional policies require a 
longer retention period. No records may be destroyed during the retention period 
without the written approval of the sponsor. No records may be transferred to 
another location or party without written notification to the sponsor. 
● In addition, sponsor or its representatives will periodically check a sample of the 
participant data recorded against source documents at the study site. The study 
may be audited by sponsor or its representatives, and/or regulatory agencies at 
any time. Investigators will be given notice before an audit occurs. 
Data Capture System 
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.  
An EDC will be used in this study for the collection of CRF data. The investigator maintains a 
separate source for the data entered by the investigator or designee into the sponsor-provided 
EDC system. The investigator is responsible for the identification of any data to be considered 
source and for the confirmation that data reported are accurate and complete by signing the CRF. 
Additionally, the skin assessment using the Fitzpatrick Skin Type scale will be collected by the 
authorized study personnel via a paper source document and will be transcribed by the 
authorized study personnel into the EDC system. 
Additionally, electronic clinical outcomes assessment (COA) data (participant-focused outcome 
instrument) will be directly recorded by the participant/investigator site personnel, into an 
instrument (for example, handheld smart phone or tablet). The electronic COA data will serve as 
the source documentation, and the investigator does not maintain a separate written or electronic 
record of these data. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
75 
Data collected via the sponsor-provided data capture system(s) will be stored at third parties. The 
investigator will have continuous access to the data during the study and until decommissioning 
of the data capture system(s). Prior to decommissioning, the investigator will receive or access 
an archival copy of pertinent data for retention. 
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system and reports will be provided to the investigator for review 
and retention. Data will subsequently be transferred from the central vendor to the sponsor data 
warehouse. 
Data from complaint forms submitted to the sponsor will be encoded and stored in the global PC 
management system. 
10.1.7. 
Source Documents  
● Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site. 
● Data reported on or entered in the CRF and are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, depending on the study. Also, current medical records must be 
available. 
● Definition of what constitutes source data can be found in Section 10.1.6. 
10.1.8. 
Study and Site Start and Closure  
First Act of Recruitment 
The study start date is the date on which the clinical study will be open for recruitment of 
participants. 
The first act of recruitment is the first site open and will be the study start date. 
Study or Site Termination 
The sponsor or sponsor’s designee reserves the right to close the study site or terminate the study 
at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon 
study completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study site closure visit has been performed. 
The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to: 
For study termination: 
 Discontinuation of further study intervention development 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
76 
For site termination: 
● Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor’s procedures, or GCP guidelines 
● Inadequate recruitment (evaluated after a reasonable amount of time) of 
participants by the investigator 
● Total number of participants included earlier than expected. 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by the applicable 
regulatory requirements. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow-up. 
10.1.9. 
Publication Policy  
In accordance with the sponsor’s publication policy, the results of this study will be submitted 
for publication by a peer-reviewed journal. 
10.1.10. 
Investigator Information  
Researchers with appropriate education, training, and experience, as determined by the sponsor, 
will participate as investigators in this clinical trial. 
10.1.11. 
Sample Retention  
Sample retention enables use of new technologies, response to regulatory questions, and 
investigation of variable response that may not be observed until later in the development 
of lebrikizumab or after lebrikizumab become(s) commercially available.  
Sample Type 
Custodian 
Retention Period after 
Last Participant Visit 
Biomarkers 
Sponsor or Designee 
7 years 
PK 
Sponsor or Designee 
1 year 
Genetics 
Sponsor or Designee 
7 years 
Immunogenicity 
Sponsor or Designee 
7 years 
Abbreviation: PK = pharmacokinetics. 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
77 
10.2. 
Appendix 2: Clinical Laboratory Tests  
● The tests detailed in the table below will be performed by the central laboratory. 
● In circumstances where the sponsor approves local laboratory testing in lieu of 
central laboratory testing (in the table below), the local laboratory must be 
qualified in accordance with applicable local regulations. 
● Protocol-specific requirements for inclusion or exclusion of participants are 
detailed in Section 5 of the protocol. 
● Additional tests may be performed at any time during the study as determined 
necessary by the investigator or required by local regulations. 
● Investigators must document their review of the laboratory safety results. 
Clinical Laboratory Tests 
Comments 
Hematology 
Assayed by Lilly-designated laboratory 
Hemoglobin 
  
Hematocrit 
  
Erythrocyte count (RBCs) 
  
Mean cell volume  
  
Mean cell hemoglobin 
  
Mean cell hemoglobin concentration  
Absolute neutrophil count (calculation) 
(definition – include segs and bands or segs, 
bands and other immature cells) 
  
Leukocytes (WBCs)  
  
Differential 
  
Percent and absolutes count of: 
  
   Neutrophils, segmented 
  
   Neutrophils, bands 
  
   Lymphocytes 
  
   Monocytes 
  
   Eosinophils 
  
   Basophils 
  
Platelets 
  
Cell morphology (RBCs and WBCs) 
  
  
  
Clinical Chemistry 
Assayed by Lilly-designated laboratory 
Sodium 
  
Potassium 
  
Chloride 
  
Bicarbonate 
  
Total bilirubin 
  
Direct bilirubin 
  
ALP 
  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
78 
Clinical Laboratory Tests 
Comments 
ALT 
  
AST 
  
GGT 
  
BUN 
  
Creatinine  
  
CK 
  
Uric acid 
  
Total protein 
  
Albumin 
  
Calcium 
  
Phosphorus 
  
LDH 
  
  
  
Hormones (female) 
  
Serum pregnancy  
Assayed by Lilly-designated laboratory  
Urine pregnancy 
Assayed and Evaluated locally  
  
  
HIV and Hepatitis Serology 
Assayed by Lilly-designated laboratory 
HIV testing  
  
HCV testing: 
  
    HCV antibody  
  
    HCV RNA 
  
HBV testing:  
  
   HBV DNA  
Performed only for participants who test positive for HBcAb 
   HBcAb  
  
   HBsAg  
  
   HBsAb 
  
  
  
Exploratory Biomarkers  
Assayed by Lilly-designated laboratory 
Results will not be provided to the investigative sites 
  
Immunoglobulins 
Assayed by Lilly-designated laboratory 
Results will not be provided to the investigative sites 
IgE (Serum) 
  
  
  
Genetics Sample 
Assayed by Lilly-designated laboratory 
Results will not be provided to the investigative sites 
  
  
Exploratory Biomarker storage samples 
Assayed by Lilly-designated laboratory 
Results will not be provided to the investigative sites 
Serum 
  
Approved on 27 Apr 2023 GMT
CCI


CONFIDENTIAL 
J2T-MC-KGBO(a) 
79 
Clinical Laboratory Tests 
Comments 
 
 
Immunogenicity (ADA) samples 
Assayed by Lilly-designated laboratory 
Results will not be provided to the investigative sites 
Anti-LY3650150 antibodies 
 
 
 
Pharmacokinetic Samples – LY3650150 
concentration 
Assayed by Lilly-designated laboratory 
Results will not be provided to the investigative sites 
Abbreviations: ADA = anti-drug antibodies; ALP = alkaline phosphatase; ALT = alanine aminotransferase; 
AST = aspartate aminotransferase; BUN = blood urea nitrogen; CK = creatine kinase; GGT = Gamma-glutamyl 
transferase; HBcAb = hepatitis B core antibody; HBsAb = hepatitis B surface antibody; HBsAg = hepatitis B 
surface antigen; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; 
IgE = immunoglobulin E; IL = interleukin; LDH = lactic dehydrogenase; PK = pharmacokinetics; RBC = red 
blood cells; WBC = white blood cells. 
10.2.1. 
Laboratory Samples to be Obtained at the Time of a Systemic Hypersensitivity 
Event  
Purpose of collecting samples after a systemic hypersensitivity event 
The samples listed in this appendix are not collected for acute study participant management. 
The sponsor will use the laboratory tests results from these samples to characterize 
hypersensitivity events across the clinical development program. 
When to collect samples after a systemic hypersensitivity event occurs 
Collect the samples listed below if a systemic hypersensitivity event is suspected. The timing 
should be as designated in the table, assuming the participant has been stabilized. 
Obtain follow-up predose samples at the next regularly scheduled laboratory sample collection, 
ideally prior to the next dose after the event, to assess post-event return-to-baseline values. 
Timing 
Laboratory Testa 
Collect from 30 minutes to 4 hours after the start of 
the event.  
● NOTE: The optimal collection time is from 1 
to 2 hours after the start of event 
Tryptase 
Collect only if not already collected on the same day as 
the event. 
● NOTE: If collecting, collect up to 12 hours 
after the start of the event 
Lebrikizumab anti-drug antibodies 
Lebrikizumab concentration 
a All samples for hypersensitivity testing will be assayed by Lilly-designated laboratory. Results will not be 
provided to the study site. If samples are not collected or are collected outside the specified time period, this will 
not be considered a protocol deviation. 
What information to record 
Record the date and time when the samples are collected. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
80 
Allowed additional testing for participant management 
The investigator may perform additional tests locally, if clinically indicated, for acute study 
participant management. 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
81 
10.3. 
Appendix 3: Adverse Events and Serious Adverse Events: Definitions 
and Procedures for Recording, Evaluating, Follow-up, and 
Reporting  
 The definitions and procedures detailed in this appendix are in accordance with 
International Organization for Standardization (ISO) 14155. 
 Both the investigator and the sponsor will comply with all local medical device reporting 
requirements. 
 The detection and documentation procedures described in this protocol apply to all 
sponsor medical devices provided for use in the study. See Section 6.1.1 for the list of 
sponsor medical devices. 
10.3.1. 
Definition of AE  
AE Definition 
 An AE is any untoward medical occurrence in a participant administered a 
pharmaceutical product and which does not necessarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product. 
 An AE is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory finding) in study participants, users, or 
other persons, whether or not related to the investigational medical device. This 
definition includes events related to the investigational medical device or comparator 
and events related to the procedures involved except for events in users or other 
persons, which only include events related to investigational devices. 
 
Events Meeting the AE Definition 
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (for example, electrocardiogram, radiological scans, vital 
signs measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (that is, not related 
to progression of underlying disease). 
 Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency and/or intensity of the condition. 
 New condition detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study. 
 Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
82 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming 
intent. Such overdoses should be reported regardless of sequelae. 
 Lack of efficacy or failure of expected pharmacological action per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfill the definition of an AE or SAE. 
 
Events NOT Meeting the AE Definition 
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition. 
 The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition. 
 Medical or surgical procedure (for example, endoscopy, appendectomy): the condition 
that leads to the procedure is the AE. 
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
 Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
10.3.2. 
Definition of SAE  
An SAE is defined as any untoward medical occurrence that, at any dose, meets one or 
more of the criteria listed: 
a. Results in death 
b. Is life-threatening 
The term life-threatening in the definition of serious refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe. 
c. 
Requires inpatient hospitalization or prolongation of existing hospitalization 
 In general, hospitalization signifies that the participant has been admitted to hospital or 
emergency ward (usually involving at least an overnight stay) for observation and/or 
treatment that would not have been appropriate in the physician’s office or outpatient 
setting. Complications that occur during hospitalization are AEs. If a complication 
prolongs hospitalization or fulfills any other serious criteria, the event is serious. When 
in doubt as to whether hospitalization occurred or was necessary, the AE should be 
considered serious. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
83 
 Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE. 
d. Results in persistent disability/incapacity 
 The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. 
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (for example, sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption. 
e. 
Is a congenital anomaly/birth defect 
 Abnormal pregnancy outcomes (for example, spontaneous abortion, fetal death, 
stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs. 
f. 
Other situations: 
 Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations such as important medical 
events that may not be immediately life-threatening or result in death or hospitalization 
but may jeopardize the participant or may require medical or surgical intervention to 
prevent one of the other outcomes listed in the above definition. These events should 
usually be considered serious. 
 
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency or 
drug abuse.  
g. Resulted in medical or surgical intervention to prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body function.  
10.3.3. 
Definition of Product Complaints  
Product Complaint 
A PC is any written, electronic, or oral communication that alleges deficiencies related 
to the identity, quality, durability, reliability, safety, effectiveness, or performance of a 
study intervention. When the ability to use the study intervention safely is impacted, 
the following are also PCs: 
o Deficiencies in labeling information, and 
o Use errors for device or drug-device combination products due to ergonomic 
design elements of the product. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
84 
 PCs related to study interventions used in clinical trials are collected in order to ensure 
the safety of participants, monitor quality, and to facilitate process and product 
improvements. 
 Investigators will instruct participants to contact the site as soon as possible if he or she 
has a PC or problem with the study intervention so that the situation can be assessed. 
 An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a PC and as an AE/SAE. 
10.3.4. 
Recording and Follow-Up of AE and/or SAE and Product Complaints  
AE, SAE, and Product Complaint Recording 
 When an AE/SAE/PC occurs, it is the responsibility of the investigator to review all 
documentation (for example, hospital progress notes, laboratory reports, and 
diagnostics reports) related to the event. 
 The investigator will then record all relevant AE/SAE/PC information in the 
participant’s medical records, in accordance with the investigator’s normal clinical 
practice. AE/SAE information is reported on the appropriate CRF page and PC 
information is reported on the Product Complaint Form. 
NOTE: An event may meet the definition of both a PC and an AE/SAE. In such cases, 
it should be reported as both a PC and as an AE/SAE. 
 It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to Sponsor or designee in lieu of completion of the CRF page for AE/SAE and 
the Product Complaint Form for PCs. 
 There may be instances when copies of medical records for certain cases are requested 
by Sponsor or designee. In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copies of the medical records before 
submission to Sponsor or designee. 
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
85 
Assessment of Intensity 
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to one of the following categories:  
 Mild: A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally interfere with usual 
activities of daily living. 
 Moderate: A type of adverse event that is usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to the research 
participant. 
 Severe: A type of adverse event that interrupts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention. 
An AE that is assessed as severe should not be confused with a SAE. Severe is a 
category utilized for rating the intensity of an event; and both AEs and SAEs can be 
assessed as severe. 
An event is defined as “serious” when it meets at least one of the pre-defined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.  
 
Assessment of Causality 
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE. The investigator will use clinical judgment to 
determine the relationship/ 
 A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out. 
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated. 
 The investigator will also consult the IB in their assessment. 
 For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality. 
 There may be situations in which an SAE has occurred, and the investigator has 
minimal information to include in the initial report to Sponsor or designee. However, it 
is very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to Sponsor or designee. 
 The investigator may change their opinion of causality in light of follow-up 
information and send a SAE follow-up report with the updated causality assessment. 
 The causality assessment is one of the criteria used when determining regulatory 
reporting requirements. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
86 
 
Follow-up of AEs and SAEs 
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Sponsor or 
designee to elucidate the nature and/or causality of the AE or SAE as fully as possible. 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals. 
 If a participant dies during participation in the study or during a recognized follow-up 
period, the investigator will provide Sponsor or designee with a copy of any 
post-mortem findings including histopathology. 
10.3.5. 
Reporting of SAEs  
SAE Reporting via Paper Form 
 Facsimile transmission of the SAE paper form is the preferred method to transmit this 
information to the medical monitor or the SAE coordinator. 
 Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames. 
 Contacts for SAE reporting can be found in SAE form.  
10.3.6. 
Regulatory Reporting Requirements  
SAE Regulatory Reporting 
 Prompt notification by the investigator to the sponsor of a SAE is essential so 
that legal obligations and ethical responsibilities toward the safety of 
participants and the safety of a study intervention under clinical investigation 
are met. 
● The sponsor has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will evaluate the reported SAEs, 
including confirmation of relatedness and assessment of expectedness. The 
sponsor has processes for safety reports for identification, recording, and 
expedited reporting of suspected unexpected serious adverse reactions 
according to local regulatory requirements. The sponsor will comply with 
country-specific regulatory requirements relating to safety reporting to the 
regulatory authority, Institutional Review Boards (IRB)/Independent Ethics 
Committees (IEC), and investigators. 
● An investigator who receives an investigator safety report describing a SAE or 
other specific safety information (for example, summary or listing of SAEs) 
from the sponsor will review and then file it along with the IB will notify the 
IRB/IEC, if appropriate according to local requirements.  
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
87 
10.4. 
Appendix 4: Contraceptive and Barrier Guidance  
10.4.1. 
Definitions  
Women of child-bearing potential (WOCBP) 
Females are considered WOCBP if they have had at least 1 cycle of menses. 
Any amount of spotting or bleeding should be considered menarche.  
Women not of child-bearing potential (WNOCBP) 
Females are considered WNOCBP if they 
 have a congenital anomaly such as Mullerian agenesis 
 are infertile due to surgical sterilization, or  
 are postmenopausal. 
Examples of surgical sterilization include total hysterectomy, bilateral salpingo-oophorectomy, 
bilateral salpingectomy, or bilateral oophorectomy. 
Postmenopausal 
The postmenopausal state is defined as ≥1 year without a menstrual period confirmed by follicle 
stimulating hormone test.  
10.4.2. 
Contraception Guidance  
Guidance for WOCBP 
This outlines the rules for WOCBP to ensure they do not become pregnant during the study.  
 
WOCBP who are completely abstinent as their preferred and usual lifestyle, or in a same-sex 
relationship as their preferred and usual lifestyle: 
Must… 
Must not… 
agree to either 
remain abstinent or 
stay in a same-sex 
relationship without 
sexual relationships 
with males 
 use periodic abstinence methods 
o calendar  
o ovulation  
o symptothermal, or 
o post-ovulation  
 declare abstinence just for the duration of a trial, or 
 use the withdrawal method 
 
WOCBP, who are NOT completely abstinent as their preferred and usual lifestyle, or NOT in a 
same-sex relationship as their preferred and usual lifestyle, must do the following: 
Topic 
Condition 
Pregnancy testing 
Have a negative serum test result at screening (or upon a participant 
that reaches menarche during the trial and is sexually active) followed 
by a negative urine result within 24 hours prior to treatment exposure. 
See the protocol SoA for subsequent pregnancy testing requirements. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
88 
Topic 
Condition 
Contraception 
Agree to use 1 highly effective method of contraception, or a 
combination of 2 effective methods of contraception. 
 
These forms of contraception must be used for the duration of the 
study. 
Examples of different forms of contraception 
Methods 
Examples 
Highly effective contraception 
(less than 1% failure rate) 
 
female sterilization 
 
combination oral contraceptive pill 
 progestin-only contraceptive pill (mini-pill) 
 
implanted contraceptives 
 
injectable contraceptives 
 
contraceptive patch (only women <198 pounds or 90 kg) 
 
total abstinence 
 
vasectomy, if only sexual partner 
 
fallopian tube implants, if confirmed by 
hysterosalpingogram 
 
combined contraceptive vaginal ring, or  
 
intrauterine devices 
Effective contraception  
 
male or female condoms with spermicide  
 
diaphragms with spermicide or cervical sponges 
 
barrier method with use of a spermicide 
o condom with spermicide 
o diaphragm with spermicide, or 
o female condom with spermicide. 
NOTE: The barrier method must include use of a spermicide, that 
is, condom with spermicide, diaphragm with spermicide, and 
female condom with spermicide, to be considered effective. 
Ineffective forms of contraception 
 
spermicide alone  
 
immunocontraceptives 
 
periodic abstinence 
 
fertility awareness (calendar method, temperature 
method, combination of above 2, cervical mucus, 
symptothermal) 
 
withdrawal 
 
post coital douche, and 
 
lactational amenorrhea 
 
Guidance for all men 
Males may participate in this trial.  
No male contraception is required except in compliance with specific local government study 
requirements. 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
89 
10.5. 
Appendix 5: Genetics  
Use/Analysis of DNA 
● Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Variable response to 
study intervention may be due to genetic determinants that impact drug 
absorption, distribution, metabolism, and excretion; mechanism of action of the 
drug; disease etiology; and/or molecular subtype of the disease being treated. 
Therefore, where local regulations and IRB/IEC allow, a sample will be collected 
for DNA analysis from consenting participants. 
● DNA samples will be used for research related to lebrikizumab or moderate-to-
severe AD and related diseases. They may also be used to develop tests or assays 
including diagnostic tests related to lebrikizumab and moderate-to-severe AD. 
Genetic research may consist of the analysis of one or more candidate genes or 
the analysis of genetic markers throughout the genome or analysis of the entire 
genome (as appropriate). 
● The samples may be analyzed as part of a multi-study assessment of genetic 
factors involved in the response to lebrikizumab or study interventions of this 
class to understand study disease or related conditions. 
● The results of genetic analyses may be reported in the CSR or in a separate study 
summary. 
● The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality. 
● The samples will be retained while research on lebrikizumab continues but no 
longer than 15 years or other period as per local requirements. 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
90 
10.6. 
Appendix 6: Liver Safety: Suggested Actions and Follow-up 
Assessments  
Hepatic Evaluation Testing 
See Section 8.2.2 for guidance on appropriate test selection. 
The Lilly-designated central laboratory should complete the analysis of all selected testing 
except for testing listed in the investigator-designated local laboratory table. The central 
laboratory will report results if a validated test or calculation is available. 
Local testing may be performed in addition to central testing when necessary for immediate 
participant management. 
The local laboratory must be qualified in accordance with applicable local regulations. 
Tests assayed by Lilly-designated central laboratory 
Hepatic Hematology Panel 
Hepatitis A virus (HAV) testing: 
   Hemoglobin 
    HAV total antibody 
   Hematocrit 
    HAV IgM antibody 
   Erythrocytes (RBCs - red blood cells) 
Hepatitis B virus (HBV) testing: 
   Leukocytes (WBCs - white blood cells) 
    Hepatitis B surface antigen (HBsAg) 
   Differential: 
    Hepatitis B surface antibody (anti-HBs) 
       Neutrophils, segmented 
    Hepatitis B core total antibody (anti-HBc) 
       Lymphocytes 
    Hepatitis B core IgM antibody 
       Monocytes 
    HBV DNA a 
       Basophils 
Hepatitis C virus (HCV) testing: 
       Eosinophils 
    HCV antibody 
   Platelets 
    HCV RNA a 
   Cell morphology (RBC and WBC) 
Hepatitis D virus (HDV) testing: 
Hepatic Clinical Chemistry Panel 
    HDV antibody 
   Total bilirubin 
Hepatitis E virus (HEV) testing: 
   Direct bilirubin 
    HEV IgG antibody 
   Alkaline phosphatase (ALP) 
    HEV IgM antibody 
   Alanine aminotransferase (ALT) 
    HEV RNA a 
   Aspartate aminotransferase (AST) 
Anti-nuclear antibody (ANA) 
   Gamma-glutamyl transferase (GGT) 
Anti-smooth muscle antibody (ASMA) b 
   Creatine kinase (CK) 
Anti-actin antibody c 
Hepatic Coagulation Panel 
Immunoglobulin IgA (quantitative) 
   Prothrombin time, INR (PT-INR) 
Immunoglobulin IgG (quantitative) 
Urine Chemistry 
Immunoglobulin IgM (quantitative) 
   Drug screen 
Epstein-Barr virus (EBV) testing: 
Haptoglobin 
    EBV antibody 
a 
Reflex/confirmation dependent on regulatory requirements, testing availability, or both. 
b 
Not required if anti-actin antibody is tested. 
c 
Not required if anti-smooth muscle antibody (ASMA) is tested. 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
91 
 
Tests assayed ONLY by investigator-designated local laboratory  
Acetaminophen 
Cytomegalovirus (CMV) testing: 
Acetaminophen protein adducts 
    CMV antibody 
Alkaline phosphatase isoenzymes 
    CMV DNA a 
Ceruloplasmin 
Herpes simplex virus (HSV) testing: 
Copper 
    HSV (Type 1 and 2) antibody 
Ethyl alcohol (EtOH) 
    HSV (Type 1 and 2) DNA a 
Phosphatidylethanol (PEth) 
Liver kidney microsomal type 1 (LKM-1) antibody 
Urine Chemistry 
Microbiology  
    Ethyl glucuronide (EtG) 
Culture: 
Epstein-Barr virus (EBV) testing: 
    Blood 
    EBV DNA a 
    Urine 
 
a 
Reflex/confirmation dependent on regulatory requirements, testing availability, or both. 
 
 
 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
92 
10.7. 
Appendix 7: American Academy of Dermatology: Criteria for the 
Diagnosis and Assessment of Atopic Dermatitis  
Features to be considered in diagnosis of patients with AD: 
Essential Features—Must be present: 
 
pruritus 
 
eczema (acute, subacute, chronic) 
o typical morphology and age-specific patterns* 
o chronic or relapsing history 
*Patterns include: 
1) facial, neck, and extensor involvement in infants and children  
2) current or previous flexural lesions in any age group 
3) sparing of the groin and axillary regions 
Important Features—Seen in most cases, adding support to the diagnosis: 
 
early age of onset 
 
atopy 
o personal and/or family history 
o Immunoglobulin E reactivity 
 
xerosis 
 
Associated Features—These clinical associations help to suggest the diagnosis of AD 
but are too nonspecific to be used for defining or AD for research and epidemiologic 
studies: 
 
atypical vascular responses (e.g., facial pallor, white dermographism, delayed blanch 
response) 
 
keratosis pilaris/pityriasis alba/hyperlinear palms/ichthyosis 
 
ocular/periorbital changes 
 
other regional findings (for example, perioral changes/periauricular lesions) 
 
perifollicular accentuation/lichenification/prurigo lesions 
 
Exclusionary Features—It should be noted that a diagnosis of AD depends on 
excluding conditions, such as: 
 
scabies 
 
seborrheic dermatitis 
 
contact dermatitis (irritant or allergic) 
 
ichthyoses 
 
cutaneous T-cell lymphoma 
 
psoriasis 
 
photosensitivity dermatoses 
 
immune deficiency diseases 
 
erythroderma of other causes 
Source: Eichenfield et al. Guidelines of care for the management of atopic dermatitis: section 1. 
Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-3351. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
93 
10.8. 
Appendix 8: Medical Device Adverse Events (AEs), Adverse Device 
Effects (ADEs), Serious Adverse Events (SAEs) and Device 
Deficiencies: Definition and Procedures for Recording, Evaluating, 
Follow-up, and Reporting  
Refer to Appendix 3 for definitions and procedures for recording, evaluating, follow-up, and 
reporting of all events. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
94 
10.9. 
Appendix 9: Examples of Infections That May Be Considered 
Opportunistic in the Setting of Biologic Therapy  
This table lists examples of infections that may be considered opportunistic in the context of 
biologic therapy. This table is provided to aid the investigator in recognizing infections that may 
be considered opportunistic. This list is not exhaustive. For data analysis, infections will be 
categorized by Lilly as opportunistic according to the article by Winthrop et al. (2015). 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
95 
Examples of infections that may be considered opportunistic in the setting of biologic 
therapy 
Bacterial 
 
Bartonellosis (disseminated disease only) 
 
Campylobacteriosis (invasive disease only) 
 
Legionellosis 
 
Listeriosis (invasive disease only) 
 
Nocardiosis 
 
Tuberculosis 
 
Non-tuberculous mycobacterial disease  
 
Salmonellosis (invasive disease only)  
 
Shigellosis (invasive disease only) 
 
Vibriosis (invasive disease due to Vibrio vulnificus) 
Viral 
 
BK virus disease including polyomavirus-associated nephropathy 
 
Cytomegalovirus disease 
 
Hepatitis B virus reactivation 
 
Hepatitis C virus progression 
 
Herpes simplex (invasive disease only) 
 
Herpes zoster (any form) 
 
Post-transplant lymphoproliferative disorder (Epstein-Barr virus) 
 
Progressive multifocal leukoencephalopathy (PML), John Cunningham (JC) virus  
Fungal 
 
Aspergillosis (invasive disease only) 
 
Blastomycosis 
 
Candidiasis (invasive disease or oropharyngeal, esophageal. Not isolated lingual) 
 
Coccidioidomycosis 
 
Cryptococcosis 
 
Histoplasmosis 
 
Paracoccidioides infections 
 
Penicilliosis 
 
Pneumocystosis 
 
Sporotrichosis 
 
Other invasive molds: Mucormycosis (zygomycosis) (Rhizopus, Mucor, and Lichtheimia), 
Scedosporium/Pseudallescheria boydii, Fusarium 
Parasitic 
 
Leishmaniasis (visceral only) 
 
Strongyloidiasis (hyperinfection syndrome or disseminated disease) 
 
Microsporidiosis 
 
Toxoplasmosis 
 
Trypanosoma cruzi infection (Chagas’ disease progression) (disseminated disease only) 
 
Cryptosporidiosis (chronic disease only) 
Source: Based on Winthrop et al. (2015). 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
96 
10.10. Appendix 10: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  
Implementation of this appendix 
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by the sponsor in partnership with the 
investigator. 
Exceptional circumstances 
Exceptional circumstances are rare events that may cause disruptions to the conduct of the study. 
Examples include pandemics or natural disasters. These disruptions may limit the ability of the 
investigators, participants, or both to attend on-site visits or to conduct planned study procedures. 
Implementing changes under exceptional circumstances 
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by local regulations.  
After approval by local Ethical Review Boards, regulatory bodies, and any other relevant local 
authorities, implementation of these exceptional circumstance changes will not typically require 
additional notification to these groups, unless they have specific requirements in which 
notification is required, for example, upon implementation and suspension of changes. All 
approvals and notifications must be retained in the study records. 
If the sponsor grants written approval for changes in study conduct, the sponsor will also provide 
additional written guidance, if needed. 
Considerations for making a change 
The prevailing consideration for making a change is ensuring the safety of study participants. 
Additional important considerations for making a change are compliance with GCP, enabling 
participants to continue safely in the study and maintaining the integrity of the study.  
Changes in study conduct during exceptional circumstances 
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed. 
The following changes in study conduct will not be considered protocol deviations if written 
sponsor approval is given.  
Screening period guidance  
If the study screening window exceeds 30 days due to the exceptional circumstances, the 
participant would be considered a screen failure and may be rescreened if written sponsor 
approval is given.  
The screening procedures per the SoA in the protocol should be followed (starting at Visit 1) to 
ensure participant eligibility by the baseline visit (Visit 2). Before rescreening, the participant 
must sign a new ICF and receive a new identification number through IWRS. 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
97 
Adjustments to visit windows 
Whenever possible and safe to do so, as determined by the investigator’s discretion, participants 
should complete the usual SoA. To maximize the possibility that these visits can be conducted as 
on-site visits, the windows for visits may be adjusted, upon further guidance and written 
approval from the sponsor. This minimizes missing data and preserves the intended conduct of 
the study. 
This table describes the allowed adjustments to visit windows. 
Visit Number 
Tolerance 
Weeks 2-14 
±7 days 
Week 16 
±7 days 
Post-treatment safety follow-up (12 
weeks after last dose) 
±14 days 
For participants whose visits have extended windows, subsequent dosing should be a minimum 
of 7 days apart if the visit window is expanded due to exceptional circumstances.  
NOTE: Every effort should be made to enable participants to return to on-site visits as soon as 
reasonably possible, while ensuring the safety of both the participants and the site staff. 
Documentation 
Changes to study conduct will be documented 
Sites will identify and document the details of how participants, visit window adjustments, and 
or rescreening were affected by exceptional circumstances. 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
98 
10.11. Appendix 11: Abbreviations and Definitions  
Term 
Definition 
AD 
atopic dermatitis 
ADA 
anti-drug antibody 
AE 
adverse event 
AESI 
adverse event of special interest 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
BSA 
body surface area 
CDLQI 
Children’s Dermatology Life Quality Index 
CI 
confidence interval 
Companion 
diagnostic  
An in vitro diagnostic device (assay or test) that provides information that is essential 
for the safe and effective use of a corresponding therapeutic product 
complaint 
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system. 
compliance 
Adherence to all study-related, good clinical practice (GCP), and applicable regulatory 
requirements. 
CRF 
case report form; a printed, optical, or electronic document designed to record all of the 
protocol-required information to be reported to the sponsor for each trial participant. 
CRP 
clinical research physician: Individual responsible for the medical conduct of the study. 
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer. 
CSR 
Clinical study report 
DLQI 
Dermatology Life Quality Index 
DMC 
data monitoring committee. A data monitoring committee, or data monitoring board 
(DMB) is a group of independent scientists who are appointed to monitor the safety and 
scientific integrity of a human research intervention, and to make recommendations to 
the sponsor regarding the stopping of a study for efficacy, or for harms, or for futility. 
The composition of the committee is dependent upon the scientific skills and 
knowledge required for monitoring the particular study. 
Device deficiencies 
equivalent to product complaint 
EASI 
Eczema Area and Severity Index 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
99 
EDC 
electronic data capture system 
enroll 
The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment. 
enter 
Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives. 
FLG 
filaggrin 
GCP 
Good Clinical Practice 
HBV 
hepatitis B virus 
HCV 
hepatitis C virus 
HE 
hand eczema 
HIV 
human immunodeficiency virus 
IB 
Investigator’s Brochure 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
IGA 
Investigator’s Global Assessment 
IL 
interleukin 
IL-4R 
IL-4 receptor alpha 
IL-13R1 
IL-13 receptor alpha 1 
IMP 
Investigational Medicinal Product 
informed consent 
A process by which a participant voluntarily confirms their willingness to participate in 
a particular study, after having been informed of all aspects of the study that are 
relevant to the participant’s decision to participate. Informed consent is documented by 
means of a written, signed and dated informed consent form. 
interim analysis 
An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked. 
investigational 
product 
A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form. 
IRB/IEC 
Institutional Review Board/Independent Ethics Committee 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
100 
ITT 
intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a participant (that is, the 
planned treatment regimen) rather than the actual treatment given. It has the 
consequence that participant allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment. 
IWRS 
interactive web-response system 
JAK 
Janus kinase 
LOR 
loricrin 
NIMP 
non-investigational medicinal product 
NRS 
Pruritus Numeric Rating Scale 
participant 
Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control 
PC 
product complaint 
PDE4 
phosphodiesterase-4 
PD/PK 
pharmacodynamics/pharmacokinetics 
PPS 
per-protocol set: The set of data generated by the subset of participant who sufficiently 
complied with the protocol to ensure that these data would be likely to exhibit the 
effects of treatment, according to the underlying scientific model. 
Q2W 
once every 2 weeks 
Q4W 
once every 4 weeks 
QTc 
corrected QT interval 
QoL 
Quality of Life 
SC 
subcutaneous 
SCORAD 
SCORing Atopic Dermatitis 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
screen 
The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.  
SoA 
Schedule of Activities 
TARC 
thymus- and activation-regulated chemokine 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
101 
TBL 
total bilirubin 
TCI 
topical calcineurin inhibitors 
TCS 
topical corticosteroids 
TEAE 
Treatment-emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment. 
Th1 
T-helper type 1 
Th2 
T-helper type 2 
Th17 
T-helper type 17 
WOCBP 
women of child-bearing potential 
 
 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
102 
11. 
References  
Auriemma M, Vianale G, Amerio P, Reale M. Cytokines and T cells in atopic dermatitis. 
Eur Cytokine Netw. 2013;24(1):37-44. https://doi.org/10.1684/ecn.2013.0333 
Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference 
and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 
2015;230(1):27-33. https://doi.org/10.1159/000365390 
Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-1494. 
https://doi.org/10.1056/nejmra074081 
Bieber T, Novak N. Pathogenesis of atopic dermatitis: new developments. Curr Allergy Asthma 
Rep. 2009;9(4):291-294. https://doi.org/10.1007/s11882-009-0041-2 
Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and 
stratified medicine. Allergy. 2012;67(12):1475-1482. https://doi.org/10.1111/all.12049 
Bieber T. Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 
2020;75(1):54-62. https://doi.org/10.1111/all.13954 
Bieber T, Straeter B. Off-label prescriptions for atopic dermatitis in Europe. Eur J Aller Clin 
Immunol. 2015;70(1):6-11. https://doi.org/10.1111/all.12498 
Bissonnette R, Diepgen T, Elsner P. Redefining treatment options in chronic hand eczema 
(CHE). J Eur Acad Dermatol Venereol. 2010;24(s3):1-20.   https://doi.org/10.1111/j.1468-
3083.2010.03615.x 
Caretti KL, Mehregan DR, Mehregan DA. A survey of self-reported skin disease in the elderly 
African-American population. Int J Dermatol. 2014;54(9):1034-1038. 
https://doi.org/10.1111/ijd.12520  
Choy DF, Hsu DK, Seshasayee D, et al. Comparative transcriptomic analyses of atopic 
dermatitis and psoriasis reveal shared neutrophilic inflammation. J Allergy Clin Immunol. 
2012;130(6):1335-1343. https://doi.org/10.1016/j.jaci.2012.06.044 
Diepgen T, Ofenloch R, Bruze M, et al. Prevalence of contact allergy in the general population in 
different European regions. British J Dermatol. 2016;174:319-329. 
https://doi.org/10.1111/bjd.14167 
Eckert L, Gupta S, Amand C, et al. The burden of atopic dermatitis in US adults: Health care 
resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad 
Dermatol. 2018;78(1):54-61.e1. https://doi.org/10.1016/j.jaad.2017.08.002 
Eckert L, Gupta S, Gadkari A, et al. Burden of illness in adults with atopic dermatitis: Analysis 
of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the 
United Kingdom. J Am Acad Dermatol. 2019;81(1):187-195. 
https://doi.org/10.1016/j.jaad.2019.03.037 
Esche C, de Benedetto A, Beck LA. Keratinocytes in atopic dermatitis: inflammatory signals. 
Curr Allergy Asthma Rep. 2004;4(4):276-284. https://doi.org/10.1007/s11882-004-0071-8 
Faiz S, Giovannelli J, Podevin C et al. Effectiveness and safety of dupilumab for the treatment of 
atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 
2019;81:143-51. https://doi.org/10.1016/j.jaad.2019.02.053 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
103 
Flohr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults. 
J Allergy Clin Immunol. 2013;132(3):774-774.e6. https://doi.org/10.1016/j.jaci.2013.03.016 
Fowler J, Graff O, Hamedani G. A phase 3, randomized, double-blind, placebo-controlled study 
evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic 
hand eczema refractory to potent topical corticosteroid therapy. J Drugs Dermatol. 
2014;13(10):1198-204. 
Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: A review of its use in the 
treatment of atopic dermatitis. Am Acad Dermatol. 2018;78(3):S28-S36. 
https://doi.org/10.1016/j.jaad.2017.12.022 
Hamid Q, Naseer T, Minshall EM, et al. In vivo expression of IL-12 and IL-13 in atopic 
dermatitis. J Allergy Clin Immunol. 1996;98(1):225-231. https://doi.org/10.1016/s0091-
6749(96)70246-4 
Hanifin JM, Thurston M, Omoto M, et al. EASI Evaluator Group. The eczema area and severity 
index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11-18. 
https://doi.org/10.1034/j.1600-0625.2001.100102.x 
Harrop J, Chinn S, Verlato G, et al. Eczema, atopy and allergen exposure in adults: a population-
based study. Clin Exper Aller. 2007;37:526-535. https://doi.org/10.1111/j.1365-
2222.2007.02679.x 
He JQ, Chan-Yeung M, Becker AB, et al. Genetic variants of the IL13 and IL4 genes and atopic 
diseases in at-risk children. Genes Immun. 2003;4(5):385-389. 
Heibel H, Henddricks A, Foshee J, Shi V. Rosacea associated with dupilumab therapy. J 
Dermatol Treat. 2021;32(1):114-116. https://doi.org/10.1080/09546634.2019.1624683 
High WA, Tomasini CF, Argenziano G, Zalaudek I. Basic principles of dermatology. In: 
Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology (3rd ed.). China: Elsevier; 2012: pp. 
8. 
Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into 
practice: What do dermatology life quality index scores mean? J Invest Dermatol. 
2005;125(4):659-664. https://doi.org/10.1111/j.0022-202x.2005.23621.x 
Howell MD, Fairchild HR, Kim BE, et al. Th2 cytokines act on S100/A11 to downregulate 
keratinocyte differentiation. J Invest Dermatol. 2008;128(9):2248-2258. 
https://doi.org/10.1038/jid.2008.74 
Hua TC, Hwang CY, Chen YJ, et al. The natural course of early-onset atopic dermatitis in 
Taiwan: a population-based cohort study. Br J Dermatol. 2014;170(1):130-135. 
https://doi.org/10.1111/bjd.12603 
Hummelshoj T, Bodtger U, Datta P, et al. Association between an interleukin-13 promoter 
polymorphism and atopy. Eur J Immunogenet. 2003;30(5):355-359. 
https://doi.org/10.1046/j.1365-2370.2003.00416.x 
Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 
7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925-931. 
https://doi.org/10.1016/j.jaci.2004.01.778 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
104 
Jeong CW, Ahn KS, Rho NK, et al. Differential in vivo cytokine mRNA expression in lesional 
skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR. 
Clin Exp Allergy. 2003;33(12):1717-1724. https://doi.org/10.1111/j.1365-2222.2003.01782.x 
Kiebert, G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in 
health-related quality of life. Int J Dermatol. 2002;41(3):151-158. 
https://doi.org/10.1046/j.1365-4362.2002.01436.x 
Kim BE, Leung DYM, Boguniewicz M, Howell MD. Loricrin and involucrin expression is 
down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126(3):332-337. 
https://doi.org/10.1016/j.clim.2007.11.006 
Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality 
Index scores. Br J Dermatol. 2002;147:25-54. 
Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: 
consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 
1997;195(1):10-19. https://doi.org/10.1159/000245677 
La Grutta S, Richiusa P, Pizzolanti G, et al. CD4(+)IL-13(+) cells in peripheral blood well 
correlates with the severity of atopic dermatitis in children. Allergy. 2005;60(3):391-395. 
https://doi.org/10.1111/j.1398-9995.2005.00733.x 
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360. 
https://doi.org/10.1016/s0140-6736(20)31286-1 
Marniquet M, Seneschal J, Darrigade A, et al. Reasons for discontinuation of dupilumab in adult 
atopic dermatitis in clinical practice. Br J Dermatol. 2022. https://doi.org/10.1111/bjd.20883 
Miron Y, Miller P, Hughes C, et al. Mechanistic insights into the antipruritic effects of 
lebrikizumab, an anti–IL-13 mAb. J Aller Clin Immun. 2022. 1-11. 
https://doi.org/10.1016/j.jaci.2022.01.028 
Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL-31 correlate with IL-4 and 
IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 2006;118(4):930-937. 
https://doi.org/10.1016/j.jaci.2006.07.015 
Newton L, DeLozier AM, Griffiths PC, et al. Exploring content and psychometric validity of 
newly developed assessment tools for itch and skin pain in atopic dermatitis. J Patient Rep 
Outcomes. 2019;3(1):42. https://doi.org/10.1186/s41687-019-0128-z 
Novak N, Kruse S, Kraft S, et al. Dichotomic nature of atopic dermatitis reflected by combined 
analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the 
interleukin-4/interleukin-13 receptor gene: the dichotomy of extrinsic and intrinsic atopic 
dermatitis. J Invest Dermatol. 2002;119(4):870-875. https://doi.org/10.1046/j.1523-
1747.2002.00191.x 
Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB. Practical issues on 
interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the 
three-item severity score. Br J Dermatol. 2007;157(4):645-648. https://doi.org/10.1111/j.1365-
2133.2007.08112.x 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
105 
Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic 
dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). 
Curr Med Res Opin. 2020;36(3):367-376. https://doi.org/10.1080/03007995.2019.1699516 
Purwar R, Werfel T, Wittmann M. IL-13-stimulated human keratinocytes preferentially 
attract CD4+CCR4+ T cells: possible role in atopic dermatitis. J Invest Dermatol. 
2006;126(5):1043-1051. https://doi.org/10.1038/sj.jid.5700085 
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and 
activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-365. 
https://doi.org/10.2165/00019053-199304050-00006 
Ruzicka T, Harsch M, Brown TC, et al. Modified Total Lesion Symptom Score (mTLSS). Br J 
Dermatol. 2008;158(4):808-817. 
Sacotte R, Silverberg J. Epidemiology of adult atopic dermatitis. Clin Dermatology. 
2018;36:595-605. https://doi.org/10.1016/j.clindermatol.2018.05.007 
Saeki H, Tsunemi Y, Fujita H, et al. Prevalence of atopic dermatitis determined by clinical 
examination in Japanese adults. J Dermatol. 2006;33(11):817-819. 
https://doi.org/10.1111/j.1346-8138.2006.00187.x 
Safa G, Paumier V. Psoriasis induced by dupilumab therapy. Clin Exp 
Dermatol. 2019;44(3):e49-e50. https://doi.org/10.1111/ced.13901 
Schram ME, Spuls PI, Leeflang MMG, et al. EASI, (objective) SCORAD and POEM for atopic 
eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99-
106. https://doi.org/10.1111/j.1398-9995.2011.02719.x 
Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev 
Clin Pharmacol. 2018;11(5):467-474. https://doi.org/10.1080/17512433.2018.1449642 
Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic 
dermatitis in US adults: A population-based cross-sectional study. Ann Allergy, Asthma 
Immunol. 2018;121(3):340-347. https://doi.org/10.1016/j.anai.2018.07.006 
Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy, Asthma Immunol. 
2019;123(2):144-151. https://doi.org/10.1016/j.anai.2019.04.020 
Silverberg JI, DeLozier A, Sun L, et al. Psychometric properties of the itch numeric rating scale, 
skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-
to-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19(1):247. 
https://doi.org/10.1186/s12955-021-01877-8 
Simon D, Wollenberg A, Renz H, Simon HU. Atopic dermatitis: Collegium Internationale 
Allergologicum (CIA) update 2019. Int Arch Allergy Immunol. 2019;178(3):207-218. 
https://doi.org/10.1159/000497383 
Simpson E, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo 
in atopic dermatitis. N Engl J Med. 2016;375:2335-2348. 
https://doi.org/10.1056/nejmoa1610020 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
106 
Simpson E, Eckert L, Gadkari A, et al. Validation of the Atopic Dermatitis Control Tool 
(ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC 
Dermatol. 2019;19(1):15. https://doi.org/10.1186/s12895-019-0095-3 
Stalder J, Taïeb A. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report 
of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23-31. 
https://doi.org/10.1159/000247298 
Suárez-Fariñas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and 
higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin 
Immunol. 2013;132(2):361-370. https://doi.org/10.1016/j.jaci.2013.04.046 
Suárez-Fariñas M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized 
by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin 
Immunol. 2011;127(4):954-964.e1-4. https://doi.org/10.1016/j.jaci.2010.12.1124 
Tanei R. Atopic dermatitis in the elderly. Inflamm Allergy Drug Targets. 2009;8(5):398-404. 
https://doi.org/10.2174/1871528110908050398 
Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in lesional 
skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11):459-464. 
https://doi.org/10.1007/s00403-004-0455-6 
Tracey E, Elston C, Feasel P, et al. Erythrodermic presentation of psoriasis in a patient treated 
with dupilumab. JAAD Case Reports. 2018;4(7):708-710. 
https://doi.org/10.1016/j.jdcr.2018.05.014 
Treister AD, Lio PA. Long-term off-label dupilumab in pediatric atopic dermatitis: a case series. 
Pediatr Dermatol. 2019;36(1):85-88. https://doi.org/10.1111/pde.13697 
Tsoi L, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL-13e-dominant disease with 
greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139:1480-
1489. https://doi.org/10.1016/j.jid.2018.12.018 
Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy, 
Asthma Immunol. 2017;119(6):548-552.e3. https://dx.doi.org/10.1016%2Fj.anai.2017.09.076 
Van Bever HPS, Llanora G. Features of childhood atopic dermatitis. Asian Pac J Allergy 
Immunol. 2011;29(1):15-24.  
Varma A, Levitt J. Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis. 
JAAD Case Reports. 2020;6(3):217-218. https://doi.org/10.1016/j.jdcr.2020.01.012 
Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. 
https://doi.org/10.1038/s41572-018-0001-z 
Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-1122. 
https://doi.org/10.1016/S0140-6736(15)00149-X 
Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms 
in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336-349. 
https://doi.org/10.1016/j.jaci.2016.06.010 
Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? 
J Allergy Clin Immunol. 2008;121(4):947-954.e15. https://doi.org/10.1016/j.jaci.2007.11.004 
Approved on 27 Apr 2023 GMT


CONFIDENTIAL 
J2T-MC-KGBO(a) 
107 
Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapies in 
immune-mediated inflammatory diseases: consensus recommendations for infection reporting 
during clinical trials and postmarketing surveillance. Ann Rheum Dis. 2015;74(12):2107-2116. 
https://doi.org/10.1136/annrheumdis-2015-207841 
Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric 
validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. 
Br J Dermatol. 2019;181(4):761-769. https://doi.org/10.1111/bjd.17744 
Yosipovitch G, Rams A, Baldasaro J, et al. Content Validity And Assessment Of The 
Psychometric Properties And Score Interpretation Of A Pruritus Numeric Rating Scale In 
Atopic Dermatitis. Revolutionizing Atopic Dermatitis – December, 2021. 
Zuberbier, T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic 
dermatitis. J Allergy Clin Immunol. 2006;118(1):226-232. 
https://doi.org/10.1016/j.jaci.2006.02.031 
Approved on 27 Apr 2023 GMT


Signature Page for VV-CLIN-093432 v1.0
Signature Page for VV-CLIN-093432 v1.0
Approval
27-Apr-2023 11:25:23 GMT+0000
Approval
27-Apr-2023 20:57:20 GMT+0000
Approved on 27 Apr 2023 GMT
PPD
PPD

SAP_001.pdf: 
J2T-MC-KGBO: Statistical Analysis Plan Version 2
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent 
Participants with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab
NCT05369403   
Approval Date: 23-Jun-2023 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 1 
LY3650150 
Confidential Information 
The information contained in this document is confidential and the information contained 
within it may not be reproduced or otherwise disseminated without the approval of Eli Lilly 
and Company or its subsidiaries. 
Note to Regulatory Authorities: This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries. 
Statistical Analysis Plan:  
J2T-MC-KGBO (Lebrikizumab): An Open-Label Study to 
Evaluate the Safety and Efficacy of Lebrikizumab in Adult 
and Adolescent Participants with Moderate-to-Severe Atopic 
Dermatitis Previously Treated with Dupilumab 
Lebrikizumab (LY3650150) 
Eli Lilly and Company 
Indianapolis, Indiana USA 46285 
[Protocol J2T-MC-KGBO] 
[Phase 3b] 
Statistical Analysis Plan Version 2 
Approved on 23 Jun 2023 GMT


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 2 
LY3650150 
1.Table of Contents
Section........................................................................................................................................ Page 
1.
Table of Contents .................................................................................................................... 2 
2.
Revision History ...................................................................................................................... 8 
3.
Study Objectives ...................................................................................................................... 9 
4.
Study Design ......................................................................................................................... 11 
4.1. 
Summary of Study Design ................................................................................................ 11 
4.1.1 Number of Participants ................................................................................................... 12 
4.1.2 Schema ............................................................................................................................ 12 
4.2. 
Determination of Sample Size .......................................................................................... 13 
4.3. 
Method of Assignment to Treatment ................................................................................ 13 
5.
A Priori Statistical Methods .................................................................................................. 14 
5.1. 
General Considerations .................................................................................................... 14 
5.1.1. 
Analysis Populations ................................................................................................ 14 
5.1.2. 
General Considerations for Analyses ....................................................................... 14 
5.2. 
Primary and Supportive Estimands .................................................................................. 15 
5.2.1. 
Primary Estimand for the Primary Endpoint ............................................................ 15 
5.2.2. 
Supportive Estimands for the Primary Endpoint ..................................................... 16 
5.2.3. 
Estimands for Secondary Endpoints at Week 16 ..................................................... 17 
5.2.4. 
Estimands for Secondary Endpoints at Week 24 ..................................................... 17 
5.3. 
Adjustments for Covariates .............................................................................................. 19 
5.4. 
Handling of Dropouts or Missing Data ............................................................................ 19 
5.4.1. 
As Observed Analysis .............................................................................................. 20 
5.4.2. 
Last Observation Carried Forward ........................................................................... 20 
5.4.3. 
Markov chain Monte Carlo - Multiple Imputation (MCMC- 
MI) ........................................................................................................................... 20 
5.5. 
Multicenter Studies ........................................................................................................... 23 
5.6. 
Multiple Comparisons/Multiplicity .................................................................................. 23 
5.7. 
Patient Disposition ............................................................................................................ 23 
5.8. 
Patient Characteristics ...................................................................................................... 23 
5.8.1. 
Demographics and Baseline Characteristics ............................................................ 23 
5.8.2. 
Medical History ........................................................................................................ 25 
5.9. 
Treatment Compliance ..................................................................................................... 26 
5.10. Prior and Concomitant Therapy ....................................................................................... 27 
5.11. Efficacy Analyses ............................................................................................................. 27 
5.12. Health Outcomes/Quality-of-Life Analyses ..................................................................... 38 
5.13. Safety Analyses ................................................................................................................ 38 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 3 
LY3650150 
5.13.1. 
Extent of Exposure ................................................................................................... 38 
5.13.2. 
Adverse Events ......................................................................................................... 39 
5.13.2.1. 
Common Adverse Events ................................................................................... 40 
5.13.2.2. 
Deaths, Other Serious Adverse Events and Other Notable 
Adverse Events ................................................................................................... 40 
5.13.3. 
Clinical Laboratory Evaluation ................................................................................ 40 
5.13.4. 
Vital Signs and Other Physical Findings .................................................................. 41 
5.13.5. 
Immunogenicity ....................................................................................................... 41 
5.13.6. 
Special    Safety     Topics     including     Adverse     Events     of     Special 
Interest ...................................................................................................................... 43 
5.13.6.1. 
Hepatic Safety .................................................................................................... 43 
5.13.6.2. 
Eosinophilia and Eosinophil-Related Disorders ................................................. 43 
5.13.6.3. 
Infections, including herpes infections and relevant 
parasitic infections .............................................................................................. 44 
5.13.6.4. 
Conjunctivitis ..................................................................................................... 44 
5.13.6.5. 
Hypersensitivity ................................................................................................. 44 
5.13.6.6. 
Injection Site Reactions (ISRs) .......................................................................... 45 
5.13.6.7. 
Malignancies ...................................................................................................... 45 
5.13.6.8. 
Atopic Dermatitis Exacerbation ......................................................................... 45 
5.13.6.9. 
Suicide/Self-Injury ............................................................................................. 45 
5.14. Subgroup Analyses ........................................................................................................... 46 
5.15. Protocol Deviations .......................................................................................................... 46 
5.16. Interim Analyses and Data Monitoring ............................................................................ 46 
5.17. Annual Report Analyses ................................................................................................... 47 
5.18. Clinical Trial Registry Analyses ....................................................................................... 47 
5.19. Biomarker Analysis .......................................................................................................... 47 
6.
Unblinding Plan ..................................................................................................................... 49 
7.
References ............................................................................................................................. 50 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 4 
LY3650150 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 5 
LY3650150 
List of Abbreviations  
Term 
Definition 
ADA 
anti-drug antibodies 
AD 
atopic dermatitis 
ADCT 
Atopic Dermatitis Control Tool 
AE 
adverse event 
AESI 
adverse events of special interest 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
AST 
aspartate transaminase 
BMI 
body mass index 
BSA 
body surface area 
CDC 
Centers for Disease Control and Prevention 
CDISC 
Clinical Data Interchange Standards Consortium 
CDLQI 
Children’s Dermatology Life Quality Index 
CRF 
case report form 
CSR 
clinical study report 
CTR 
Clinical Trial Registry 
DBL 
database lock 
DLQI 
Dermatology Life Quality Index 
DSUR 
Development Safety Update Report 
EASI 
Eczema Area and Severity Index 
EASI-75 
Eczema Area and Severity Index improvement of ≥75% 
EASI-90 
Eczema Area and Severity Index improvement of ≥90% 
eCRF 
electronic case report form 
HLT 
high-level term 
ICH 
International Conference on Harmonisation 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 6 
LY3650150 
IGA 
Investigator's Global Assessment 
ISR 
injection site reactions 
Lilly 
Eli Lilly and Company 
MCMC 
Markov chain Monte Carlo 
MedDRA 
Medical Dictionary for Regulatory Activities 
MI 
multiple imputation 
mTLSS 
Modified Total Lesion Symptom Scale 
NAb 
Neutralizing anti-drug antibodies 
NMSC 
non-melanoma skin cancer 
NRS 
Numeric rating scale 
OI 
opportunistic infection 
PD 
pharmacodynamic 
PhUSE 
Pharmaceutical Users Software Exchange 
PK 
pharmacokinetic 
PROMIS 
Patient-Reported Outcomes Information System 
PRSQ 
Participant Reported Satisfaction Question 
PT 
Preferred Term 
Q2W 
every 2 weeks 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SC 
subcutaneously 
SCORAD 
SCORing Atopic Dermatitis 
SE 
standard error 
SMQ 
Standardized MedDRA Query 
SOC 
System Organ Class 
TBL 
total bilirubin 
TE-ADA 
treatment-emergent ADA 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 7 
LY3650150 
 
 
 
TEAE 
treatment-emergent adverse event 
WHO 
World Health Organization 
WPAI-AD 
Work Productivity and Activity Impairment Questionnaire–Atopic Dermatitis 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 8 
LY3650150 
2. Revision History 
Statistical Analysis Plan Version 1 was approved prior to first patient first visit on December 19, 
2022. 
Changes in Version 2 are documented in the following table. Minor corrections/additions may 
not be included. 
Revisions in SAP Version 2: 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 9 
LY3650150 
Section
Description of Change
Rationale
Section 4.1 
Updated the Summary of Study Design to 
reflect KGBO Protocol Addendum 2. 
To account for the Continued Access 
Period. 
Section 4.3 
Updated to state that participants will 
receive Q2W or Q4W dosing after Week 
16 based on their IGA or EASI score. 
Clarification; this is only a single-arm study 
until Week 16. 
Section 5.1.1 
1.
Added Treatment Period II as an
analysis population to Table 5.1.
2.
Added text to Table 5.1 to explain
what analysis populations will be
used for each analysis.
1.
To explicitly define the patient
population of interest for efficacy
analyses after Week 16.
2.
Clarification.
Section 5.1.2 
Added the baseline period definition for 
outcomes collected via eDiary as well as 
what is considered missing. 
Clarification. 
Section 5.2 
Added a “Primary and Supportive 
Estimand” section describing the five 
estimands of interest. 
To clarify the clinical research questions 
and estimands of interest in this study, and 
to stay in alignment with LY3650150 
KGBO(a) Harmonized Clinical Protocol. 
Section 5.4 
Added how missing data including those 
because of intercurrent events will be 
handled for each estimand. 
Clarification. 
Section 5.4.1. 
Removed language explaining how the 
primary estimand is conditional and not 
causal. 
This is a single-arm, open-label study until 
Week 16 so there is no causal inference no 
matter how the estimand is defined. 
Section 5.4.2. 
1.
Removed the word “sensitivity”.
2.
Added that baseline values will be
used for imputation if there is no
postbaseline observation.
3.
Removed the sentence indicating
LOCF will be performed for all
efficacy data.
1.
This is a supportive analysis and not a 
sensitivity analysis.
2.
Clarification.
3.
LOCF is only being performed for
primary and secondary endpoints.


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 10 
LY3650150 
Section 5.4.3. 
1.
Removed the term “long-term
systemic” from references to rescue
medication.
2.
Added text to explain that MCMC-MI
imputation will be conducted
independently for three distinct groups.
3.
Added the following 5 endpoints to
Table 5.3: Sleep-Loss Scale, Skin Pain
NRS, DLQI, cDLQI, and SCORAD.
4.
Added a second set of seed numbers to
Tabel KGBO.5.3.
1.
Rescue medication includes high- 
potency TCS > 10 days.
2.
So that the pattern of missing
observations in one treatment group
cannot influence missing value
imputation in another.
3.
MCMC-MI will be performed for all
primary and secondary endpoints.
4.
MCMC-MI is being performed
separately for Weeks 0-16 and Weeks
16-24 of the Treatment Period and
therefore requires two different sets of
seed numbers.
Section 5.8.2. 
Updated the eCRF name for both medical 
history and prespecified medical history. 
Correction. 
Section 5.9 
Updated the names of the eCRF 
pages that will be used to compute 
the total number of injections 
administered. 
Correction. 
Section 5.10 
1.
Revised the definition of concomitant
medication.
2.
Added text stating that rescue
medications use will be summarized.
1.
To reflect the addition of the
Treatment Period II analysis
population.
2.
Clarification.
Section 5.11 
Added that Pruritus NRS, Skin Pain NRS, 
and Sleep-Loss Scale will be reported by 
clinic visit. 
Clarification. 
Section 5.12 
Updated to state that summaries will be 
provided for the data as-observed and after 
implementation of LOCF and MCMC-MI 
imputation. 
Data will be presented as-observed and 
after implementation of LOCF and 
MCMC-MI imputation for all primary and
secondary endpoints.
Section 5.13.1 
Updated the name of the eCRF page that 
will be used to derive the total number of 
injections received. 
Correction. 
Section 5.13.2 
Added the facial dermatitis follow-up form 
to Table KGBO.5.5. 
Data collected on the facial dermatitis 
follow-up form will be summarized using 
descriptive statistics. 
Section 5.13.3. 
Removed scatterplots of baseline-by- 
maximum values and baseline-by- 
minimum values from Table KGBO.5.4. 
This figure is not required by Version 4 of 
the Program Safety Analysis Plan. 
Section 5.13.4. 
Removed scatterplots of baseline-by- 
maximum values and baseline-by- 
minimum values from Table KGBO.5.4. 
This figure is not required by Version 4 of 
the Program Safety Analysis Plan. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 11 
LY3650150 
Section 5.15 
Updated to state that the primary endpoint, 
EASI-75, is measured at Week 16. 
Clarification. 
Section 5.16 
Added that additional analyses and 
snapshots of study data may be performed 
to fulfill the need for regulatory interactions 
or publication purposes. 
To stay in alignment with LY3650150 
KGBO(a) Harmonized Clinical Protocol. 
Appendix 1 
Added definition of rescue medications. 
To provide detailed instructions on how to 
determine rescue medications for this 
study. 
Abbreviations: AD = atopic dermatitis; CDLQI = Children’s Dermatology Life Quality Index; DLQI = Dermatology 
Life Quality Index; EASI = Eczema Area and Severity Index; LOCF = last observation carried forward; MCMC- 
MI = Markov chain Monte Carlo-multiple imputation; NRS = numeric rating scale; Q2W = once every 2 weeks; 
Q4W = once every 4 weeks; SCORAD = SCORing Atopic Dermatitis; TCS = topical corticosteroids. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 12 
LY3650150 
3. Study Objectives 
Table KGBO.3.1 shows the protocol-defined objectives and endpoints of the study. 
Table KGBO.3.1. 
Protocol-Defined Objectives and Endpoints 
Study Primary Objective: 
To evaluate efficacy of lebrikizumab 250 mg Q2W on reducing signs and symptoms of AD at Week 16 in 
participants with moderate-to-severe AD previously treated with dupilumab 
Study Secondary Objective: 
To evaluate the efficacy of lebrikizumab 250 mg Q2W on reducing signs and symptoms of AD at Week 16 and 
Week 24 in participants with moderate-to-severe AD previously treated with dupilumab 
Study Exploratory Objectives 

To evaluate the efficacy of lebrikizumab 250 mg Q2W in participants with moderate-to-severe AD
previously treated with dupilumab

To discern responder variability within the study and to track response variability to lebrikizumab
Primary Endpoint: 
Percentage of participants achieving EASI-75 at Week 16 
Secondary Endpoints: 

Percentage of participants achieving EASI-75 at Week 24

Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from baseline to Weeks
16 and 24

Percentage change in EASI from baseline to Weeks 16 and 24

Change in EASI from baseline to Weeks 16 and 24

Percentage of participants achieving EASI-90 from baseline to Weeks 16 and 24

Percentage of participants with a Pruritus NRS of ≥4 points at baseline who achieve at least 4-point
reduction at Weeks 16 and 24

Percentage of participants with a Pruritus NRS ≥3 points at baseline who achieve at least 3-point
reduction at Weeks 16 and 24

Percentage change in Pruritus NRS score from baseline to Weeks 16 and 24

Percentage of participants with a Sleep-Loss Scale of ≥2 points at baseline who achieve at least 2-point
reduction at Weeks 16 and 24

Change in Sleep-Loss Scale from baseline at Weeks 16 and 24

Percentage of participants with a Skin Pain NRS of ≥4 points at baseline who achieve a 4-point
reduction from baseline at Weeks 16 and 24

Change in Skin Pain NRS from baseline to Weeks 16 and 24

Change in DLQI from baseline to Weeks 16 and Week 24 for participants >16 years of age at baseline

Percentage of participants with at least 4-point at baseline achieving ≥4-point improvement in DLQI
from baseline at Weeks 16 and 24 for participants >16 years of age at baseline

Change in cDLQI from baseline to Weeks 16 and 24 for participants <16 years of age at baseline

Percentage change in SCORAD from baseline to Week 16 and Week 24
Exploratory Endpoints: 

Percentage change from baseline in mTLss (hands) at Weeks 16 and 24

Percentage change in ADCT from baseline by visit

Proportion of TCS/TCI-free days from baseline to Weeks 16 and 24

Change in body surface area (BSA) from baseline by visit

Using WPAI-AD by visit, change in baseline in:

absenteeism, in those who are currently employed (working for pay)

presenteeism, in those who are currently employed (working for pay),


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 13 
LY3650150 
 
 
 
 
 
overall work impairment, in those who are currently employed (working for pay), 
 
impairment in activities (all participants) 
 
Percentage of participants with an F-IGA score of 0 or 1 and a reduction ≥2 points from baseline by visit 
in those who have baseline at least 2 points 
 
Percentage of participants achieving EASI75 by visit 
 
Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from baseline by visit 
 
Percentage change in EASI by visit 
 
Change in EASI by visit 
 
Percentage of participants achieving EASI90 by visit 
 
Percentage of participants with a Pruritus NRS of ≥4 points at baseline who achieve a 4-point reduction 
by visit 
 
Percentage of participants with a Pruritus NRS of ≥3 points at baseline who achieve a 3-point reduction 
by visit 
 
Percentage change in Pruritus NRS score from baseline by visit 
 
Percentage of participants with a Sleep-Loss Scale of ≥2 points at baseline who achieve a 2-point 
reduction by visit 
 
Change in Sleep-Loss Scale from baseline by visit 
 
Percentage of participants with a Skin Pain NRS of ≥4 points at baseline who achieve a 4-point 
reduction from baseline by visit 
 
Change in Skin Pain NRS from baseline by visit 
 
Distribution of responses for participant satisfaction (1 question) at Weeks 16 and 24 
 
Changes from baseline in serum proteins related to AD pathogenesis; Refer to Section 10.2, Appendix 2 
of the protocol 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 14 
LY3650150 
 
 
4. Study Design  
4.1. Summary of Study Design  
Study J2T-MC-KGBO (KGBO) is an open-label, phase 3b study, which is 24 weeks in treatment 
duration. The study is designed to evaluate the safety and efficacy of lebrikizumab in male and 
female adult and adolescent participants with moderate-to-severe AD who have been previously 
treated with dupilumab. 
 
Study Periods  
This trial has 4 study periods: 
 Screening (Visit 1: ≤30 days prior to baseline) 
 Treatment (Visits 2-9: 24 weeks) 
 Safety follow-up (Visit 801: at Week 34 or approximately 12 weeks after last treatment) 
 Continued Access (Visits 501, 502, and 503) 
Participants who enroll into KGBO Protocol Addendum 2 will move directly into the Continued 
Access Period after completing the 24-week treatment period. Such participants will not 
complete Visit 801. A post-treatment follow-up visit (V901) will occur approximately 12 weeks 
post the last dose at the end of the Continued Access Period for the participants who do not move 
to commercial lebrikizumab or who discontinued early from the Continued Access Period. 
Please refer to KGBO Protocol Addendum 2 for more information. 
Visit Types  
Study visits at Week 12 (Visit 6) and Week 20 (Visit 8) will be performed virtually, that is, via 
telephone or telemedicine tools. 
All other visits will be conducted at the clinical trial site. 
Dosing  
During the 24-week Treatment Period, approximately 120 participants will receive treatment: 
 500 mg subcutaneous (SC) loading dose at baseline and Week 2, followed by 250 mg SC 
Q2W until Week 16. 
 Responders, defined as achieving IGA(0,1) or EASI-75 at Week 16, will receive Q4W 
dosing and will administer study intervention at Week 20. 
 Inadequate responders at Week 16 will receive Q2W dosing and will administer study 
intervention at Weeks 18, 20, and 22. 
During the Continued Access Period, eligible participants will continue lebrikizumab on the 
same dosing regimen (Q2W or Q4W) they were assigned at Week 16. Please refer to KGBO 
Protocol Addendum 2 for more information. 
The study population is described in Section 5.1.1. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 15 
LY3650150 
 
 
The efficacy and safety assessments are described in Sections 5.11 and 5.13 respectively. 
 
4.1.1 Number of Participants  
Approximately 120 participants previously treated with dupilumab will be enrolled to study 
intervention. Among those, approximately 80 participants will be enrolled who discontinued 
dupilumab due to: a) no response to treatment, b) a partial response to treatment, or c) who lost 
response to treatment. Additionally, approximately 15 participants will be enrolled who 
discontinued dupilumab treatment due to intolerance or adverse events (AEs). Finally, 
approximately 25 participants will be enrolled who stopped dupilumab treatment for other 
reasons (for example, cost, insurance coverage, access to medication, previous trial participants). 
Approximately 10% (n=12) of participants will be adolescents (≥12 to <18 years, weighing ≥40 
kg). Patients will be evaluated for study eligibility before the baseline visit (Day 1). 
4.1.2 Schema  
Figure KGBO.4.1  
 
Abbreviations: EASI = Eczema Area and Severity Index; IGA = Investigator’s Global Assessment; n = number; 
Q2W = once every 2 weeks; Q4W = once every 4 weeks; SC = subcutaneous; W = week. 
a Weeks 12 and 20 are phone visits. 
 
b 30-day screening window. 
 
c Lebrikizumab loading dose of 500 mg SC will be administered at baseline and Week 2. 
 
d Responders: Participants who reach IGA 0 or 1 (clear or almost clear) or a 75% reduction in the EASI score from 
baseline (EASI-75). Inadequate responders are participants who do not reach these criteria. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 16 
LY3650150 
 
 
e The safety follow-up visit will occur approximately 12 weeks after last study intervention injection. 
 
f The planned maximum duration of Continued Access treatment will vary for each participant enrolled into KGBO 
Protocol Addendum 2 and will end if and when the participant meets criteria for discontinuation of study 
intervention or discontinuation from the study. Participants may remain in the Continued Access Period as long as 
these criteria for discontinuation are not met and until the sponsor stops the study and addendum. 
g Participants in the Continued Access Period will receive the same dose they were taking during Weeks 16 to 24 of 
the Treatment Period. 
4.2. Determination of Sample Size  
Based on available data, the anticipated EASI-75 response rate is approximately 50%. A total 
sample size of 120 enrolled participants will provide >95% probability that the half-width of the 
2-sided 90% CI of the EASI-75 response rate is at most 10%. 
Example point estimates for EASI-75 response rates and corresponding 2-sided 90% CIs based 
on the Wilson-Score method for a sample size of 120 participants are summarized in the table 
below. The CIs are provided as reference rather than a basis of any decision criteria. 
Table KGBO.4.1 Estimated 90% CI with Sample Size of 120 Participants  
 
Example Point Estimates 
Lower Bound of 90% CI 
Upper Bound of 90% CI 
40% 
32.9% 
47.5% 
45% 
37.7% 
52.5% 
50% 
42.6% 
57.4% 
55% 
47.5% 
62.3% 
60% 
52.5% 
67.1% 
 
 
4.3. Method of Assignment to Treatment  
This is an open-label study. All enrolled patients will be assigned to 250-mg lebrikizumab Q2W 
at the baseline visit. At Week 16, patients will be assigned to 250-mg lebrikizumab Q2W or 250- 
mg lebrikizumab Q4W based on their IGA or EASI score. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 17 
LY3650150 
 
 
5.A Priori Statistical Methods  
5.1. General Considerations  
Statistical analysis of this study will be the responsibility of ICON. The latest version of the 
MedDRA will be used. 
Summaries from assessment of endpoints described in the protocol are planned to be included in 
a CSR. Summaries for key safety data are also planned to be included in the CSR. Results from 
additional efficacy summaries and other safety summaries may also be provided in the CSR as 
deemed appropriate. 
Any change to the data analysis methods described in the protocol will require a protocol 
amendment ONLY if it changes a principal feature of the protocol. Any other change to the data 
analysis methods described in the protocol and the justification for making the change will be 
described in the CSR. 
All statistical processing will be performed using SAS® 9.4 unless otherwise stated. 
The schedule of visits and procedures outlined in the protocol specifies the allowable windows 
for assessments. Assessments performed outside these windows will not be excluded from any 
summaries, unless specified otherwise. 
5.1.1. Analysis Populations  
Analysis populations are defined in Table KGBO.5.1 along with the analyses they will be used to 
conduct. The number of patients included in each population will be summarized. 
Table KGBO.5.1. Analysis Populations 
 
Population 
Description 
All Entered Patients 
All patients who signed informed consent. Patient flow will be summarized. 
Intent-to-Treat (ITT) 
Population 
All enrolled patients according to their planned intervention. Unless otherwise 
specified, efficacy and health outcomes analyses for Weeks 0 to 16 of the 
Treatment Period will be conducted on this population. 
Safety Population 
All enrolled patients who received at least 1 confirmed dose of lebrikizumab 
250 mg. Safety analyses will be conducted on this population. 
Treatment Period II 
Population 
All enrolled patients who received at least 1 confirmed dose of lebrikizumab 
250 mg during Weeks 16 to 24 of the Treatment Period. Unless otherwise 
specified, efficacy and health outcomes analyses for Weeks 16 to 24 of the 
Treatment Period will be conducted on this population. Additional efficacy 
analyses for Weeks 0 to 24 of the Treatment Period may also be conducted on 
this population. 
 
 
5.1.2. General Considerations for Analyses  
All analyses will be descriptive. Frequencies, percentages, and 90% Wilson-Score CIs for 
percentages will be reported for discrete efficacy endpoints. Mean, standard deviation, minimum, 
Q1, median, Q3, maximum, and the number of participants will be reported for continuous 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 18 
LY3650150 
 
 
efficacy endpoints. AEs, discontinuation, and other categorical safety data will be summarized 
using frequencies and percentages. Continuous vital signs, body weight, and other continuous 
safety variables including laboratory variables will be summarized descriptively as well. 
Baseline  
Baseline will be defined as the last available value before the first injection for efficacy and 
health outcome analyses. In most cases, this will be the measure recorded at the baseline visit 
(Day 1). If the patient does not take any injection, the last available value on or prior to treatment 
assignment date will be used. Change from baseline will be calculated as the visit value of 
interest minus the baseline value. 
For Pruritus Numeric Rating Scale (NRS), Skin Pain NRS, and Sleep-Loss due to Pruritus 
collected via eDiary, the baseline period is the 7-day window prior to the first injection. A patient 
must have responses on at least 4 of 7 days to calculate a baseline weekly mean. If a patient has 3 
or fewer responses, the baseline mean value will be considered missing. 
For the safety analyses, the following baselines will be used. For safety analyses using a baseline 
period, the baseline period is defined as the time from the screening visit to the date/time of the 
first injection. 
 TEAEs: baseline will be all results recorded during the baseline period. 
 Treatment-emergent abnormal laboratory and vital signs results: baseline will be all 
results recorded during the baseline period. 
 Change from baseline to last post-baseline observation or to each scheduled postbaseline 
visit for laboratory and vital signs results: baseline will be the last scheduled non-missing 
assessment recorded during the baseline period. 
 
5.2. Primary and Supportive Estimands  
There will be five estimands addressing different clinical questions of interest and intercurrent 
events for the primary and secondary endpoints. 
 
5.2.1. Primary Estimand for the Primary Endpoint  
The primary estimand for the primary endpoint represents the primary clinical question of 
interest: What is the intervention effect in percentage of participants achieving at least 75% 
improvement from baseline in Eczema Area and Severity Index (EASI) after 16 weeks of 
lebrikizumab 250 mg Q2W intervention in participants with moderate-to-severe AD who have 
been previously treated with dupilumab and who remain on study treatment until Week 16? 
 
The primary estimand for the primary endpoint is described by the following attributes: 
A. Population: participants with moderate-to-severe AD who have been previously treated 
with dupilumab and who remain on study treatment until Week 16. 
B. Endpoint: whether participants achieve at least 75% improvement from baseline in EASI 
at Week 16. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 19 
LY3650150 
 
 
C. Intercurrent events: There are no intercurrent events for this population since participants 
who initiate rescue medication are discontinued from the study and hence study 
treatment. Therefore, participants who stay on study treatment through Week 16 will not 
have an intercurrent event such as initiating rescue medication or permanently 
discontinuing treatment. 
D. Population-level summary: percentage of participants achieving EASI-75 response at 
Week 16. 
 
5.2.2. Supportive Estimands for the Primary Endpoint  
There are two supportive estimands for the primary endpoint. The first is a hybrid estimand 
representing the following clinical question of interest: What is the intervention effect in 
percentage of participants achieving at least 75% improvement from baseline in Eczema Area 
and Severity Index (EASI) after 16 weeks of lebrikizumab 250 mg Q2W intervention in 
participants with moderate-to-severe AD who have been previously treated with dupilumab if all 
participants adhered to treatment except those who discontinued due to lack of efficacy? 
This estimand is described by the following attributes: 
A. Population: participants with moderate-to-severe AD who have been previously treated 
with dupilumab. 
B. Endpoint: whether participants achieve at least 75% improvement from baseline in EASI 
at Week 16. 
C. Intercurrent events (ICEs): One ICE, permanent treatment discontinuation, is considered 
by this estimand as follows: 
a. Participants who discontinue treatment due to lack of efficacy prior to Week 16 
will be considered as treatment failures, i.e. non-responders, after the ICE. 
Therefore, a composite strategy is used for this type of ICE. 
b. For participants who discontinue treatment due to reasons other than lack of 
efficacy prior to Week 16, a hypothetical strategy will be used to estimate what 
the treatment effect would have been if subjects continued with treatment. 
Therefore, a hypothetical strategy is used for this type of ICE. 
D. Population-level summary: percentage of participants achieving EASI-75 response at 
Week 16. 
The second supportive estimand for the primary endpoint is a hypothetical estimand representing 
the following clinical question of interest: What is the intervention effect in percentage of 
participants achieving at least 75% improvement from baseline in Eczema Area and Severity 
Index (EASI) after 16 weeks of lebrikizumab 250 mg Q2W intervention in participants with 
moderate-to-severe AD who have been previously treated with dupilumab if all participants 
adhered to treatment? 
This estimand is described by the following attributes: 
A. Population: participants with moderate-to-severe AD who have been previously treated 
with dupilumab. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 20 
LY3650150 
 
 
B. Endpoint: whether participants achieve at least 75% improvement from baseline in EASI 
at Week 16. 
C. Intercurrent events (ICEs): One ICE, permanent treatment discontinuation, is considered 
by this estimand as follows: 
a. For participants who discontinue treatment prior to Week 16, a hypothetical 
strategy will be used to estimate what the treatment effect would have been if all 
subjects continued with treatment. Therefore, a hypothetical strategy is used for 
this type of ICE. 
D. Population-level summary: percentage of participants achieving EASI-75 response at 
Week 16. 
 
5.2.3. Estimands for Secondary Endpoints at Week 16  
The primary estimand for the primary endpoint will be applied to all secondary endpoints at 
Week 16. The supportive estimands for the primary endpoint will also be applied to all 
secondary endpoints at Week 16. 
 
5.2.4. Estimands for Secondary Endpoints at Week 24  
The primary estimand for the primary endpoint will be applied to all secondary endpoints at 
Week 24. There are two supportive estimands for secondary endpoints at Week 24. The first is a 
hybrid estimand representing the following clinical question of interest: What is the intervention 
effect in successful responses or means after 24 weeks of lebrikizumab intervention in 
participants with moderate-to-severe AD who have been previously treated with dupilumab if all 
participants adhered to treatment except those who discontinued due to lack of efficacy? 
 
This estimand is described by the following attributes: 
 
A. Population: Treatment Period II population as described in Section 5.1.1. 
B. Endpoint: apply to all secondary endpoints at Week 24. 
C. Intercurrent events (ICEs): One ICE, permanent treatment discontinuation, is considered 
by this estimand as follows: 
a. Participants who discontinue treatment due to lack of efficacy after Week 16 will 
be considered as treatment failures, i.e. non-responders, after the ICE. Therefore, 
a composite strategy is used for this type of ICE. 
b. For participants who discontinue treatment due to reasons other than lack of 
efficacy after Week 16, a hypothetical strategy will be used to estimate what the 
treatment effect would have been if subjects continued with treatment. Therefore, 
a hypothetical strategy is used for this type of ICE. 
D. Population-level summary: percentage of successful responses or means at Week 24. 
 
The second supportive estimand for secondary endpoints at Week 24 is a hypothetical estimand 
representing the following clinical question of interest: What is the intervention effect in 
successful responses or means after 24 weeks of lebrikizumab 250 mg Q2W intervention in 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 21 
LY3650150 
 
 
participants with moderate-to-severe AD who have been previously treated with dupilumab if all 
participants adhered to treatment? 
 
This estimand is described by the following attributes: 
 
A. Population: Treatment Period II population as described in Section 5.1.1. 
B. Endpoint: apply to all secondary endpoints at Week 24. 
C. Intercurrent events (ICEs): One ICE, permanent treatment discontinuation, is considered 
by this estimand as follows: 
a. For participants who discontinue treatment after Week 16, a hypothetical strategy 
will be used to estimate what the treatment effect would have been if all subjects 
continued with treatment. Therefore, a hypothetical strategy is used for this type 
of ICE. 
D. Population-level summary: Population-level summary: percentage of successful 
responses or means at Week 24. 
 
Because participants who initiate rescue medication are required to discontinue from the study 
and hence permanently discontinue study treatment, the supportive estimands for the primary 
and secondary endpoints only consider permanent treatment discontinuation as an ICE. 
 
Analytical details on how missing data including those as a result of intercurrent events will be 
handled can be found in Section 5.4. The following table (Table KGBO.5.2) summarizes the 
analytical strategies that will be conducted on the intercurrent events for the five estimands. 
 
Table KGBO.5.2. Description of Primary and Supportive Estimands  
 
 
 
 
Estimand 
 
 
 
Population 
Analysis Strategy for the ICE of 
Permanent Treatment 
Discontinuation 
 
 
Missing 
Data 
Imputation 
Method 
 
Due to lack of 
efficacy 
Due to any other 
reasons, including 
initiation of rescue 
medication 
Primary Estimand 
for the Primary 
Endpoint and 
Secondary 
Endpoints 
ITT Population 
who remained on 
treatment 
Not applicable 
Not applicable 
Primary 
analysis: as 
observed 
Supportive 
Estimand for the 
Primary Endpoint 
and Secondary 
ITT Population 
Composite: 
Set to baseline 
Hypothetical: Set to 
missing 
MCMC-MI 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 22 
LY3650150 
 
 
 
Endpoints at Week 
16 (Hybrid) 
 
 
 
 
Supportive 
Estimand for the 
Primary Endpoint 
and Secondary 
Endpoints at Week 
16 (Hypothetical) 
ITT Population 
Hypothetical: 
Set to missing 
Hypothetical: Set to 
missing 
LOCF 
Supportive 
Estimand for 
Secondary 
Endpoints at Week 
24 (Hybrid) 
Treatment Period 
II Population 
Composite: 
Set to baseline 
Hypothetical: Set to 
missing 
MCMC-MI 
Supportive 
Estimand for 
Secondary 
Endpoints at Week 
24 (Hypothetical) 
Treatment Period 
II Population 
Hypothetical: 
Set to missing 
Hypothetical: Set to 
missing 
LOCF 
Abbreviations: ICE = intercurrent event; LOCF = last observation carried forward; MCMC = 
Markov chain Monte Carlo; MI = Multiple Imputation. 
5.3. Adjustments for Covariates  
No statistical tests will be performed. 
 
5.4. Handling of Dropouts or Missing Data  
Intercurrent events, as per the ICH guideline (ICH E9R1), are events which occur after the 
treatment initiation and make it impossible to measure a variable or influence how it should be 
interpreted. Examples of such events include treatment discontinuation due to death or AEs, 
rescue treatment, and loss to follow-up. 
This section describes missing data imputation methods handling intercurrent events, which will 
be implemented in this study. For efficacy analyses relative to the primary estimand for primary 
and secondary endpoints, the method of handling missing data will be the “as observed” strategy 
described in Section 5.4.1. 
For efficacy analyses relative to the supportive hypothetical estimands for primary and secondary 
endpoints, missing data including those because of intercurrent events will be imputed using the 
Last Observation Carried Forward (LOCF) strategy described in Section 5.4.2. 
For efficacy analyses relative to the supportive hybrid estimands for primary and secondary 
endpoints, missing data including those because of intercurrent events will be imputed using 
Markov Chain Monte Carlo Multiple Imputation (MCMC-MI) as described in Section 5.4.3. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 23 
LY3650150 
 
 
5.4.1. As Observed Analysis  
The “as observed” strategy is used in so-called “observed cases” or “completers” analysis 
ubiquitous in the literature. For this analysis, only data from completers at the visit are relevant. 
All efficacy data will be summarized using an “as observed” analysis and summaries based on 
observed data at each postbaseline visit will be provided. 
5.4.2. Last Observation Carried Forward  
In this analysis, all missing values will be imputed using last observation carried forward 
(LOCF). Baseline values will be used for imputation if there is no postbaseline observation. 
5.4.3. Markov Chain Monte Carlo - Multiple Imputation (MCMC-MI)  
The method of handling missing efficacy data relative to the supportive hybrid estimands for the 
primary and secondary endpoints at Week 16 will be based on Markov Chain Monte Carlo 
Multiple Imputation (MCMC-MI). For patients who discontinue treatment due to lack of efficacy 
prior to Week 16, set to the patient’s baseline value subsequent to this time through Week 16. 
MCMC-MI will be used to handle the remaining missing data. 
The method of handling missing efficacy data relative to the supportive hybrid estimand for 
secondary endpoints at Week 24 will be based on MCMC-MI. For patients who discontinue 
treatment due to lack of efficacy after Week 16, set to the patient’s baseline value subsequent to 
this time through Week 24. MCMC-MI will be used to handle the remaining missing data. 
Imputation will be conducted within each treatment group independently so that the pattern of 
missing observations in one treatment group cannot influence missing value imputation in 
another. 
For each imputation process, 25 datasets with imputations will be calculated. The initial seed 
values are given in Table KGBO.5.3. The response rates and their associated SEs will be 
computed for each data set using SAS PROC FREQ with the riskdiff option specified for the 
appropriate column in the TABLES statement. The response rates and SEs from the resulting 
output will be combined across the 25 imputed datasets using SAS PROC MIANALYZE. 
For binary responses related to EASI and IGA, the binary response variables will be calculated 
based on the multiply imputed datasets that have been created. Because the MCMC algorithm is 
based on the multivariate normal model, imputed values for IGA will not generally be one of the 
discrete values used in IGA scoring (0, 1, 2, 3, or 4). Therefore, to derive the binary IGA 
response variable, standard rounding rules will be applied to the imputed values. For example, if 
a patient has an IGA score imputed as 1.4 (and assuming a baseline IGA score of 3), the imputed 
value would be rounded down to 1, and the minimum change from baseline of 2 would have 
been met. This patient would be considered a responder. 
For derivation of an EASI-75 and EASI-90 response, no rounding will be performed. The 
imputed EASI value will be compared directly to the observed baseline EASI value to determine 
whether a reduction of at least 75% or 90% was achieved at each visit. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 24 
LY3650150 
 
 
For derivation of the following Pruritus NRS, Skin Pain NRS, Sleep-Loss Scale, and DLQI 
responses, no rounding will be performed. The imputed Pruritus NRS, Skin Pain NRS, and 
Sleep-Loss Scale values will be compared directly to the observed mean baseline values to 
determine whether a response was achieved. The imputed DLQI values will be compared 
directly to the observed baseline values to determine whether a response was achieved. 
 Proportion of patients with a Pruritus NRS of ≥3 points at baseline achieving at least a 3- 
point reduction by visit. 
 Proportion of patients with a Pruritus NRS of ≥4 points at baseline achieving at least a 4- 
point reduction by visit. 
 Proportion of patients with a Skin Pain NRS of ≥4 points at baseline achieving at least a 
4-point reduction by visit. 
 Proportion of patients with a Sleep-Loss Scale of ≥2 points at baseline achieving at least 
a 2-point reduction by visit. 
 Proportion of patients with DLQI of ≥4 points at baseline achieving at least a 4-point 
reduction by visit. 
Note that the estimate and 90% confidence interval bounds output by this SAS PROC 
MIANALYZE are percents (i.e, they are in terms of the response rate). To obtain the number of 
responders, the estimated percent is multiplied by the number of individuals in the analysis 
population and rounded to the nearest integer. 
Imputation of continuous data will parallel that of binary variables. IGA, EASI, Sleep-Loss, Skin 
Pain NRS, Pruritus NRS, DLQI, CDLQI, and SCORAD will be summarized using an MCMC- 
MI analysis. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 25 
LY3650150 
 
 
Table KGBO.5.3. Seed Values for MCMC-Multiple Imputation  
 
 
Analysis 
Seed Values for Weeks 0- 
16 of the Treatment 
Period; 
LEB 250mg Q2W 
Seed Values for Weeks 16- 
24 of the Treatment Period; 
LEB 250mg Q2W or Q4W 
Proportion of patients achieving IGA of 0 or 1 with 
a ≥2 -point improvement from baseline by visit. 
661769200 
893745627 
Percent change from baseline in EASI score by 
visit. EASI-75 and EASI-90 will leverage 
imputation from EASI and therefore use the same 
seed numbers. 
153233047 
345987238 
Change from baseline in Pruritis NRS Score by 
visit. Proportion of patients with a Pruritus NRS 
Score of ≥3 or ≥4 points at baseline achieving at 
least a 3--point or 4-point reduction will leverage 
imputation from Pruritis NRS Score and therefore 
use the same seed numbers. 
502899349 
302781834 
Change from baseline in Sleep-Loss Scale by visit. 
Proportion of patients with a Sleep-Loss Scale of 
≥2 points at baseline who achieve at least a 2-point 
reduction at each visit will leverage imputation 
from Sleep-Loss Scale and therefore use the same 
seed numbers. 
691405299 
999692612 
Change from baseline in Skin Pain NRS from 
baseline by visit. Proportion of patients with a 
Pruritus NRS Score of ≥4 points at baseline 
achieving at least a 4-point reduction will leverage 
imputation from Pruritis NRS Score and therefore 
use the same seed numbers. 
81969225 
20532740 
Change from baseline in DLQI by visit. Proportion 
of patients with DLQI ≥4 points at baseline 
achieving at least a 4-point reduction will leverage 
imputation from DLQI and therefore use the same 
seed numbers. 
66350097 
60458639 
Change from baseline in CDLQI by visit. 
93794487 
34792746 
Change from baseline in SCORAD by visit. 
90372454 
71154457 
Abbreviations: CDLQI = Children’s Dermatology Life Quality Index; DLQI = Dermatology Life 
Quality Index ; EASI = Eczema Area and Severity Index; EASI-75 = Eczema Area and Severity 
Index improvement of ≥75%; EASI-90 = Eczema Area and Severity Index improvement of 
≥90%; IGA = Investigator’s Global Assessment for Atopic Dermatitis; LEB = lebrikizumab; 
MCMC = Markov chain Monte Carlo; NRS = Numeric Rating Scale; Q2W = every 2 weeks; 
Q4W = every 4 weeks; SCORAD = SCORing Atopic Dermatitis. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 26 
LY3650150 
 
 
5.5. Multicenter Studies  
This study will be conducted by multiple investigators at multiple sites. 
 
5.6. Multiple Comparisons/Multiplicity  
No statistical tests will be performed in this study so there is no need to account for multiple 
comparisons. 
5.7. Patient Disposition  
The following patient disposition summaries will be provided (details of the analysis populations 
can be found in Section 5.1.1): 
 The total number and percentage of patients entering each statistical analysis population 
as defined in Section 5.1.1 (analysis population: all entered patients). 
 The number and percentage of patients who entered the study, were treated, and screen 
failed will be provided overall and by screen fail reason (analysis population: all entered 
patients). 
 The number and percentage of patients who completed Week 16, and the number and 
percentage of patients who discontinued the treatment at any time before Week 16, by 
primary reason for discontinuation of treatment (analysis population: ITT). 
 The number and percentage of patients who completed Week 24, and the number and 
percentage of patients who discontinued the treatment at any time before Week 24, by 
primary reason for discontinuation of treatment (analysis population: ITT). 
 The number and percentage of patients who were treated and completed the study, and 
the number and percentage of patients who discontinued the study at any time, by 
primary reason for discontinuation (analysis population: ITT). 
All enrolled participants (that is, in the ITT population) who discontinued from study treatment 
will be listed together with the discontinuation reason, and the timing of discontinuation from the 
study will be reported. 
Patient allocation by center/site will be summarized with the number of patients who entered the 
study, number of ITT patients, number of patients discontinued from study treatment, and 
number of patients discontinued from the study. 
5.8. Patient Characteristics  
5.8.1. Demographics and Baseline Characteristics  
Patient demographic variables and baseline characteristics will be summarized for the ITT and 
Treatment Period II populations. The continuous variables will be summarized using descriptive 
statistics (mean, median, standard deviation, and range [minimum and maximum]), and the 
categorical variables will be summarized using frequency counts and percentages. 
The following demographic information will be included: 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 27 
LY3650150 
 
 
 age 
 sex (male, female) 
 reason of prior dupilumab discontinued 
 Fitzpatrick skin phototype 
 race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White, Multiple, Other, or Not Reported) 
 ethnicity (Hispanic or Latino, Not Hispanic or Latino, Not reported, or Unknown) 
 weight (kg) 
 weight category (40-<60 kg, ≥60 to <100 kg, or ≥100 kg) 
 height (cm) 
 BMI (kg/m2), and 
 BMI category (Underweight [<18.5 kg/m2], Normal [≥18.5 and <25 kg/m2], Overweight 
[≥25 and <30 kg/m2], Obese [≥30 and <40 kg/m2], or Extreme obese [≥40 kg/m2]). 
By-patient listings of basic demographic information for the ITT population will be provided. 
The following baseline disease/clinical characteristics will be included: 
 age at onset (years): calculated as the difference between date of onset of AD and the date 
of birth collected on the CRF 
 duration since AD onset (years): calculated as the difference between date of informed 
consent and the date of onset of AD collected on the CRF 
 duration since AD onset category (0 to <2 years, 2 to <5 years, 5 to <10 years, or 
≥10 years) 
 anatomical area affected by AD: 
o head 
o trunk (internal/medial axillae and groin) 
o upper extremities (includes external axillae) 
o lower extremities (includes buttocks and feet), and 
o at least 2 areas 
 AD treatment used in the past: 
o none 
o topical corticosteroids 
o topical calcineurin inhibitors 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 28 
LY3650150 
 
 
o immunosuppressive/immunomodulating drugs: systemic corticosteroids, 
cyclosporine, mycophenolate-mofetil, IFN-γ, janus kinase inhibitors, 
azathioprine, methotrexate, phototherapy, photochemotherapy, and other 
biologics (eg, B-cell depleting biologics) 
The following efficacy instruments will be included: 
 IGA 
 F-IGA score 
 EASI score 
 BSA 
 SCORAD 
 mTLSS 
 Pruritus NRS 
 Sleep-Loss Scale 
 Skin Pain NRS 
 DLQI/CDLQI 
 ADCT 
 Participant-Reported Satisfaction Question 
 Fitzpatrick Skin Phototype Assessment 
 WPAI-AD. 
5.8.2. Medical History  
Medical histories are defined as the conditions/events recorded on the Pre-existing Conditions 
and Medical History eCRF with a start date prior to the first study drug injection. Notice if a 
medical history worsens in severity on or after the date of first injection it will be recorded as an 
AE on the Adverse Event eCRF with the date of worsening as the start date. 
The number and percentage of patients with medical histories will be summarized for the ITT 
population using the MedDRA Preferred Term (PT) nested within System Organ Class (SOC). 
The number and percentage of patients with specific medical history events of interest 
prespecified on the Prespecified Medical History eCRF will be summarized for the ITT 
population. 
5.9. Treatment Compliance  
Beginning Week 4 (Visit 4) the participant/caregiver will be encouraged to administer the study 
intervention while in the clinic or at home. Participants may choose to continue to receive study 
drug injections administered by trained clinic staff for any visit occurring in the clinic. Home 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 29 
LY3650150 
 
 
dosing must be self-administered or given by a caregiver that has received proper injection 
technique training. 
When participants self-administer study intervention(s) at home, compliance with study 
intervention will be assessed at each visit. Compliance will be assessed by direct questioning, 
counting returned injection supplies, and documented in the source documents. 
Treatment compliance with investigational product will be summarized for patients who receive 
at least 1 confirmed dose of lebrikizumab (ie, the Safety Population) during the Treatment 
Period. Treatment compliance for each patient will be calculated as: 
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑒𝑟𝑒𝑑 
𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑎𝑛𝑐𝑒 ሺ%ሻ ൌ 100 ൈ 
 
 
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 
 
 The number of injections expected can be derived from the study drug dispense dataset. 
 The total number of injections administered will be based on the Exposure as 
Collected eCRF page and on the Exposure as Collected: Missed Injections at 
Home eCRF page. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 30 
LY3650150 
 
 
A patient will be considered compliant if he or she received ≥75% of the expected number of 
injections while enrolled in the study. Descriptive statistics for percent compliance will be 
summarized. Subintervals of interest, such as compliance between visits, may also be presented. 
5.10. Prior and Concomitant Therapy  
Medications will be classified into anatomical therapeutic chemical (ATC) drug classes using the 
latest version of the World Health Organization (WHO) drug dictionary. Medication start and 
stop dates will be compared to the date of first dose of treatment during Weeks 0-16 of the 
Treatment Period and Weeks 16-24 of the Treatment Period to be classified as concomitant for 
each treatment period. 
Prior medications are those medications that start and stop prior to the date of first dose of study 
treatment. Concomitant medications are those medications that start before, on, or after the first 
day of study treatment of the defined study period (that is, Weeks 0-16 or Weeks 16-24 of the 
Treatment Period) and continue into that period. Concomitant medications are assigned to the 
study period in which they are actually ongoing. For example, if a participant is receiving a 
concomitant medication during Weeks 0-16 but has a stop date prior to Week 16, the same 
medication would not be listed as a concomitant medication for Weeks 16-24 unless the patient 
has a new start date. 
Prior medication will be summarized by drug class and PT for the ITT population. Concomitant 
medication used during Weeks 0-16 and Weeks 16-24 will be presented separately for the ITT 
and Treatment Period II populations. 
 
Rescue medications used during Weeks 0-16 and Weeks 16-24 will be presented separately for 
the ITT and Treatment Period II populations. This will include: (1) topical therapy and (2) 
systemic therapy (e.g., systemic corticosteroids, phototherapy, cyclosporin, etc.). More 
information on the definition of rescue medications can be found in Appendix 1. 
5.11. Efficacy Analyses  
Table KGBO.5.4 includes the description and derivation of the efficacy measures and endpoints. 
For categorical parameters, the number and percentage of patients in each category will be 
presented, as well as a 90% Wilson-Score confidence interval for the percentage. For continuous 
parameters, descriptive statistics will include n (number of patients), mean, standard deviation, 
Q1, median, Q3, minimum, and maximum. These summaries will be provided for the data as- 
observed and after implementation of LOCF and MCMC-MI imputation as described in Sections 
5.4.2 and 5.4.3. 
The IGA, F-IGA, EASI, BSA, Pruritus NRS, Skin Pain NRS, and Sleep-Loss Scale will be 
reported by clinic visit. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 31 
LY3650150 
 
 
 
 
Table KGBO.5.4.Description and Derivation of Efficacy/Health Outcomes Measures and Endpoints 
 
 
 
 
 
 
 
 
Measure 
 
Description 
 
Variable 
 
Derivation/Comment 
Imputation Approach if 
Missing Components 
Investigator’s 
The IGA is a static assessment and rates 
IGA score 
Single item. Range: 0-4 
Single item, missing if 
Global 
the severity of a patient’s AD. The IGA  
0 represents “clear” 
missing 
Assessment 
is comprised of a 5-point scale ranging 
 
4 represents “severe” 
 
(IGA) 
from 0 (clear) to 4 (severe), and a score 
is selected using descriptors that best 
 
IGA (0,1) with 
≥2-point 
improvementa 
IGA (0) 
 
Observed score of 0 or 1 and 
change from baseline ≤-2 
 
Observed score of 0 
Missing if baseline or 
observed value is missing 
 
describe the overall appearance of the 
 
 
lesions at a given time point. 
Single item, missing if 
missing 
 
 
 
Face- 
The F-IGA is a static assessment and 
F-IGA Score 
Single item. Range: 0-4, 0 represents 
Single item, missing if 
Investigator’s 
Global 
Assessment 
rates the severity of a patient’s AD on 
the face. The F-IGA is comprised of a 
5-point scale ranging from 0 (clear) to 4 
 
IGA (0,1) with ≥2-point 
improvementa 
“clear”, 4 represents “severe” 
Observed score of 0 or 1 and change 
from baseline ≤-2 
missing 
Missing if baseline or 
observed value is missing 
(F-IGA) 
(severe), and a score is selected using 
 
 
 
 
descriptors that best describe the overall 
IGA (0) 
Observed score of 0 
Single item, missing if 
 
appearance of the lesions at a given 
 
 
missing 
 
time point. 
 
 
 
Eczema Area 
and Severity 
Index 
(EASI) 
The EASI scoring system uses a defined 
process (Steps 1-5 below) to grade the 
severity of the signs of eczema and the 
extent affected. The extent of disease 
(percentage of skin affected: 0 = 0%; 
1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 
4 = 50-69%; 5 = 70-89%; 6 = 90-100%) 
and the severity of 4 clinical signs 
(erythema, edema/papulation, 
excoriation, and lichenification) each on 
a scale of 0-3 (0 = none, absent; 
1 = mild; 2 = moderate; 3 = severe) at 4 
EASI score 
Derive EASI region score for each of 
head and neck, trunk, upper limbs, and 
lower limbs as follows: 
EASIregion = (erythema + 
edema/papulation + excoriation + 
lichenification)*(value from percentage 
involvement), where erythema, 
edema/papulation, excoriation, and 
lichenification are evaluated on a scale 
of 0 to 3, and value from percentage 
involvement is on a scale of 0 to 6. 
Then total EASI score is as follows: 
NA: partial assessments 
cannot be saved. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 32 
LY3650150 
 
 
 
 
body sites (head and neck, trunk, upper 
 
EASI = 0.1*EASIhead and neck + 
 
limbs, and lower limbs). Half scores are 
0.3*EASItrunk + 0.2*EASIupper limbs + 
allowed between severities 1, 2, and 3. 
0.4*EASIlower limbs 
Each body site will have a score that 
 
Change from 
Change from baseline: observed EASI 
score – baseline EASI score 
 
 
% change from baseline: 
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑠𝑐𝑜𝑟𝑒 െ 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 
100 ൈ 
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 
Missing if baseline or 
ranges from 0-72, and the final EASI 
baseline in EASI 
observed value is missing 
score will be obtained by weight- 
score 
 
averaging these 4 scores. Hence, the 
 
 
final EASI score will range from 0-72 
Percent change from 
 
for each time point. 
baseline EASI scorea 
 
 
EASI-75a 
% improvement in EASI score from 
Missing if baseline or 
 
 
baseline ≥75%: 
observed value is missing 
 
 
% change from baseline ≤-75 
 
 
EASI-90a 
% improvement in EASI score from 
Missing if baseline or 
 
 
baseline ≥90%: 
observed value is missing 
 
 
% change from baseline ≤-90 
 
Body Surface 
Area (BSA) 
Affected by 
AD 
The BSA assessment estimates the 
extent of disease or skin involvement 
with respect to AD and is expressed as a 
percentage of total body surface. BSA 
will be determined by the investigator 
or designee using the patient palm = 1% 
rule. 
BSA score 
BSA Total = BSAhead and neck + 
BSAtrunk + BSAupper limbs + BSAlower 
limbs 
NA: partial assessments 
cannot be saved. 
Change from baseline in 
BSA scorea 
Change from baseline: observed BSA 
score - baseline BSA score 
Missing if baseline or 
observed value is missing. 
Dermatology 
The DLQI is a validated, dermatology- 
DLQI total score 
A DLQI total score is calculated by 
summing all 10 question responses and 
has a range of 0-30 (less to more 
impairment) (Finlay and Khan 1994; 
Basra et al. 2008). 
Score of 1 unanswered 
Life Quality 
specific, patient-reported measure that 
 
question = 0; If 2 or more 
Index (DLQI) 
evaluates a patient’s HRQoL. This 
 
questions are missing, the 
 
questionnaire has 10 items that are 
 
total score is missing. Note: 
 
grouped in 6 domains, including 
 
#7B could be a valid 
 
symptoms and feelings, daily activities,  
missing while #7A is not 
 
leisure, work and school, personal 
 
“No.” That is, #7 should be 
 
relationships, and treatment. The recall 
 
considered as 1 question. 
 
period of this scale is over the “last 
DLQI (0,1) 
A DLQI (0,1) response is defined as a 
Missing if DLQI total score 
 
week”. 
 
postbaseline DLQI total score of 0 or 1. 
is missing 
 
 
 
A DLQI total score of 0-1 is considered  
 
 
 
as having no effect on a patient’s 
 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 33 
LY3650150 
 
 
 
 
Response categories and corresponding 
scores are: 
Very much = 3 
A lot = 2 
A little = 1 
Not at all = 0 
Not relevant = 0 
 
Scores range from 0-30, with higher 
scores indicating greater impairment of 
QoL. A DLQI total score of 0-1 is 
considered as having no effect on a 
patient’s HRQoL (Hongbo et al. 2005), 
and a 4-point change from baseline is 
considered as the minimal clinically 
important difference threshold (Khilji et 
al. 2002; Basra et al. 2015). 
 
HRQoL (Khilji et al. 2002; Hongbo et 
al. 2005). 
 
4-point improvementa 
Change from baseline ≤-4 
Missing if baseline is 
missing or observed value is 
missing. 
DLQI total score and 
domain scores change 
from baselinea 
Calculated as: observed DLQI (total 
score or domain scores) - baseline 
DLQI (total score or domain scores) 
Missing if baseline or 
observed value is missing 
DLQI symptoms and 
feelings domain 
Sum of responses of questions 1 and 2: 
1. How itchy, sore, painful or stinging 
has your skin been? 
2. How embarrassed or self-conscious 
have you been because of your 
skin? 
If 1 question in a domain is 
missing, that domain is 
missing. 
DLQI daily activities 
domain 
Sum of responses of questions 3 and 4: 
3. How much has your skin interfered 
with you going shopping or looking 
after your home or garden? 
4. How much has your skin influenced 
the clothes you wear? 
If 1 question in a domain is 
missing, that domain is 
missing. 
DLQI leisure domain 
Sum of responses of questions 5 and 6: 
5. How much has your skin affected any 
If 1 question in a domain is 
missing, that domain is 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 34 
LY3650150 
 
 
 
 
 
 
social or leisure activities? 
6. How much has your skin make it 
difficult for you to do any sport? 
missing. 
DLQI work and school 
domain 
Sum of responses of questions 7A and 
7B: 
7A. Has your skin prevented you from 
working or studying? 
7B. If No: how much has your skin 
been a problem at work or 
studying? 
If the answer to question 7A 
is missing, this domain is 
missing. If 7A is No, and 
7B is missing, this domain 
is missing. 
DLQI personal 
relationships domain 
Sum of responses of questions 8 and 9: 
8. How much has your skin created 
problems with your partner or any 
of your close friends or relatives? 
9. How much has your skin caused any 
sexual difficulties? 
If 1 question in a domain is 
missing, that domain is 
missing. 
DLQI treatment domain 
Response of question 10: 
10. How much of a problem has the 
treatment for your skin been, for 
example by making your home 
messy, or by taking up time? 
If 1 question in a domain is 
missing, that domain is 
missing. 
Children’s 
Dermatology 
Life Quality 
Index 
(CDLQI) 
The CDLQI is designed to measure the 
impact of any skin disease on the lives 
of children. Patients ≤16 years will 
complete the CDLQI and should 
continue to complete the CDLQI for the 
duration of the study. 
 
The scoring of each question is: 
 
Very much = 3 
 
Quite a lot = 2 
 
Only a little = 1 
 
Not at all = 0 
 
Question unanswered = 0 
CDLQI total score 
A CDLQI total score is calculated by 
summing all 10 question responses and 
has a range of 0-30 (less to more 
impairment) (Waters A et al. 2010). 
Score of 1 unanswered 
question = 0; If 2 or more 
questions are missing, the 
total score is missing. 
CDLQI (0,1) 
A CDLQI (0,1) response is defined as a 
postbaseline CDLQI total score of 0 or 
1. 
Missing if CLQI total score 
is missing 
4-point improvementa 
Change from baseline ≤-4 
Missing if baseline or 
observed value is missing 
CDLQI total score and 
domain scores change 
from baselinea 
Calculated as: observed CDLQI (total 
score or domain scores) - baseline 
CDLQI (total score or domain scores) 
Missing if baseline or 
observed value is missing 
CDLQI symptoms and 
feelings domain 
Sum of responses of questions 1 and 2: 
1. Over the last week, how itchy, 
If 1 question in a domain is 
missing, that domain is 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 35 
LY3650150 
 
 
 
 
 
Question 7: 'Prevented school' 
(text-only questionnaire) = 3 
 
“scratchy”, sore or painful has your 
skin been? 
2. Over the last week, how embarrassed 
or self conscious, upset or sad 
have you been because of your 
skin? 
missing. 
CDLQI sleep domain 
Response of question 9 
9. Over the last week, how much has 
your sleep been affected by your 
skin problem? 
Single item, missing if 
missing 
CDLQI leisure domain 
Sum of responses of questions 4, 5, and 
6: 
4. Over the last week, how much have 
you changed or worn different or 
special clothes/shoes because of 
your skin? 
5. Over the last week, how much has 
your skin trouble affected going 
out, playing, or doing hobbies? 
6. Over the last week, how much have 
you avoided swimming or other 
sports because of your skin 
trouble? 
If 1 question in a domain is 
missing, that domain is 
missing. 
CDLQI school or 
holiday domain 
Responses of questions 7: 
If select 'Prevented school', score = 3 
Single item, missing if 
missing 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 36 
LY3650150 
 
 
 
 
 
 
If school time: 
Last week, 
Over the last 
was it 
week, how much 
school time? 
did your skin 
affect your 
OR 
school work? 
 
was it 
If holiday time: 
holiday time? 
How much over 
the last week, 
has your skin 
problem 
interfered with 
your enjoyment 
of the holiday? 
 
CDLQI personal 
relationships domain 
Sum of responses of questions 3 and 8: 
3. Over the last week, how much has 
your skin affected your 
friendships? 
8. Over the last week, how much 
trouble have you had because of 
your skin with other people calling 
you names, teasing, bullying, 
asking questions or avoiding you? 
If 1 question in a domain is 
missing, that domain is 
missing. 
CDLQI treatment 
domain 
Response of question 10: 
10. How much of a problem has the 
treatment for your skin been? 
Single item, missing if 
missing. 
SCORing 
Atopic 
Dermatitis 
(SCORAD) 
SCORAD is a validated clinical tool for 
assessing the extent and intensity of 
atopic dermatitis. There are 3 
components to the assessment: 
 
The extent of AD is assessed 
as a percentage of each 
SCORAD Score 
SCORAD = A/5 + 7B/2 + C, where 
A is extent of disease, range 0-100 
B is disease severity, range 0-18 
C is subjective symptoms, range 0-20 
Missing if components A 
and B are missing or if 
component C is missing. 
Partial assessments 
performed by physician 
cannot be saved and partial 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 37 
LY3650150 
 
 
 
 
defined body area and 
reported as the sum of all 
areas, with a maximum score 
of 100% (assigned as “A” in 
the overall SCORAD 
calculation). 
 
The severity of 6 specific 
symptoms of AD (redness, 
swelling, oozing/crusting, 
excoriation, skin 
thickening/lichenification, 
dryness) is assessed using the 
following scale: none (0), 
mild (1), moderate (2), or 
severe (3) (for a maximum of 
18 total points, assigned as 
“B” in the overall SCORAD 
calculation). 
 
Subjective assessment of itch 
and of sleeplessness is 
recorded for each symptom by 
the patient or relative on a 
VAS, where 0 is no itch (or 
sleeplessness) and 10 is the 
worst imaginable itch (or 
sleeplessness), with a 
maximum possible score of 20 
(assigned as “C” in the overall 
SCORAD calculation. 
 
 
--Change from baseline 
in SCORAD score 
 
 
--Percent change from 
baseline in SCORAD 
score 
 
 
SCORAD75 
 
 
 
SCORAD90 
 
 
Change from baseline: observed 
SCORAD score – baseline SCORAD 
score 
 
% change from baseline: 
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑠𝑐𝑜𝑟𝑒 െ 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 
100 ൈ 
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 
 
 
% Improvement in SCORAD from 
baseline ≥75%: 
% change from baseline ≤-75 
 
% Improvement in SCORAD from 
baseline ≥90%: 
% change from baseline ≤-90 
assessments performed by 
subject cannot be saved. 
 
Missing if baseline or 
observed value is missing. 
 
 
 
 
 
 
 
Missing if baseline or 
observed value is missing. 
 
 
Missing if baseline or 
observed value is missing. 
Modified 
Total Lesion 
Symptom 
Scale 
The Modified Total Lesion Symptom 
Scale is an investigator-reported scale 
that combines the evaluation of hand 
eczema (HE) lesion severity (erythema, 
edema, desquamation, fissures, 
hyperkeratosis or lichenification, and 
vesicles) with the intensity of pruritus 
Percent change from 
baseline in mTLSS 
This composite score assigns 0 (mild) to 
3 (severe) to each component, giving a 
maximum disease severity of 21. The 
recall period for this scale is the present 
time. 
If 1 question in a domain is 
missing, that domain is 
missing. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 38 
LY3650150 
 
 
 
 
or pain to assess the severity of 
symptoms. 
 
 
 
Pruritis 
Numeric 
Rating Scale 
(NRS) 
The Pruritus Numeric Rating Scale 
(NRS) is a participant-reported, single- 
item, daily, 11-point scale. 
Percent change from 
baseline Pruritis NRS 
Score 
 
4-point improvement in 
Pruritis NRS Score 
 
3-point improvement in 
Pruritus NRS Score 
The Pruritus NRS is used by 
participants to rate their worst itch 
severity over the past 24 hours with 0 
indicating “No itch” and 10 indicating 
“Worst itch imaginable.” Assessments 
will be recorded daily by the 
participant. The minimal clinically 
important change is 3 points. 
Participants will record the pruritus 
assessments daily using an electronic 
diary at home. As indicated in the SoA 
(Section 1.3), initial electronic diary 
entries for Pruritus NRS should be 
completed a minimum of 4 of 7 days 
before baseline. 
Baseline weekly mean score 
is missing if the patient has 
3 or fewer responses within 
the week before baseline. 
Post-baseline weekly mean 
score is missing if the 
patient has no responses 
within the week. 
Skin Pain 
Numeric 
Rating Scale 
(NRS) 
The Skin Pain NRS is a participant- 
reported, 11-point horizontal scale 
anchored at 0 and 10, with 0 
representing “no pain” and 10 
representing “worst pain imaginable.” 
Percent change from 
baseline in Skin Pain 
NRS Score 
 
4-point improvement in 
Skin Pain NRS Score 
Overall severity of a participant’s skin 
pain is indicated by selecting the 
number that best describes the worst 
level of skin pain in the past 24 hours. 
Assessment will be recorded daily by 
the participant. 
Baseline weekly mean score 
is missing if the patient has 
3 or fewer responses within 
the week before baseline. 
Post-baseline weekly mean 
score is missing if the 
patient has no responses 
within the week. 
Sleep-Loss 
Scale 
The Sleep-Loss Scale is a participant- 
reported, single-item, daily scale that 
measures the extent of sleep loss due to 
interference of itch over the last night. 
Percent change from 
baseline in Sleep Loss 
Score 
 
2-point improvement in 
Sleep Loss Score 
The Sleep-Loss Scale is rated based 
on a 5-point Likert scale (0 [not at all] 
to 4 [unable to sleep at all]). 
Assessment will be recorded daily by 
the participant. The minimal clinically 
important change is 3 points. 
Baseline weekly mean score 
is missing if the patient has 
3 or fewer responses within 
the week before baseline. 
Post-baseline weekly mean 
score is missing if the 
patient has no responses 
within the week. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 39 
LY3650150 
 
 
 
Atopic 
Dermatitis 
Control Tool 
The Atopic Dermatitis Control Tool is a 
patient-reported, simple, brief tool for 
adults and adolescents that evaluates 6 
symptoms and effects associated with 
AD over the past week 
Percent change from 
baseline in ADCT Total 
Score 
Each of the 6 Atopic Dermatitis Control 
Tool items has a score range from 0 (no 
problem) to 4 (worst), rating the 
severity of each concept; the total score 
ranges from 0 to 24, which is the 
summation of the responses to all the 
items. A score of ≥7 points was derived 
as the threshold to identify participants 
“not in control.” The threshold for 
meaningful within-person change was 
estimated 
to be 5 points. 
If 1 question in a domain is 
missing, that domain is 
missing. 
Participant 
Reported 
Satisfaction 
Question 
The question on participant satisfaction 
asks “How satisfied are you with this 
treatment’s ability to treat your skin 
condition?” 
PRSQ Score 
The response options range from 1 (not 
satisfied) to 5 (completely satisfied). 
Single item, missing if 
missing. 
WPAI-AD 
The Work Productivity and Activity 
Impairment Questionnaire–Atopic 
Dermatitis is a participant-reported, 6- 
item questionnaire that records 
impairment due to AD over the past 7 
days in adolescents and adults 
Percent change from 
baseline in WPAI AD 
Absenteeism Score 
 
Percent change from 
baseline in WPAI AD 
Presenteeism Score 
 
Percent change from 
baseline in WPAI AD 
Work Productivity Loss 
Score 
 
Percent change from 
baseline in WPAI AD 
Activity Impairment 
Score 
The Work Productivity and Activity 
Impairment Questionnaire– Atopic 
Dermatitis consists of 6 items grouped 
into 4 domains: absenteeism (work time 
missed), presenteeism (impairment at 
work or reduced on the job 
effectiveness), work productivity loss 
(overall work impairment or 
absenteeism plus presenteeism), and 
activity impairment. Absenteeism, 
presentism, and work productivity will 
only be reported by those who are 
currently employed (working for pay) at 
the time of the scale completion. The 
recall period for the scale is 
over the past 7 days. Scores are 
calculated as impairment percentages 
(Reilly et al. 1993), with 
higher scores indicating greater 
If 1 question in a domain is 
missing, that domain is 
missing. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 40 
LY3650150 
 
 
 
 
 
 
impairment and less productivity 
 
Abbreviations: AD = atopic dermatitis; HRQoL = health-related quality of life; NA = not applicable; QoL = quality of life. 
a Secondary endpoints. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 41 
LY3650150 
 
 
 
5.12. Health Outcomes/Quality-of-Life Analyses  
The description and derivation of the health outcomes/QoL analyses are described in Table 
KGBO.5.4. For categorical parameters, the number and percentage of patients in each category 
will be presented, as well as a 90% Wilson-Score confidence interval for the percentage. For 
continuous parameters, descriptive statistics will include n (number of patients), mean, standard 
deviation, Q1, median, Q3, minimum, and maximum. These summaries will be provided for the 
data as-observed and after implementation of LOCF and MCMC-MI imputation as described in 
Sections 5.4.2. and 5.4.3. Patient-Reported Outcomes Information System and DLQI/CDLQI 
will be reported by clinic visit. 
5.13. Safety Analyses  
The planned analyses of safety data will be performed with an intent to maintain consistency 
with compound-level standard safety analyses. These standards are based on internal standards 
which were informed by CDISC standards, regulatory guidance (eg, FDA Clinical Review 
Template), and cross-industry standardization efforts (eg, PhUSE white papers from the Standard 
Analyses and Code Sharing Working Group provided in the PhUSE Computational Science 
Deliverables Catalog [WWW]). 
The laboratory (including hormone), vital sign (including growth), and immunogenicity safety 
summaries will be based on the safety population. The extent of exposure and AE tables will be 
based on the safety population. 
These analysis populations are fully defined in Table KGBO.5.1. 
Not all displays described in this section will necessarily be included in the CSRs. Any display 
described and not provided in the CSR would be available upon request. Not all displays will 
necessarily be created as a “static” display. Some may be incorporated into interactive display 
tools instead of or in addition to a static display. Any display created interactively will be 
included in the CSR if deemed relevant to the discussion. 
5.13.1. Extent of Exposure  
A by-patient listing of exposure duration with the number of active injections and total dose will 
be provided for the Safety Population. 
The duration of exposure will be calculated as: 
Duration of exposure (days) = 
Date of last visit (scheduled or unscheduled) in the Treatment Period – 
Date of first dose+1 
The number and percentage of patients in each of the following categories will be included in the 
summaries: 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 42 
LY3650150 
 
 
>0, ≥7 days, ≥14 days, ≥30 days, ≥60 days, ≥90 days, ≥112 days, ≥120 days, >=168 days. Note 
that patients may be included in more than 1 category. 
The summaries will also include the following information: 
 total exposure in patient years, calculated as: 
𝑇𝑜𝑡𝑎𝑙 𝑒𝑥𝑝𝑜𝑠𝑢𝑟𝑒 𝑖𝑛 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑦𝑒𝑎𝑟𝑠 
𝑆𝑢𝑚 𝑜𝑓 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑒𝑥𝑝𝑜𝑠𝑢𝑟𝑒𝑠 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑖𝑛 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑔𝑟𝑜𝑢𝑝 
ൌ 
365.25 
 mean and median total dose; total dose (in mg) is calculated by the number of active 
injections taken multiplied by 250. 
 Total number of injections received will be derived from the Exposure as Collected 
eCRF page and on the Exposure as Collected: Missed Injections at Home eCRF page. 
 
5.13.2. Adverse Events  
A TEAE is defined as an event that first occurred or worsened in severity after baseline (ie, AEs 
with an onset date on or after the date of the first injection of study drug). The MedDRA lowest- 
level term will be used in the treatment-emergent computation. The maximum severity for each 
lowest-level term during the baseline period will be used as baseline. The treatment period will 
be included as post-baseline for the summaries. For events with a missing severity during the 
baseline period, the events will be treated as ‘mild’ in severity for determining treatment- 
emergence. Events with a missing severity during the postbaseline period will be treated as 
‘severe’, and treatment-emergence will be determined by comparing to baseline severity. For 
events occurring on the day of first taking study medication, the events will be assumed to be 
posttreatment. 
The planned summaries for AEs are provided in Table KGBO.5.5 and are described more fully 
in compound-level safety standards and in the AE-related PhUSE white paper [Analysis and 
Displays Associated with Adverse Events: Focus on Adverse Events in Phase 2-4 Clinical Trials 
and Integrated Summary Document (PhUSE 2017)]. 
Summary tables will be presented for the safety population. Summary tables will include the 
number and percentage of patients reporting an event. For events that are gender-specific (as 
defined by MedDRA), the number of participants at risk will include only patients from the 
given gender. 
Table KGBO.5.5.Summary Tables/Listings Related to Adverse Events 
 
Summaries 
Population 
Overview of AEs 
Safety 
Summary of TEAEs by PTs 
Safety 
Summary of TEAEs by PTs within SOC 
Safety 
Summary of TEAE PTs by maximum severity 
Safety 
Summary of SAEs by PT within SOC 
Safety 
Summary of AEs leading to treatment discontinuation by PT with SOC 
Safety 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 43 
LY3650150 
 
 
 
Summary of TEAEs possibly related to study drug by PTs within SOC 
Safety 
Summary of treatment-emergent adverse events – facial dermatitis follow-up form 
Safety 
Listing of SAEs (including Death) 
Safety 
Listing of primary AEs leading to study treatment discontinuation 
Safety 
Listing of TEAEs 
Safety 
Abbreviations: AE = adverse event; PT = Preferred Term; SAE = serious adverse event; SOC = System Organ 
Class; TEAE = treatment-emergent adverse event. 
5.13.2.1. Common Adverse Events  
The percentages of patients with TEAEs will be summarized using MedDRA PT for the common 
TEAEs (occurred in 1% before rounding in any column in the table). 
5.13.2.2. Deaths, Other Serious Adverse Events and Other Notable Adverse 
Events  
The number and percentage of patients reported with an SAE during the treatment period will be 
summarized using MedDRA PT. A listing of SAEs will be provided. 
The number and percentage of patients who permanently discontinued from study treatment due 
to an AE (including AEs that led to death) during the treatment period will be summarized using 
MedDRA PT. Events will be ordered by decreasing frequency. 
5.13.3. Clinical Laboratory Evaluation  
As described more fully in compound-level safety standards and in the laboratory-related PhUSE 
white papers (PhUSE 2013; PhUSE 2015), the clinical laboratory evaluations will be 
summarized as described in Table KGBO.5.6. Hormone analytes are summarized/plotted 
similarly. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 44 
LY3650150 
 
 
Table KGBO.5.6.Summary Tables/Listing of Clinical Laboratory Evaluations 
 
Summaries 
Population 
Box plots of observed values by visit 
Box plots for change from baseline values by visit 
Safety 
Change from baseline to last observations 
Safety 
Treatment-emergent abnormal high lab values (ie, patients shifting from a 
normal/low maximum baseline value to a high maximum postbaseline value) or 
abnormal low lab values (ie, patients shifting from normal/high minimum baseline 
value to a low minimum postbaseline value) 
Safety 
Shift tables showing the number of patients who shift from each category of 
maximum (minimum) baseline observation to each category of maximum 
(minimum) postbaseline observation. Here categories may be low, normal, or high 
with cut-offs defined in the compound-level safety standards. 
Safety 
Listing of abnormal findings for laboratory analyte measurements, including 
qualitative measures 
Safety 
 
5.13.4. Vital Signs and Other Physical Findings  
As described more fully in compound-level safety standards and in the laboratory-related PhUSE 
white papers (PhUSE 2013; PhUSE 2015), vital signs will be summarized similarly to the 
clinical laboratory evaluation (Table KGBO.5.7). For vital signs, treatment-emergent low and 
high are based on a combination of a specified value and a change or percentage change as 
defined in the compound-level safety standards. 
Table KGBO.5.7. 
Summary Tables/Figures Related to Vital Signs 
 
Summaries 
Population 
Box plots for observed values by visit 
Safety 
Box plots for change from baseline values by visit 
Safety 
Tables with the number and percentage of subjects who shift from normal/high to low (ie, 
treatment-emergent low) and the number and percentage of subjects who shift from 
normal/low to high (ie, treatment-emergent high); the limits are defined in the compound- 
level safety standards 
Safety 
 
 
5.13.5. Immunogenicity  
Anti-drug antibodies (ADA) analysis will only occur upon request from, for example, regulatory 
or a business need. An individual sample will be potentially examined multiple times in a 
hierarchical procedure to produce a sample ADAs assay result and may yield a sample NAb 
assay result. Treatment-emergent ADAs are defined as those with a titer 2-fold (1 dilution) 
greater than the minimum required dilution if no ADAs were detected at baseline (treatment- 
induced ADA) or those with a 4-fold (2 dilutions) increase in titer compared to baseline if ADAs 
were detected at baseline (treatment-boosted ADA). A patient is considered TE-ADA positive 
when at least 1 postbaseline ADA sample meets the definition of TE-ADA. 
Compound-level safety standards will be followed in the analyses of immunogenicity. Listings 
of immunogenicity assessments will be provided along with the summary of specified TEAEs by 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 45 
LY3650150 
 
 
TE-ADA status. The summary of TE-ADA and NAb status will be produced for the Safety 
Population. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 46 
LY3650150 
 
 
5.13.6. Special Safety Topics including Adverse Events of Special 
Interest  
This section includes areas of interest whether due to observed safety findings, potential findings 
based on drug class, or safety topics anticipated to be requested by a regulatory agency for any 
reason. In general, potential AESI relevant to these special safety topics will be identified by 1 or 
more SMQs, by a Lilly-defined MedDRA PT listing based upon the review of the most current 
version of MedDRA, or by treatment-emergent relevant laboratory changes, as described below. 
Additional special safety topics may be added as warranted. 
Unless otherwise specified, the AESI will be summarized for the safety population. 
Full details of the search terms and rules for deriving AESI in each of the sections below are 
described in the compound-level safety standards along with information about the types of 
summaries and listings to be provided. In the event that the listing of terms or analysis changes 
for a special safety topic, it will be documented in the compound-level safety standards, which 
will supersede this document; it will not warrant an amendment to the individual study SAP. 
5.13.6.1. Hepatic Safety  
Hepatic labs include alanine aminotransferase (ALT) aspartate transaminase (AST), total 
bilirubin (TBL), and serum alkaline phosphatase (ALP). 
Table KGBO.5.8. 
Summary Tables/Figure Related to Hepatic Safety 
 
Summaries 
Population 
ALT and AST: The number and percentage of subjects with a measurement greater than 
or equal to 3 times (3X), 5 times (5X), and 10 times (10X) the performing lab ULN 
during the treatment period for all subjects with a postbaseline value and for subsets 
based on various levels of baseline value 
TBL and ALP: The number and percentage of subjects with a measurement greater than 
or equal to 2 times (2X) the performing lab ULN during the treatment period will be 
summarized for all subjects with a postbaseline value and for subsets based on various 
levels of baseline value 
Safety 
Plot of maximum postbaseline ALT vs. maximum postbaseline total bilirubin 
Safety 
Abbreviations: ALP = serum alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate transaminase; 
TBL = total bilirubin; ULN = upper limit of normal. 
5.13.6.2. Eosinophilia and Eosinophil-Related Disorders  
In addition to the standard laboratory summaries (Section 5.13.3), eosinophilia and eosinophil- 
related AEs will be summarized. Details regarding- eosinophil-related PTs are in the compound- 
level safety standards. 
Table KGBO.5.9. 
Summary Tables Related to Eosinophilia and Eosinophil-Related 
Adverse Events 
 
Summaries 
Population 
Shift table summarizing the number and percentage of participants within each 
maximum baseline category versus each maximum postbaseline category 
Safety 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 47 
LY3650150 
 
 
 
Summary of eosinophil-related TEAE by PT 
Safety 
Abbreviations: AE = adverse event; PT = Preferred Term; TEAE = treatment-emergent adverse event. 
 
5.13.6.3. Infections, including herpes infections and relevant parasitic infections 
Infections will be defined using the PTs from the MedDRA Infections and Infestations SOC. The 
MedDRA terms used to identify infections considered to be opportunistic infections (OI) in 
patients with immune-mediated inflammatory conditions treated with immunomodulatory drugs 
are based on Winthrop et al. (2015) and are listed in the compound-level safety standards. The 
list contains narrow (more specific) and broad (less specific) PTs with respect to these 
prospectively defined OIs. Definitions of herpes infections, parasitic infections, and skin 
infections are listed in the compound-level safety standards. 
Table KGBO.5.10. 
Summary Tables/Listing Related to Infection Related Adverse 
Events 
 
Summaries 
Population 
Summary of treatment-emergent infections by maximum severity 
Safety 
Summary of serious infections by PT 
Safety 
Summary of infection AEs resulting in permanent study drug discontinuation 
Safety 
Treatment-emergent adverse events - opportunistic and potential opportunistic infections 
Safety 
Treatment-emergent adverse events - herpes and parasitic infections 
Safety 
Treatment-emergent adverse events - skin infections 
Safety 
Treatment-emergent adverse events - infections characterization and follow-up form 
Safety 
Listing of patients with potential OIs, serious infections, herpes, and parasitic infections 
Safety 
Abbreviations: AE = adverse event; OI = opportunistic infections; PT = Preferred Term. 
 
5.13.6.4. Conjunctivitis  
Conjunctivitis events are events of special interest and will be identified using PTs nested within 
the categories of conjunctivitis and keratitis as described in the compound-level safety standards: 
Table KGBO.5.11. 
Summary Table/Listing Related to Conjunctivitis 
 
Summaries 
Population 
Summary of TEAE of conjunctivitis and keratitis clusters 
Safety 
Treatment-emergent adverse events - conjunctivitis and eye inflammation 
characterization follow-up form 
Safety 
Listing of patients with conjunctivitis 
Safety 
Abbreviation: TEAE = treatment-emergent adverse event. 
 
5.13.6.5. Hypersensitivity  
Potential hypersensitivity reactions will be determined using the following SMQs: anaphylactic 
reaction, hypersensitivity, and angioedema. Potential hypersensitivity will be categorized as 
immediate (ie, occurring the same day as drug administration) and non-immediate (ie, occurring 
after the day of study drug administration but prior to subsequent drug administration). The 
planned summaries are provided in Table KGBO.5.12. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 48 
LY3650150 
 
 
Table KGBO.5.12. 
Summary Tables/Listing Related to Hypersensitivity 
 
Summaries 
Population 
Treatment-emergent adverse events - potential immediate hypersensitivity reactions 
(events occurring on day of study drug administration) 
Safety 
Treatment-emergent adverse events - potential nonimmediate hypersensitivity reactions 
(events occurring after day of study drug administration) 
Safety 
 
 
5.13.6.6. Injection Site Reactions (ISRs)  
Injection site reactions are AEs localized to the immediate site of the administration of a drug. 
The evaluation of study drug related ISRs will be through the unsolicited reporting of ISR 
TEAEs. Injection site reactions will be defined using the MedDRA high-level term (HLT) of 
ISR, excluding certain PTs (eg, those PTs related to injections into a joint) and administration 
site reactions as described in the compound-level safety standards. 
Table KGBO.5.13. 
Summary Tables Related to Injection Site Reactions 
 
Summary 
Population 
Summary of TEAE of ISR overall, and by PT 
Safety 
Abbreviations: HLT = high-level term; ISR = injection site reaction; PT = Preferred Term; TEAE = treatment- 
emergent adverse event. 
 
5.13.6.7. Malignancies  
Malignancies will be defined using PTs from the Malignant tumors SMQ and summarized 
separately for the 2 categories: Non-melanoma skin cancer (NMSC) and malignancies excluding 
NMSC. 
Table KGBO.5.14. 
Summary Tables Related to Malignancies 
 
Summary 
Population 
Summary of TEAE of malignancies within categories of NMSC and malignancy 
excluding NMSC 
Safety 
Abbreviations: NMSC = non-melanoma skin cancer; TEAE = treatment-emergent adverse event. 
 
5.13.6.8. Atopic Dermatitis Exacerbation  
Atopic dermatitis exacerbation will be defined using PTs specified in the Compound Level 
Safety Standards and summarized for the Safety Population. 
Table KGBO.5.15. 
Summary Tables Related to Atopic Dermatitis Exacerbation 
 
Analysis 
Population 
Summary of TEAE of atopic dermatitis exacerbation 
Safety 
Abbreviations: TEAE = treatment-emergent adverse event. 
 
5.13.6.9. Suicide/Self-Injury  
The PTs from the suicide/self-injury SMQ [20000037] will be summarized. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 49 
LY3650150 
 
 
Table KGBO.5.16. 
Summary Tables Related to Suicidal Ideation and Behavior 
 
Analysis 
Population 
Summary of TEAE of suicide/self-injury 
Safety 
Abbreviations: TEAE = treatment-emergent adverse event. 
 
5.14. Subgroup Analyses  
Subgroup analyses will be conducted for the primary endpoint, EASI-75 at Week 16, using 
descriptive statistics. 
The following subgroups will be analyzed: 
 weight category (<60 kg, ≥60 to <100 kg, or ≥100 kg). 
 Age (12 to <18, 18+) 
 Dupilumab Treatment Response (No response, Partial response, Lost Response) 
Some additional subgroup analyses may be added. The analysis of additional subgroups will not 
require an amendment to the SAP. 
5.15. Protocol Deviations  
Protocol deviations will be identified throughout the study. Important protocol deviations are 
defined as those deviations from the protocol likely to have a significant impact on the 
completeness, accuracy, and/or reliability of the study data or that may significantly affect a 
patient’s rights, safety, or well-being. 
Potential examples of important protocol deviations include patients who violated the 
inclusion/exclusion criteria, used an interfering concomitant medication, and significant non- 
compliance with study medication (<75% of expected injections). Refer to a separate document 
called “KGBO Trial Issues Management Plan” for the important protocol deviations with 
categorizations. 
The number and percentage of patients having important protocol deviations will be summarized 
within category and subcategory of deviation for Weeks 0-16 of the Treatment Period using the 
ITT population and for Weeks 16-24 of the Treatment Period using the Treatment Period II 
Population. 
A by-patient listing of important protocol deviations will be provided for the ITT population. 
 
5.16. Interim Analyses and Data Monitoring  
Interim Analysis: 
One interim analysis (primary lock) will be conducted after all enrolled participants have been 
evaluated at Week 16 or discontinued prior to Week 16. This interim database lock will include 
all efficacy and safety data collected by the cutoff date. Due to the open-label and descriptive 
nature of this study, there is no unblinding nor alpha adjustment. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 50 
LY3650150 
Additional analyses and snapshots of study data may be performed to fulfill the need for 
regulatory interactions or publication purposes. 
Final DBL: A final DBL will occur after all patients have either completed the study through the 
12-week safety follow-up period of the study or discontinued the current study.
5.17. Annual Report Analyses 
Based on regulatory requirements for the DSUR, reports will be produced (if not already 
available from the study CSR) for the reporting period covered by the DSUR. 
5.18. Clinical Trial Registry Analyses  
Additional analyses will be performed (if not already available from the study CSR) for the 
purpose of fulfilling the CTR requirements. 
Analyses provided for the CTR requirements include the following: 
Summary of AEs, provided as a dataset, will be converted to an XML file. Both SAEs and 
‘other’ AEs are summarized by MedDRA PT. 

An AE is considered ‘serious’ whether or not it is a TEAE.

An AE is considered in the ‘other’ category if it is both a TEAE and is not serious. For
each SAE and ‘other’ AE, for each term the following are provided:
o
the number of participants at risk of an event
o
the number of participants who experienced each event term, and
o
the number of events experienced.

Consistent with www.ClinicalTrials.gov requirements, ‘other’ AEs that occur in ˂5% of
patients/subjects may not be included if a 5% threshold is chosen (5% is the minimum
threshold).

AE reporting is consistent with other document disclosures (eg, the CSR, manuscripts,
and so forth).
5.19. Biomarker Analysis 
Serum samples will be collected to discern responder variability within the study and to 
track response variability to lebrikizumab. Biomarkers will include but are not limited to: 
CCI


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 51 
LY3650150 
Samples will be collected according to the schedule described in the SoA and as detailed 
in the laboratory manual provided separately to sites. 
CCI


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 52 
LY3650150 
 
 
6. Unblinding Plan  
 
Not applicable. 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 53 
LY3650150 
 
 
7. 
References  
Auriemma M, Vianale G, Amerio P, Reale M. Cytokines and T cells in atopic dermatitis. Eur 
Cytokine Netw. 2013;24(1):37-44. https://doi.org/10.1684/ecn.2013.0333 
Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference 
and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 
2015;230(1):27-33. https://doi.org/10.1159/000365390 
Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-1494. 
https://doi.org/10.1056/nejmra074081 
Bieber T, Novak N. Pathogenesis of atopic dermatitis: new developments. Curr Allergy Asthma 
Rep. 2009;9(4):291-294. https://doi.org/10.1007/s11882-009-0041-2 
Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and 
stratified medicine. Allergy. 2012;67(12):1475-1482. https://doi.org/10.1111/all.12049 
Bieber T. Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 
2020;75(1):54-62. https://doi.org/10.1111/all.13954 
Bieber T, Straeter B. Off-label prescriptions for atopic dermatitis in Europe. Eur J Aller Clin 
Immunol. 2015;70(1):6-11. https://doi.org/10.1111/all.12498 
Bissonnette R, Diepgen T, Elsner P. Redefining treatment options in chronic hand eczema 
(CHE). J Eur Acad Dermatol Venereol. 2010;24(s3):1-20. 
https://doi.org/10.1111/j.14683083.2010.03615.x 
Caretti KL, Mehregan DR, Mehregan DA. A survey of self-reported skin disease in the elderly 
African-American population. Int J Dermatol. 2014;54(9):1034-1038. 
https://doi.org/10.1111/ijd.12520 
Choy DF, Hsu DK, Seshasayee D, et al. Comparative transcriptomic analyses of atopic 
dermatitis and psoriasis reveal shared neutrophilic inflammation. J Allergy Clin Immunol. 
2012;130(6):1335-1343. https://doi.org/10.1016/j.jaci.2012.06.044 
Diepgen T, Ofenloch R, Bruze M, et al. Prevalence of contact allergy in the general population in 
different European regions. British J Dermatol. 2016;174:319-329. 
https://doi.org/10.1111/bjd.14167 
Eckert L, Gupta S, Amand C, et al. The burden of atopic dermatitis in US adults: Health care 
resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad 
Dermatol. 2018;78(1):54-61.e1. https://doi.org/10.1016/j.jaad.2017.08.002 
Eckert L, Gupta S, Gadkari A, et al. Burden of illness in adults with atopic dermatitis: Analysis 
of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the 
United Kingdom. J Am Acad Dermatol. 2019;81(1):187-195. 
https://doi.org/10.1016/j.jaad.2019.03.037 
Esche C, de Benedetto A, Beck LA. Keratinocytes in atopic dermatitis: inflammatory signals. 
Curr Allergy Asthma Rep. 2004;4(4):276-284. https://doi.org/10.1007/s11882-004-0071-8 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 54 
LY3650150 
 
 
Faiz S, Giovannelli J, Podevin C et al. Effectiveness and safety of dupilumab for the treatment of 
atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 
2019;81:143-51. https://doi.org/10.1016/j.jaad.2019.02.053 
Faiz S, Giovannelli J, Podevin C et al. Effectiveness and safety of dupilumab for the treatment of 
atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019 
Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: A review of its use in the 
treatment of atopic dermatitis. Am Acad Dermatol. 2018;78(3):S28-S36. 
https://doi.org/10.1016/j.jaad.2017.12.022 
Hamid Q, Naseer T, Minshall EM, et al. In vivo expression of IL-12 and IL-13 in atopic 
dermatitis. J Allergy Clin Immunol. 1996;98(1):225-231. 
https://doi.org/10.1016/s00916749(96)70246-4 
Hanifin JM, Thurston M, Omoto M, et al. EASI Evaluator Group. The eczema area and severity 
index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11-18. 
https://doi.org/10.1034/j.1600-0625.2001.100102.x 
Harrop J, Chinn S, Verlato G, et al. Eczema, atopy and allergen exposure in adults: a population 
based study. Clin Exper Aller. 2007;37:526-535. 
https://doi.org/10.1111/j.13652222.2007.02679.x 
He JQ, Chan-Yeung M, Becker AB, et al. Genetic variants of the IL13 and IL4 genes and atopic 
diseases in at-risk children. Genes Immun. 2003;4(5):385-389. 
Heibel H, Henddricks A, Foshee J, Shi V. Rosacea associated with dupilumab therapy. J 
Dermatol Treat. 2021;32(1):114-116. https://doi.org/10.1080/09546634.2019.1624683 
High WA, Tomasini CF, Argenziano G, Zalaudek I. Basic principles of dermatology. In: 
Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology (3rd ed.). China: Elsevier; 2012: pp. 
8. 
Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into 
practice: What do dermatology life quality index scores mean? J Invest Dermatol. 
2005;125(4):659-664. https://doi.org/10.1111/j.0022-202x.2005.23621.x 
Howell MD, Fairchild HR, Kim BE, et al. Th2 cytokines act on S100/A11 to downregulate 
keratinocyte differentiation. J Invest Dermatol. 2008;128(9):2248-2258. 
https://doi.org/10.1038/jid.2008.74 
Hua TC, Hwang CY, Chen YJ, et al. The natural course of early-onset atopic dermatitis in 
Taiwan: a population-based cohort study. Br J Dermatol. 2014;170(1):130-135. 
https://doi.org/10.1111/bjd.12603 
Hummelshoj T, Bodtger U, Datta P, et al. Association between an interleukin-13 promoter 
polymorphism and atopy. Eur J Immunogenet. 2003;30(5):355-359. 
https://doi.org/10.1046/j.1365-2370.2003.00416.x 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 55 
LY3650150 
 
 
Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 
years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925-931. 
https://doi.org/10.1016/j.jaci.2004.01.778 
Jeong CW, Ahn KS, Rho NK, et al. Differential in vivo cytokine mRNA expression in lesional 
skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR. Clin Exp 
Allergy. 2003;33(12):1717-1724. https://doi.org/10.1111/j.1365-2222.2003.01782.x 
Kiebert, G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in 
health-related quality of life. Int J Dermatol. 2002;41(3):151-158. https://doi.org/10.1046/j.1365- 
4362.2002.01436.x 
Kim BE, Leung DYM, Boguniewicz M, Howell MD. Loricrin and involucrin expression is 
down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126(3):332-337. 
https://doi.org/10.1016/j.clim.2007.11.006 
Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality 
Index scores. Br J Dermatol. 2002;147:25-54. 
Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: 
consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 
1997;195(1):10-19. https://doi.org/10.1159/000245677 
La Grutta S, Richiusa P, Pizzolanti G, et al. CD4(+)IL-13(+) cells in peripheral blood well 
correlates with the severity of atopic dermatitis in children. Allergy. 2005;60(3):391-395. 
https://doi.org/10.1111/j.1398-9995.2005.00733.x 
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360. 
https://doi.org/10.1016/s0140-6736(20)31286-1 
Marniquet M, Seneschal J, Darrigade A, et al. Reasons for discontinuation of dupilumab in adult 
atopic dermatitis in clinical practice. Br J Dermatol. 2022. https://doi.org/10.1111/bjd.20883 
Miron Y, Miller P, Hughes C, et al. Mechanistic insights into the antipruritic effects of 
lebrikizumab, an anti–IL-13 mAb. J Aller Clin Immun. 2022. 1-11. 
https://doi.org/10.1016/j.jaci.2022.01.028 
Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL-31 correlate with IL-4 and 
IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 2006;118(4):930-937. 
https://doi.org/10.1016/j.jaci.2006.07.015 
Newton L, DeLozier AM, Griffiths PC, et al. Exploring content and psychometric validity of 
newly developed assessment tools for itch and skin pain in atopic dermatitis. J Patient Rep 
Outcomes. 2019;3(1):42. https://doi.org/10.1186/s41687-019-0128-z 
Novak N, Kruse S, Kraft S, et al. Dichotomic nature of atopic dermatitis reflected by combined 
analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the 
interleukin-4/interleukin-13 receptor gene: the dichotomy of extrinsic and intrinsic atopic 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 56 
LY3650150 
 
 
dermatitis. J Invest Dermatol. 2002;119(4):870-875. 
https://doi.org/10.1046/j.15231747.2002.00191.x 
Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB. Practical issues on 
interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the 
three-item severity score. Br J Dermatol. 2007;157(4):645-648. 
https://doi.org/10.1111/j.13652133.2007.08112.x 
Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic 
dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr 
Med Res Opin. 2020;36(3):367-376. https://doi.org/10.1080/03007995.2019.1699516 
Purwar R, Werfel T, Wittmann M. IL-13-stimulated human keratinocytes preferentially attract 
CD4+CCR4+ T cells: possible role in atopic dermatitis. J Invest Dermatol. 2006;126(5):1043- 
1051. https://doi.org/10.1038/sj.jid.5700085 
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and 
activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-365. 
https://doi.org/10.2165/00019053-199304050-00006 
Ruzicka T, Harsch M, Brown TC, et al. Modified Total Lesion Symptom Score (mTLSS). Br J 
Dermatol. 2008;158(4):808-817. 
Sacotte R, Silverberg J. Epidemiology of adult atopic dermatitis. Clin Dermatology. 
2018;36:595-605. https://doi.org/10.1016/j.clindermatol.2018.05.007 
Saeki H, Tsunemi Y, Fujita H, et al. Prevalence of atopic dermatitis determined by clinical 
examination in Japanese adults. J Dermatol. 2006;33(11):817-819. 
https://doi.org/10.1111/j.1346-8138.2006.00187.x 
Safa G, Paumier V. Psoriasis induced by dupilumab therapy. Clin Exp Dermatol. 
2019;44(3):e49-e50. https://doi.org/10.1111/ced.13901 
Schram ME, Spuls PI, Leeflang MMG, et al. EASI, (objective) SCORAD and POEM for atopic 
eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99106. 
https://doi.org/10.1111/j.1398-9995.2011.02719.x 
Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev 
Clin Pharmacol. 2018;11(5):467-474. https://doi.org/10.1080/17512433.2018.1449642 
Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic 
dermatitis in US adults: A population-based cross-sectional study. Ann Allergy, Asthma 
Immunol. 2018;121(3):340-347. https://doi.org/10.1016/j.anai.2018.07.006 
Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy, Asthma Immunol. 
2019;123(2):144-151. https://doi.org/10.1016/j.anai.2019.04.020 
Silverberg JI, DeLozier A, Sun L, et al. Psychometric properties of the itch numeric rating scale, 
skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 57 
LY3650150 
 
 
moderateto-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19(1):247. 
https://doi.org/10.1186/s12955-021-01877-8 
Simon D, Wollenberg A, Renz H, Simon HU. Atopic dermatitis: Collegium Internationale 
Allergologicum (CIA) update 2019. Int Arch Allergy Immunol. 2019;178(3):207-218. 
https://doi.org/10.1159/000497383 
Simpson E, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo 
in atopic dermatitis. N Engl J Med. 2016;375:2335-2348. 
https://doi.org/10.1056/nejmoa1610020 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 58 
LY3650150 
 
 
 
 
Appendix 1. 
Definition of Rescue Medications  
 
The AD rescue therapy in this study is defined as: high-potency TCS >10 days, topical JAK 
inhibitors (i.e. topical Ruxolitinib), and systemic AD therapy. The topical and systemic 
treatments are defined as follows: 
1. Topical AD Treatment (including TCSs, TCI, crisaborole, and Ruxolitinib)  
Route of topical treatments includes: Topical and Transdermal. 
TCS: ATC code is D07 
High Potency TCS: ATC codes are D07AC or D07AD 
Low or moderate potency TCS: ATC code is D07, excluding D07AC or D07AD 
TCI: PT includes: TACROLIMUS, PIMECROLIMUS 
Crisaborole: PT includes: CRISABOROLE 
Topical Ruxolitinib: ATC code is D11AH09 
2. Systemic AD Treatment (including systemic corticosteroids, immunosuppressant, 
biologics, and phototherapy/PUVA)  
Route of systemic treatments administration includes: Oral, Intra-Arterial, Intramuscular, 
Intraperitoneal, Intravenous, Subcutaneous, and Transdermal. (This condition applies to 
the following categories except for phototherapies.) 
Systemic Corticosteroids: ATC code is H02 
Immunosuppressant: Defined as: ATC2 is L04 or PTs of Abrocitinib or Ruxolitinib 
excluding PTs mentioned in Biologics 
Biologics: Defined as following PTs: 
Infliximab, Infliximabum, Etanercept, Etanerceptum, Adalimumab, Adalimumabum, 
Certolizumab, Certolizumabum, Certolizumab pegol, Golimumab, Golimumabum, 
Ozoralizumab, Afelimomab, Afelimomabum, Tumor Necrosis Factor Alpha (TNF-) 
Inhibitors, Tabalumab, Tregalizumab, Anakinra, Basiliximab, Basiliximabum, 
Daclizumab, Daclizumabum, Tocilizumab, Tocilizumabum, Mepolizumab, 
Mepolizumabum, Rilonacept, Rilonaceptum, Ustekinumab, Canakinumab, Briakinumab, 
Fezakinumab, Sirukumab, Sarilumab, Lebrikizumab, Secukinumab, Olokizumab, 
Gevokizumab, Brodalumab, Ladarixin, Ixekizumab, Dupilumab, Tildrakizumab, 
Tildrakizumabum, Reslizumab, Reslizumabum, Guselkumab, Guselkumabum, 
Olamkicept, Fletikumab, Bimekizumab, Mirikizumab, Risankizumab, Abatacept, 
Ligelizumab, Vedolizumab, Belimumab, Nemolizumab, Tralokinumab, Omalizumab 


J2T-MC-KGBO (Lebrikizumab) Statistical Analysis Plan Version 2 
Page 59 
LY3650150 
 
 
Phototherapy or PUVA: 
Programming search of medication name (actual term or PT) contains ‘photo’ then 
medicals to manually review to confirm whether the medication in question is indeed 
‘Phototherapy’ or ‘Photochemotherapy’. 
 
 
 
 
 
PPD